

40 0791536 X



ProQuest Number: 10183148

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



ProQuest 10183148

Published by ProQuest LLC (2017). Copyright of the Dissertation is held by the Author.

All rights reserved.

This work is protected against unauthorized copying under Title 17, United States Code  
Microform Edition © ProQuest LLC.

ProQuest LLC.  
789 East Eisenhower Parkway  
P.O. Box 1346  
Ann Arbor, MI 48106 – 1346

**THE ROLE OF THE BK<sub>Ca</sub> CHANNEL IN  
ADENOSINE RECEPTOR-MEDIATED  
CYTOPROTECTION**

**LAURICE V. FRETWELL**

A thesis submitted in partial fulfilment of the  
requirements of Nottingham Trent University for the  
degree of Doctor of Philosophy

December 2009

This work is the intellectual property of the author and Nottingham Trent University. You may copy up to 5% of this work for private study, or personal, non-commercial research. Any re-use of the information contained within this document should be fully referenced, quoting the author, title, university, degree level and pagination.

Queries or requests for any other use, or if a more substantial copy is required, should be directed in the first instance to the author.



## Proceedings and Publications

Data from the following thesis has been published in The European Journal of Pharmacology and has been presented at EPHAR 2007, LifeSciences 2008 and a conference held by Nottingham Trent University (2007):

- Fretwell & Dickenson. Role of  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels in  $\text{A}_1$  adenosine receptor-mediated pharmacological preconditioning in H9c2 cells – Eur J Pharmacol. 2009; 681(1-3):37-44.
- Fretwell & Dickenson. Role of  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels in adenosine  $\text{A}_1$  receptor-mediated protection against hypoxia-induced cell death in myocardial H9c2 cells – Fund & Clin Pharm EPHAR. 2008; P156
- Fretwell & Dickenson. Functional expression of the adenosine  $\text{A}_1$  and  $\kappa$ -opioid receptor in myocardial H9c2 cells – LifeSciences. 2007; Proc Life Sciences PC289

## Abstract

The rat embryonic cardiomyoblast-derived H9c2 cell line is increasingly used for studies into cardioprotection, as these cells display similar properties to primary cardiomyocytes. Adenosine receptors are well known mediators of cardioprotection and trigger effectors such as the mitochondrial  $K_{ATP}$  channel – however, the role of the mitochondrial  $BK_{Ca}$  channel in adenosine receptor-mediated cardioprotection has not been investigated. GPCR assays provided evidence for functional expression of  $G_i$ -coupled adenosine  $A_1$  and  $\kappa$ -opioid receptors,  $G_s$ -coupled  $\beta_2$  adrenergic receptors and  $G_q$ -coupled UTP-binding P2Y purinergic receptors on H9c2 cells. Activation of the adenosine  $A_1$  receptor with CPA (N(6)-cyclopentyladenosine) provided significant protection against hypoxia-induced cell death in these cells, as did opening of a  $BK_{Ca}$  channel with NS1619. The location of this  $BK_{Ca}$  channel was confirmed to be the mitochondria by the probing of subcellular fractions with  $BK_{Ca}$ -specific antibodies. Interestingly, CPA-induced protection against hypoxia was blocked by inhibition of the  $BK_{Ca}$  channel. In a model of hypoxia/reoxygenation in H9c2 cells both CPA and NS1619 significantly reduced cell death when used as postconditioning agents, and in both cases the protection was abolished by blockade of the  $BK_{Ca}$  channel. This data suggests for the first time that, in H9c2 cells, the  $BK_{Ca}$  channel is involved in  $A_1$  receptor-mediated cytoprotection. To confirm this finding in a more physiologically relevant model – and validate the use of H9c2 cells as a model for cardioprotection – hypoxia/reoxygenation in isolated rat ventricle strips was investigated. It was discovered that blockade of the  $BK_{Ca}$  channel significantly attenuated protection afforded by hypoxia preconditioning and preconditioning triggered by activation of the adenosine  $A_1$  and  $A_{2A}$  receptors.

For the first time, this report has shown an important role for the  $BK_{Ca}$  channel in adenosine receptor-mediated cytoprotection.

## Acknowledgements

I'd like to say a massive thank you to my supervisors John and Stewart for their constant help, support and understanding throughout my PhD – I feel very lucky to have had you as my supervisory team. And an extra thank you to John for remaining calm and positive during the hard times.

Stewart, Shiva and Chris also deserve thanks for giving me plenty of demonstrating hours and allowing me to share my love of tissue baths with unsuspecting students!

As for my family and friends, I couldn't have asked for better. Special thanks to my mum, dad and Adam for putting up with me, Ale, Renee, Shakthi and Amar for making life in Lab 107 so much fun, and Sara for making me laugh no matter what mood I'm in. And last but not least, thank you James for generally just being great!

# Contents

<b>1. Introduction</b> .....	9
1.1. Cardiovascular disease .....	9
1.2. Ischaemia and ischaemia/reperfusion-induced cell death .....	9
1.3. A role for the mitochondria.....	16
1.4. Ischaemia as a trigger of cardioprotection .....	20
1.5. G protein-coupled receptors .....	29
1.6. Adenosine receptors .....	33
1.7. Large conductance calcium-activated potassium channels.....	38
1.8. H9c2 cells and rat ventricle strips – models for studies into cardioprotection ...	41
1.9. Aims of this project.....	42
<b>2. Methods</b> .....	43
2.1. Cell Culture .....	43
<b>2.2. Functional Expression of GPCRs</b> .....	43
i) Measurement of cAMP accumulation .....	43
ii) Inositol triphosphate Assay .....	44
2.3. Protection against hypoxia- and hypoxia/reoxygenation-induced cell death.....	45
i) MTT Assay .....	48
ii) Lactate dehydrogenase (LDH) Assay.....	48
iii) Caspase-3 Assay.....	49
iv) DC Lowry Protocol – Protein Assay .....	50
2.4. Western blot analysis of BK <sub>Ca</sub> channel subunit expression and protein kinase phosphorylation .....	51
2.5. Subcellular fractionation .....	53
2.6. Right Ventricle Strip Preparation.....	54

2.7. Data analysis .....	57
2.8. Materials.....	57
<b>3. Functional GPCR studies .....</b>	<b>59</b>
3.1. Functional expression of adenosine receptors on H9c2 cells.....	59
3.2. Functional expression of opioid receptors on H9c2 cells .....	66
3.3: Functional expression of beta-adrenergic receptors on H9c2 cells.....	70
3.4: Functional expression of other G <sub>i</sub> and G <sub>q</sub> protein-coupled receptors on H9c2 cells.....	74
<b>4. Cardioprotective potential of functionally expressed receptors on H9c2 cells</b> .....	<b>79</b>
4.1. Determining the effects of GPCR agonists against hypoxia-induced cell death in H9c2 cells .....	79
4.2: Establishing a role for the ATP-sensitive potassium channel (K <sub>ATP</sub> ) and the large-conductance calcium-activated potassium channel (BK <sub>Ca</sub> channel).....	85
4.3: Determining a link between the adenosine A <sub>1</sub> receptor and the BK <sub>Ca</sub> channel...	91
<b>5. The role of protein kinases ERK1/2 and PKB in adenosine A<sub>1</sub> receptor and BK<sub>Ca</sub> channel-mediated cytoprotection .....</b>	<b>94</b>
<b>6. The role of the BK<sub>Ca</sub> channel in adenosine receptor-mediated protection against hypoxia-reoxygenation.....</b>	<b>109</b>
6.1. A model for hypoxia-reoxygenation in H9c2 cells.....	109
6.2. A model for hypoxia-reoxygenation in rat ventricle strips .....	117
<b>7. Discussion.....</b>	<b>124</b>
7.1. Summary of main findings.....	124
7.2. Characterisation of GPCRs functionally expressed on H9c2 cells .....	126
7.3. The cardioprotective potential of functionally expressed receptors and K <sup>+</sup> channels on H9c2 cells .....	129
7.4. The role of protein kinases ERK1/2 and PKB in adenosine A <sub>1</sub> receptor and BK <sub>Ca</sub> channel-mediated cytoprotection.....	134

7.5. The role of the BK <sub>Ca</sub> channel in adenosine receptor-mediated protection against hypoxia-reoxygenation.....	137
7.6. Conclusions and further work .....	141
<b>8. References .....</b>	<b>145</b>

## **1. Introduction**

### **1.1. Cardiovascular disease**

Cardiovascular disease is currently the leading cause of death in the developed world, with ischaemic heart disease accounting for over 94,000 deaths in the United Kingdom in 2006 alone (British Heart Foundation Statistics Database). Although heart disease is often thought to be an affliction of the elderly, since risk does increase with age, it is also the foremost cause of premature death in the UK in men and women (British Heart Foundation Statistics Database). Ischaemic heart disease, or coronary heart disease, is caused when a coronary artery becomes blocked - often as a result of a thrombus or atherosclerotic plaque. Blood flow to myocardial tissue is reduced leading to symptoms such as dyspnea, angina pectoris and myocardial infarction. As the populace increases in age, and risk factors such as obesity and diabetes become more common, the incidence of ischaemic heart disease will be raised – creating a substantial burden on the National Health Service. Research regarding the mechanisms involved in cardiac ischaemia and protection against the resultant tissue damage is plentiful, but as yet very few pharmacological agents have successfully transferred from producing positive experimental data (in cell and animal models) to encouraging clinical outcomes. Therefore, any insight into the complex pathways involved in ischaemia and ischaemia/reperfusion injury could help identify future, or potentiate existing, targets for therapy.

### **1.2. Ischaemia and ischaemia/reperfusion-induced cell death**

Myocardial cells exhibit a variety of metabolic responses to ischaemia; the extent of the response depends on the degree of ischaemia experienced by the cells and so not all myocytes exhibit the same behaviour. Cellular responses to ischaemia include


myocardial stunning, hibernation and preconditioning. The phenomena of myocardial stunning has been described in a number of animal models including the isolated rabbit heart (Flameng *et al*, 1991) and dogs (Phillips & Ko, 2007), and has also been proven to occur in humans (Gerber *et al*, 1999). It describes the delayed return of myocardial contractile function following ischaemia, despite full restoration of blood flow, so allowing myocytes time to “repair” during a period of reduced energy requirement (Depre & Taegtmeyer, 2000). Alternatively, repeated stunning may lead to myocardial hibernation (Kim *et al*, 2003). This is often in response to chronic ischaemia/hypoxia and is a process where myocardial function is lessened in alignment with the reduced supply of oxygen and nutrients. These processes allow irreversible tissue damage to be avoided, so upon restoration of normal blood flow contractile function can eventually return. Another process that can occur in response to ischaemia is preconditioning, which enhances the resistance of the myocardium to irreversible damage and will be described later on in more detail (see section 1.4).

During ischaemia the reduced availability of oxygen and metabolic substrates is insufficient to support normal oxidative phosphorylation. This triggers the mitochondria to switch from aerobic to anaerobic respiration, so reducing formation of ATP and producing intracellular acidosis with accumulation of hydrogen ions ( $H^+$ ) and lactate (see Figure 1.1, page 12). This leads to inhibition of the ATP-dependant sodium/potassium pump ( $Na^+/K^+$ -ATPase) and activation of the sodium/hydrogen exchanger (NHE) – both of these actions augmenting intracellular  $Na^+$  accumulation. The increase in  $Na^+$  activates the  $Na^+/Ca^{2+}$  exchanger, leading to intracellular accumulation of  $Ca^{2+}$ . Osmotic swelling occurs due to influx of  $Cl^-$  and  $H_2O$ . The reduction of ATP also reduces uptake of  $Ca^{2+}$  by the sarco/endoplasmic reticulum



Ca<sup>2+</sup>-ATPase (SERCA), so further intracellular Ca<sup>2+</sup> accumulation occurs. Ca<sup>2+</sup>-dependent proteases are then activated, causing damage to the membranes and cytoskeleton. This, combined with the swelling of the cell, can lead to membrane rupture and oncotic necrosis. Oncosis, or “ischaemic cell death” (Schaper & Kostin, 2005), is a form of accidental cell death caused by failure of ion pumps. It is characterised by cell swelling, increased membrane permeability, blebbing and non-specific DNA degradation (Majno & Joris, 1995). In the literature the term “necrosis” is often used in place of oncotic necrosis, however, necrosis specifically refers to the changes that occur following any kind of cell death. This is characterised by further changes to the nucleus and cytoplasmic constituents and breakdown of the plasma membrane; up until this point it is thought that cells can be rescued, and the onset of necrosis represents irreversible cell death (for review see Trump & Berezesky, 1996). To remain consistent with the literature, from this point “necrosis” will be used to describe non-apoptotic cell death in this report.

Apoptosis is a distinct form of cell death and can be initiated by a cell’s “internal clock” or an external signal (Majno & Joris, 1995). Unlike necrosis, it is characterised by cell shrinkage, nuclear condensation and specific nuclear cleavage, and budding of apoptotic bodies – these are then phagocytosed without stimulating an inflammatory response.



**Fig.1.1: Proposed series of events leading from myocardial ischaemia to irreversible cell death.** The reduced formation of ATP and intracellular acidosis caused by lack of oxygen disrupts ion transporters within the cell, leading to cell swelling and damage – resulting in irreversible necrosis.


It was originally thought that necrosis was the predominant form of cell death initiated by hypoxia/ischaemia, and there is evidence for and against a role for apoptosis. For example, hypoxia-induced apoptosis has been detected in neonatal and adult rat cardiomyocytes (Tanaka *et al*, 1994; de Moissac *et al*, 2000), but a study by Webster *et al* (1999) reported that apoptosis could only be measured when hypoxia was accompanied with reoxygenation or a shift in pH – and this was found to be the case in neonatal rat cardiomyocytes and the Langendorff-perfused mouse heart. Such discrepancies may arise due to the model used, different conditions for hypoxia and/or different methods of measuring apoptosis. It has been shown that different apoptotic pathways can be stimulated depending on culture conditions; one study utilising Jurkat cells (Malhotra *et al*, 2001) described caspase-3-dependent apoptosis following hypoxia in a glucose-free medium, but caspase-3-independent apoptosis following hypoxia in glucose-containing medium – suggesting that a caspase-independent death receptor pathway had been activated. Overall, the data regarding hypoxia-induced cell death is varied, but there is a large body of evidence in favour of a role for apoptosis.

However, it is now believed that a combination of apoptosis and necrosis occurs – with apoptosis being the preferred pathway until ATP levels are too low to sustain the energy-dependent process, after which necrosis takes over (Tatsumi *et al*, 2003; Otani *et al*, 2006).

Initially the damage observed in myocardial tissue following an infarction (in the clinical setting and experimental models) was believed to be inflicted purely during the period of ischaemia. However, in 1987 Olafsson *et al* provided evidence that some injury occurs due to the reinstatement of blood flow during reperfusion. The Olafsson group used a canine model and reported that treatment with adenosine for

the first hour of reperfusion after a 90 minute period of ischaemia reduced infarct size and improved ventricular function compared to untreated controls (Olafsson *et al*, 1987). The observation that the outcome of the ischaemic insult could be improved by pharmacological treatment during reperfusion suggested that some of the damage was generated at this stage. Since this report it has been found that treatment with several pharmacological agents at the start of reperfusion can ease myocardial injury (for review see Gross & Auchampach, 2007).

Reperfusion is essential to “rescue” the ischaemic tissue, but it is now known to lead to further problems such as arrhythmia, decreased contractile function and irreversible cell death. During ischaemia neutrophils accumulate at the damaged tissue, and this process is accelerated upon reoxygenation (Hansen, 1995). Neutrophils release ROS, proteases and inflammatory mediators, which in turn recruit more neutrophils so amplifying the inflammatory-like response (Jordan *et al*, 1999). Alongside the inflammatory-like response, mitochondria are thought to be the main mediators of reperfusion injury (see Figure 1.2, page 15); it is postulated that the reintroduction of oxygen re-energises the mitochondrial respiration machinery, leading to excessive production of reactive oxygen species (ROS) (Korge *et al*, 2008). SERCA (Sarco/Endoplasmic Reticulum  $\text{Ca}^{2+}$ -ATPase) is activated when ATP production proceeds, placing the sarcoplasmic reticulum under severe calcium overload. Calcium is released via ryanodine receptors then taken up again by SERCA – this leads to intracellular calcium oscillations and mechanical irregularities (Piper *et al*, 2006). The accumulation of calcium activates  $\text{Ca}^{2+}$ -dependant proteases, such as calpains, which degrade intracellular proteins and compromise the integrity of the cell membrane.



**Figure 1.2: Proposed series of events leading from myocardial ischaemia/reperfusion to irreversible cell death.** Upon reoxygenation the increase in oxygen and activation of neutrophils sets off a series of events. Common features of both pathways are excessive ROS production and activation of the mPTP – eventually culminating in cell death.

### 1.3. A role for the mitochondria

Precise regulation of cytoplasmic potassium ion concentration is essential to maintain ion homeostasis and cell volume, and it is thought that  $K^+$  homeostasis is the main regulator of mitochondrial matrix volume. Efflux of  $K^+$  from the cell can lead to osmotic shrinkage, which stimulates mitochondrial release of cytochrome-c, activation of executioner caspase-3 and eventual cell death. This intrinsic apoptotic pathway is mediated by the mitochondria.

Mitochondria are responsible for generating cellular energy in the form of ATP via oxidative phosphorylation. Oxidative phosphorylation involves generation of a proton gradient across the inner mitochondrial membrane by the electron transport chain; inner membrane-bound ATP synthase then utilises the gradient to power the production of ATP from ADP and phosphate ( $P_i$ ). If ATP synthesis is disrupted the whole cell is affected as ion homeostasis is disturbed, leading to a change in cell volume.

Several ion channels have been described that are located on the mitochondrial inner mitochondrial membrane, including two  $K^+$  channels – the ATP-sensitive potassium channel (mitoK<sub>ATP</sub>) and the large-conductance calcium-activated potassium channel (mitoBK<sub>Ca</sub>). Both of these channels have been implicated in cardioprotection against ischaemia/reperfusion injury (for review see Nishida *et al*, 2009). The proton gradient across the mitochondrial membrane (formed by the mitochondrial electron transport chain) leads to a negative potential in the mitochondrial matrix compared to the cytosol, and this leads to  $Ca^{2+}$  influx into the mitochondria (Gunter & Pfeiffer, 1990). During ischaemia, when conditions favour  $Ca^{2+}$  influx, activation of  $K^+$  channels partially depolarises the mitochondrial membrane so reducing the negative




gradient, and this attenuates the potentially damaging  $\text{Ca}^{2+}$  influx. This has been shown in an isolated cardiac mitochondrial preparation using the  $\text{K}_{\text{ATP}}$  openers diazoxide and pinacidil, and in intact cardiomyocytes with diazoxide (Holmuhamedov *et al*, 1999) and the  $\text{BK}_{\text{Ca}}$  channel opener NS1619 (Sato *et al*, 2005) – in each case treatment with the channel openers depolarised the mitochondrial membrane and reduced mitochondrial  $\text{Ca}^{2+}$  uptake.

It is thought that activation of the  $\text{mitoK}_{\text{ATP}}$  channel evokes cardioprotection through a pathway involving inhibition of the mitochondrial transition pore (Facundo *et al*, 2005; Krolkowski *et al*, 2005), however, the precise mechanisms by which  $\text{mitoK}_{\text{ATP}}$  channels mediate cardioprotection are debatable. The structure of  $\text{mitoK}_{\text{ATP}}$  channels is not fully known, but it is postulated that they are similar to the plasma membrane  $\text{K}_{\text{ATP}}$  channels and are composed of an inward rectifier potassium channel subunit (Kir) associated with a sulfonylurea receptor (SUR) (Mironova *et al*, 2004; O'Rourke, 2004). The cardioprotective role of the mitochondrial  $\text{BK}_{\text{Ca}}$  channel will be discussed later on (see section 1.7).

Not all mitochondrial channels exert such a cardioprotective effect. Also on the inner mitochondrial membrane is the mitochondrial permeability transition pore (mPTP), which is thought to be a key player in ischaemia/reperfusion injury. The mPTP consists of several proteins spanning the inner and outer mitochondrial membranes, so allowing the passage of solutes  $<1.5$  kDa through the usually impermeable inner mitochondrial membrane. The structure of the mPTP is under debate, but the main components are proposed to be adenine nucleotide translocase (ANT), cyclophilin-D (CyP-D), mitochondrial phosphate carrier (PiC) and voltage-dependent anion channel (VDAC) – although recent evidence contrasts the original model for the mPTP where VDAC had a major role.

The mPTP opens in response to an increase in mitochondrial  $\text{Ca}^{2+}$ , facilitating the release of pro-apoptotic molecules into the cytosol (Rodriguez-Enriquez *et al*, 2004); though during periods of increased oxidative stress the mPTP is sensitised to  $\text{Ca}^{2+}$ , so increased  $\text{Ca}^{2+}$  is not actually required for pore opening (Halestrap *et al*, 1997). However, when ATP depletion occurs to an extent that is too low to support apoptosis the mPTP can also mediate necrosis (for review see Crompton, 1999; see Figure 1.3).



**Figure 1.3: Regulation of cell death by the mPTP.** Mitochondrial permeability transition can set off a series of events culminating in necrotic and/or apoptotic cell death. (Green/blue bars, open mPTP).



It has been suggested that mPTP is formed by a CyP-D-facilitated conformational change of the PiC, and that this is modulated by the conformational state of an associated ANT (Halestrap *et al*, 1997; for review see Halestrap, 2009). Evidence for these associated proteins arises from various reports. For example, it has been shown that livers from CyP-D knock-out mice are extremely resistant to  $\text{Ca}^{2+}$ -induced opening of the mPTP (Basso *et al*, 2005), pointing to an important role for this protein in mPTP formation. In 2008 it was discovered that PiC binds to CyP-D in a cyclosporine-sensitive manner (cyclosporine interacts with CyP-D, preventing pore formation), and that PiC can also associate with ANT – suggesting that PiC may also play a role in mPTP formation (Leung *et al*, 2008). The modulatory (i.e. not essential) role for the ANT arises from the evidence that livers from mice without ANT1 or ANT2 still present a permeability transition (Kokoszka *et al*, 2004). It is important to note, however, that only nucleotides transported by ANT (i.e. ATP and ADP) can inhibit mPTP opening, implicating ANT in regulation of the pore (Halestrap *et al*, 1997; the role of ANT is reviewed in Leung & Halestrap, 2008).

VDAC was originally proposed to be an important part of the mPTP by Zoratti & Szabo in 1994, as it had been co-purified with ANT. The role of VDAC is controversial though, as more recently it has been shown that mitochondria from VDAC-null mice exhibited a  $\text{Ca}^{2+}$  - and oxidative stress-inducible permeability transition comparable to that observed in mitochondria from wild-type mice (Baines *et al*, 2007).

However, in comparison to this role in the initiation of cell death it has also been suggested that transient opening of this channel can have a cytoprotective effect (Hausenloy *et al*, 2004). Despite this, the mPTP appears to play a key role in regulation of ischaemia/reperfusion injury, and provides a good target for

cardioprotective therapies – and the potential modulation of the mPTP by the  $K_{ATP}$  channel, or  $BK_{Ca}$  channel, provides an exciting area of research.

It is proposed that during oxidative stress, while the energy state still favours apoptosis, the mPTP opens allowing influx of water and solutes into the mitochondria, increasing matrix volume and rupturing the outer membrane. This allows the release of cytochrome c from the intermembrane space, formation of the apoptosome (a complex of cytochrome c, APAF-1 and pro-caspase-9) and initiation of the caspase cascade – resulting in apoptotic cell death (see Figure 1.3). As oxidative stress increases, necrosis is favoured. Opening of the mPTP leads to ATP hydrolysis, so worsening energy metabolism and causing further  $Ca^{2+}$  deregulation. This feeds back to the mitochondria – initiating more mPTP opening and eventual loss of energy and  $Ca^{2+}$  regulation, culminating in necrosis (see Figure 1.3). However, although prolonged exposure is ultimately damaging, ischaemia can also have a beneficial effect.

#### **1.4. Ischaemia as a trigger of cardioprotection**


It is now well accepted that a brief period of ischaemia and reperfusion (I/R) can protect against a subsequent, prolonged I/R. This phenomenon, termed ischaemic preconditioning, has been demonstrated in various models including swine (Schott *et al*, 1990) and dog (Murry *et al*, 1986), as well as several in vitro models such as isolated rabbit cardiomyocytes (Armstrong *et al*, 1994). There is also evidence suggesting that ischaemic preconditioning can be beneficial when used in a clinical setting with coronary artery bypass graft surgery (CABG). For example, Wu *et al* (2002) found that brief periods of ischaemia before CABG, in patients with 3 vessel disease, significantly reduced the occurrence of ventricular fibrillation and

tachycardia after the operation. The same group (Laurikka *et al*, 2002) used the same preconditioning protocol in patients with 2 vessel disease and found that, following CABG, myocardial enzyme release was attenuated, heart rate was stabilised and recovery of stroke volume was increased compared to the control group.

The ischaemic preconditioning phenomenon first described by Murry *et al* (1986) is now described as “classical”, or “early phase” preconditioning. This form of preconditioning refers to transient beneficial effects (1-2 hours) that develop within minutes of the cardioprotective stimulus, e.g. a brief period of sublethal ischaemia (see figure 1.4). It involves rapid modulation of pre-existing proteins within the cell, such as activation of GPCRs, protein kinases and ion channels, and provides protection in many models against ischaemia/reperfusion injury (for reviews see Sanada & Kitakaze, 2004; Bolli, 2007).

In 1993 two separate groups (Kuzuya *et al*, 1993; Marber *et al*, 1993) reported that some effects of myocardial protection could still be observed 24 hours after the initial preconditioning stimulus. This is now termed “late phase” or “second window” preconditioning, and describes long lasting effects (peak protection at 24-72 hours) that develop from 6 hours of the preconditioning stimulus. As the longer time span would suggest, the late phase of preconditioning arises from different signal transduction mechanisms to the early phase – although some commonalities do occur. A key feature of late phase preconditioning is up-regulation of cardioprotective genes and the synthesis of new proteins, e.g. inducible nitric oxide synthase (iNOS), which is a well known mediator of late phase preconditioning and is reported to provide protection via inhibition of mitochondrial swelling and inhibition of the mPTP (West *et al*, 2008). It has also been reported that anti-


apoptotic, prosurvival genes are also “switched on” and proteins synthesised during the late phase of preconditioning (Stein *et al*, 2007) – further strengthening the role of apoptosis in ischaemia/reperfusion injury. These two forms of ischaemic preconditioning can both reduce infarct size in various animal models (see Yellon & Downey, 2003, for comprehensive review), but in mice the early phase is reported to be more potent (Guo *et al*, 1998). However, the late phase of ischaemic preconditioning can also provide protection against myocardial stunning in conscious rabbits (Dawn *et al*, 1999). Figure 1.4 provides a basic outline of the phases involved in ischaemia/reperfusion injury and types of cardioprotection. The duration of ischaemia and reperfusion varies between experimental models, but the general outcomes are highlighted in the text.



**Figure 1.4: Graphical representation of ischaemia/reperfusion and pre/postconditioning.** Ischaemia/reperfusion leads to ischaemia/reperfusion injury (I/R injury), which can be attenuated by ischaemic pre- or postconditioning. Areas of blue indicate ischaemia, red indicated normal perfusion. Diagram adapted from Ferdinandy *et al*, 2007.


Both the early and late phases of ischaemic preconditioning rely on signal transduction pathways to link the initial trigger of cardioprotection with the overall effectors, or mediators. During the preconditioning period of ischaemia autocoid

triggers such as adenosine (Headrick, 1996), opioid peptides (Pan *et al*, 2000), bradykinin (Romano *et al*, 2004) and catecholamines (Schömig, 1990) are released from the myocardial tissue. These are thought to stimulate specific G protein-coupled receptors (GPCRs) and protein kinases, which culminate in activation of mediators such as the mitochondrial ATP-dependent potassium ( $K_{ATP}$ ) channel (for examples see Peart & Gross, 2003; Uchiyama *et al*, 2003). The precise signalling pathways involved in ischaemic preconditioning are still under debate, but extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase C (PKC), cAMP-dependent protein kinase (PKA), cGMP-dependant protein kinase (PKG), p38 mitogen-activated protein kinase (p38 MAPK) and nitric oxide (NO) all have well reported roles (Hausenloy & Yellon, 2006) (see Figure 1.5).



**Figure 1.5: Proposed series of events following the release of autacoids during ischaemic preconditioning.** Autacoids are released by myocardial cells and activate specific GPCR subtypes. The receptors bind to G proteins, which once activated can stimulate protein kinases and other effectors – culminating in activation of the mitochondrial  $K_{ATP}$  channel, ROS regulation and reduced mitochondrial permeability transition.

The MEK1/2-ERK1/2 and PI3K-PKB signalling pathways are key players in the “RISK” (Reperfusion Injury Salvage Kinase) pathway (Hausenloy & Yellon, 2004). Both of these pathways have been shown to be activated at the time of reperfusion following pharmacological preconditioning (Yang *et al*, 2004a & 2004b), leading to recruitment of downstream anti-apoptotic molecules (see Figure 1.6).



**Figure 1.6:** The basic steps leading to activation of ERK1/2 and PKB. (See main body of text for more detailed description.)

For initiation of the MEK/ERK1/2 pathway GTP-bound Ras recruits Raf to the plasma membrane, and then phosphorylates Raf. Active Raf then phosphorylates MAPK/ERK kinase 1 (MEK1) and MEK2. MEK1/2 phosphorylation leads to phosphorylation of ERK1/2, and then ERK1/2 can activate downstream targets. One anti-apoptotic pathway mediated by ERK1/2 activation is through the downstream activation of the protein kinase p90 ribosomal S6 kinase (p90RSK) (Herrera &

Sebolt-Leopold, 2002). p90RSK phosphorylates and inactivates the pro-apoptotic protein BAD, so inhibiting BAD-mediated cytochrome-c release and caspase activation (Downward, 1999).

The role of ERK1/2 in preconditioning and postconditioning is clear. For example, it has been shown that ERK1/2 phosphorylation is increased following a preconditioning stimulus in rat hearts in vitro (Hausenloy *et al*, 2005 & 2005a), and also in rat hearts in vivo – where a role for ERK1/2 was described in ischaemic preconditioning and preconditioning mediated by the  $\delta$ -opioid receptor (Fryer *et al*, 2001). ERK1/2 phosphorylation is also increased in post-conditioned in vivo pig hearts (Schwartz & Lagranha, 2006) – pointing to recruitment of similar pathways for pre- and postconditioning. In fact, it has been reported that it is the first few minutes of reperfusion following the major ischaemic insult that is critical for both pre- and postconditioning (Hausenloy & Yellon, 2007a). It is known that activation of the adenosine A<sub>1</sub> receptor leads to ERK1/2 phosphorylation, but there is variation regarding the role of ERK1/2 in adenosine receptor-mediated cardioprotection. It was shown that the anti-apoptotic effect of adenosine in neonatal rat cardiomyocytes was mediated by the A<sub>1</sub> and A<sub>3</sub> receptors, and dependent on MEK/ERK1/2 activation (Germack & Dickenson, 2005). However, a study with isolated rat ventricle strips found that inhibition of MEK did not affect adenosine A<sub>1</sub>, A<sub>2A</sub> or A<sub>3</sub> receptor-mediated preconditioning, but did attenuate hypoxic preconditioning (Button *et al*, 2005). ERK1/2 is also proposed to be involved in mitoK<sub>ATP</sub> channel signalling in isolated rabbit hearts (Naitoh *et al*, 2006).

The PI3K/PKB pathway is initiated by phosphorylation of PIP<sub>2</sub> by PI3K, generating PIP<sub>3</sub>. PIP<sub>3</sub> recruits cytoplasmic PKB and PDK to the plasma membrane, where PDK activates PKB. Activated PKB then redistributes to the mitochondria (Miyamoto *et*



*al*, 2008) or nucleus (Shiraishi *et al*, 2004), and activates anti-apoptotic pathways. One such pathway is via inhibition of BAD (Datta *et al*, 1997), which is a mechanism triggered by both the PI3K/PKB and MEK/ERK1/2 pathways. PKB is also proposed to enhance the association of hexokinase with VDAC at the outer mitochondrial membrane, so preserving mitochondrial integrity and inhibiting opening of the mPTP (Gottlob *et al*, 2001). It has been shown that PDK1 (and, therefore, phosphorylation of PKB) is essential for ischaemic preconditioning, as the beneficial effect of ischaemic preconditioning is lost in hearts and cell models from PDK1-deficient mice (Budas *et al*, 2006). Phosphorylation of PKB is increased in various models of cardioprotection, including preconditioning of in vitro rat and rabbit hearts (Hausenloy *et al*, 2005 & 2005a; Solenkova *et al*, 2005), and postconditioning of in vivo pig hearts (Schwartz & Lagranha, 2006). Increased phosphorylation of PKB has also been described in the protection of isolated rat hearts by ischaemic postconditioning and low-pressure reperfusion, where inhibition of the mPTP is the proposed target (Bopassa *et al*, 2006). As with ERK1/2, activation of PKB via opening of the mitoK<sub>ATP</sub> channel has also been reported (Ahmad *et al*, 2006), and the role of PKB phosphorylation in adenosine receptor-mediated cardioprotection is poorly understood. Qin *et al*, (2003) discovered that adenosine triggered preconditioning in isolated rabbit hearts by a PI3K-independent pathway, but another report (Solenkova *et al*, 2006), claimed that endogenous adenosine protects isolated rabbit hearts through phosphorylation of PKB during the early stage of reperfusion. In neonatal rat hearts, it was shown that PKB phosphorylation was involved in adenosine A<sub>1</sub> and A<sub>3</sub> receptor-mediated signalling, but not in A<sub>1</sub> and A<sub>3</sub> receptor-mediated cardioprotection (Germack *et al*, 2004).



It is reported that cross-talk occurs between the MEK1/2-ERK1/2 and PI3K-PKB pathways, and activation of both at the start of reperfusion is necessary to exert the protective preconditioning effect (Hausenloy *et al*, 2004; Solenkova *et al*, 2006). Taken as a whole, a role for the MEK/ERK1/2 and PI3K/PKB pathways in anti-apoptotic and cardioprotective signalling is clear, but further work is necessary to elucidate the role of these pathways in adenosine receptor-mediated cardioprotection.

The PI3K/PKB pathway can also activate endothelial nitric oxide synthetase (eNOS), which synthesises NO. NO has many roles in the cardiovascular system, including activation of the mitoK<sub>ATP</sub> channel. NO activates soluble guanylyl cyclase, which then produces cGMP from GTP. cGMP then activates PKG, which phosphorylates a target on the outer mitochondrial membrane and (via an unknown intermediate step) activates PKC and consequentially the K<sub>ATP</sub> channel (Cuong *et al*, 2006; Downey *et al*, 2008).

During ischaemia it is thought that there is an increase in cAMP which activates PKA – however the result of such activation is debatable. PKA activation prior to ischaemia has been reported to reduce infarct size in dogs (Sanada *et al*, 2004), but conversely blockade of PKA prior to ischaemia is reported to reduce infarct size and improve post-ischaemic recovery in isolated rat hearts (Makaula *et al*, 2005).

There is a large body of evidence suggesting PKC as a mediator of cardioprotection triggered by ischaemia and pharmacological agents, such as adenosine and the volatile anaesthetic isoflurane (Liu *et al*, 1999; Ludwig *et al*, 2004; Okada *et al*, 2005). There are ten isoforms of PKC, with the novel, Ca<sup>2+</sup>-independent PKC $\delta$  and PKC $\epsilon$  being dominant in murine heart with regards to protein expression and activity (Schreiber *et al*, 2001). However there are conflicting reports regarding the

expression of the different PKC isoforms; for example, in human ventricle it is reported that the  $\text{Ca}^{2+}$ -dependent PKC $\alpha$ , PKC $\beta$ I and PKC $\beta$ II are dominant, with PKC $\delta$  and PKC $\zeta$  mainly expressed in the atria and PKC $\epsilon$  and PKC $\lambda$  expressed equally in both regions (Simonis *et al*, 2007). Therefore data from different animal models must be interpreted cautiously. Despite these discrepancies, PKC $\epsilon$  is reported to be involved in cardioprotective signalling in several models as diverse as rabbit cardiomyocytes (Liu *et al*, 1999) and human myocardium (Sivaraman *et al*, 2009). Following a trigger, PKC $\epsilon$  is activated and translocates within the cell to activate downstream effectors such the mitoK<sub>ATP</sub> channel and the mPTP – where it exerts a protective effect by activation or inhibition of these proteins (for review see Budas & Mochly-Rosen, 2007). In contrast to the role for PKC $\epsilon$  as a critical mediator of ischaemic pre- and postconditioning (Zatta *et al*, 2006), PKC $\delta$  has a role in mediating ischaemia/reperfusion-induced apoptosis (Liu *et al*, 1999) – and it has been shown that inhibition of PKC $\delta$  at the time of reperfusion can improve recovery of function and reduce infarct size in murine hearts (Inagaki *et al*, 2003).

Overall, there is much evidence suggesting that protein kinases have an essential role in regulation of cardioprotective signalling, and due to the timing of activation it has been proposed that the RISK pathway has an important role in preconditioning and postconditioning (Hausenloy *et al*, 2005), although the exact mechanisms involved are unknown.


Ischaemic postconditioning is a more recently discovered cardioprotective phenomena (Zhao *et al*, 2003). This consists of brief, sublethal cycles of ischaemia/reperfusion after the prolonged ischaemic attack, and has since been observed in various experimental models, e.g. isolated rabbit hearts (Pinheiro *et al*, 2009) and isolated rat hearts (Penna *et al*, 2009).

Clarification of the signalling pathways involved in ischaemic pre- and postconditioning would provide scientists with potential targets for pharmacological treatments, so gaining the beneficial effects observed from these phenomena without the complexity of inducing ischaemia in patients. The pathways involved may be intricate, but it cannot be denied that GPCRs play an essential part in triggering the signal transduction pathways that eventually lead to cardioprotection.

### **1.5. G protein-coupled receptors**

Currently, over 30% of prescription drugs target one or more GPCR, and it is thought that many more act through GPCRs indirectly (Vaidehi *et al*, 2009). GPCRs are a super-family of cell surface receptors characterised by seven trans-membrane spanning domains (7TM  $\alpha$ -helices) with a long-chain lipid anchor to strengthen membrane association, an intracellular amino terminal and an extracellular carboxyl terminal (see Figure 1.7, page 30). They are widely distributed throughout mammalian cells and tissues, and are responsible for mediating intracellular responses to a range of extracellular signals. The binding of a ligand to the receptor sets off a cascade of events involving second messengers such as cyclic nucleotides,  $IP_3$  and  $Ca^{2+}$ .


The structure of the light-sensitive rhodopsin receptor was the first to be determined (Palczewski *et al*, 2000), and the crystalline structure of this receptor provided a basis for understanding the structure and function of further GPCRs. The rhodopsin-like/Class A receptors form the largest subgroup of GPCRs, and they can be activated by an extensive range of ligands such as light (rhodopsin receptor), peptides (e.g. opioid receptors) and hormones (e.g. follicle stimulating hormone receptor).



**Figure 1.7: Schematic diagram showing the basic structure of a Class A GPCR.** Class A GPCRs are activated when a ligand interacts with the 7TM domain, initiating a cascade of events culminating in an intracellular response.

Receptor activation occurs when a ligand binds to the receptor, creating a conformational change (see Figure 1.8 for overview, page 31). This allows the receptor to act as a guanine nucleotide exchange factor (GEF), catalysing the exchange of  $G\alpha$ -bound GDP for GTP. The heterotrimeric G protein dissociates into  $G\alpha$ -GTP and  $G\beta\gamma$  subunits which then act upon downstream targets. The  $G\beta\gamma$  subunit is generally thought to remain as a tightly associated heterodimer throughout the signalling process, however there is an exception to this rule. It has been shown that a  $G\beta$  subunit exists in the brain and retina that only associates with the  $\gamma$ -like domain of a regulator of G protein signalling (RGS), instead of a traditional  $G\gamma$  protein (Cabrera *et al*, 1998; Witherow *et al*, 2000). Once dissociated from the  $G\alpha$  subunit,  $G\beta\gamma$  is able to activate signalling enzymes such as phospholipase  $A_2$  ( $PLA_2$ ), or directly act upon ion channels such as L-type  $Ca^{2+}$  channels and G protein-coupled


inward rectifying K<sup>+</sup> channels (Jelsema & Axelrod, 1987; Viard, 1999; Hommers *et al*, 2003).



**Figure 1.8: Conformational changes during GPCR activation.** (1) In the unoccupied, resting state the inactive heterotrimeric G protein is bound to GDP. (2) Upon ligand binding a conformational change occurs in the receptor, exposing a catalytic component that exchanges GDP for GTP. (3) The active Gα-GTP subunit dissociates from the membrane-bound Gβγ subunit and both trigger downstream effectors and signalling pathways. (4) The signal is terminated by hydrolysis of GTP to GDP by intrinsic GTPase activity of the α-subunit, and the receptor/G protein complex returns to resting state.

GPCRs are further classified by the associated G protein α subunit (see Figure 1.9, page 32).





**Figure 1.9: Signalling pathways mediated by the main classes of G protein.**  $G\alpha_s$  and  $G\alpha_i$  proteins have respective stimulatory and inhibitory effects on adenylate cyclase and its downstream effectors.  $G\alpha_{q/11}$  protein activates phospholipase C, leading to protein kinase C activation and calcium signalling.  $G\alpha_{12/13}$  proteins act upon guanine nucleotide exchange factors of the Rho family.

The main subtypes are  $G\alpha_s$ ,  $G\alpha_{i/o}$  and  $G\alpha_{q/11}$ .  $G\alpha_s$  proteins are so named because of the stimulatory effect of the subunit on the enzyme adenylate cyclase, which produces second messenger cAMP.  $G\alpha_s$  proteins are selectively activated by cholera

toxin. The  $G\alpha_{i/o}$  protein subunit, on the other hand, has an inhibitory effect on adenylate cyclase, and is sensitive to pertussis toxin. The  $G\alpha_{q,11}$  proteins affect the phosphoinositide system by activating phospholipase C- $\beta$  (PLC $\beta$ ), which cleaves phosphatidylinositol bisphosphate (PIP<sub>2</sub>) into diacylglycerol (DAG) and inositol trisphosphate (IP<sub>3</sub>). DAG then activates protein kinase C (PKC) while IP<sub>3</sub> stimulates the release of intracellular calcium. These proteins are also distinguished from  $G\alpha_s$  and  $G\alpha_{i/o}$  proteins as they are insensitive to both cholera toxin and pertussis toxin.

The G protein-mediated signal is terminated by hydrolysis of GTP to GDP and re-association of the inactive  $G\alpha\beta\gamma$  heterotrimer. The  $G\alpha$  subunit has innate GTPase activity, but this does not always terminate the signal fast enough. Regulators of G protein signalling (RGS) proteins enhance the speed of hydrolysis by acting as GTPase-activating proteins (GAPs), this is possible as they contain a RGS domain that binds to the  $G\alpha$  subunit and stimulates GTPase activity (for review see Hendriks-Balk *et al*, 2008).

There are many cardioprotective GPCRs expressed in the heart, including adenosine receptors, the signalling mechanisms of which are of interest with regard to finding pharmacological targets to protect against myocardial injury.

### **1.6. Adenosine receptors**

Adenosine is a purine nucleotide released from myocardial tissue during periods of metabolic stress. It equilibrates the balance between cellular energy supply and demand, as well as having important roles in normal physiological regulation. Research has shown that adenosine is released during ischaemia or ischaemia/reperfusion, and it has been reported that the extracellular concentration of adenosine in the body can increase 100-fold up to 10  $\mu$ M during hypoxia or

ischaemia (Schulte & Fredholme, 2003). This endogenous adenosine then exerts a cardioprotective effect against ischaemia/reperfusion-induced injury and cell death (Mubagwa & Flameng 2001; Fryer et al, 2002).

Four adenosine receptors ( $A_1$ ,  $A_{2A}$ ,  $A_{2B}$  and  $A_3$ ) belonging to the GPCR superfamily have been cloned and characterised (Fredholm *et al*, 2001). The  $A_1$  and  $A_3$  receptors are negatively coupled to adenylate cyclase via pertussis toxin-sensitive  $G_i/o$  proteins, therefore inhibit cAMP production (Fredholm *et al* 2001). It is well known that the  $A_1$  and  $A_3$  receptors are involved in cardioprotection (Mubagwa & Flameng 2001; Fryer, Auchampach & Gross 2002). Adenosine  $A_{2A}$  and  $A_{2B}$  receptors are positively coupled to adenylate cyclase via  $G_s$  proteins, and have high and low affinities for adenosine, respectively. All four of the adenosine receptor subtypes are expressed in the heart (see Auchamp & Bolli, 1999), but the presence of  $A_{2A}$  receptors on cardiomyocytes is debateable. Adenosine  $A_{2A}$  receptors are widespread throughout coronary vessels where activation causes potent vasodilation, but are reported to be absent from porcine cardiomyocytes (Hein *et al*, 2001). In 2002 it was reported that rat ventricular myocytes express  $A_{2A}$  receptors, but these receptors are not functional as no response was observed from selective agonism (Kilpatrick *et al*, 2002). However, in separate studies functional  $A_{2A}$  receptors have been described in adult and neonatal rat cardiomyocytes (Xu *et al*, 1996; Germack & Dickenson, 2004) and human atrial myocytes (Hove-Madsen *et al*, 2006).

Ischaemic preconditioning reduces infarct size in intact rabbits, and this protection has been shown to be abolished by infusion of different non-selective adenosine receptor antagonists prior to the preconditioning phase (Liu *et al*, 1991). This pointed to an important role for adenosine and one or more adenosine receptor subtypes in ischaemic preconditioning. This report also progressed on to show that



selective antagonism of the A<sub>1</sub> receptor blocked the protection afforded by ischaemic preconditioning. Further strengthening the role for the A<sub>1</sub> receptor in preconditioning, the same group (Thornton *et al*, 1992) demonstrated that infusion of a selective A<sub>1</sub> agonist prior to ischaemia reduced infarct size to the same extent as ischaemic preconditioning – but an A<sub>2A</sub> agonist had no effect. It has also been shown that activation of the A<sub>1</sub> receptor is an effective trigger of the early and late phases of preconditioning in isolated hearts from normal and hypertensive rats (Hochhauser *et al*, 2007); in addition, this report showed that activation of the A<sub>3</sub> receptor was partially effective as a preconditioning trigger, particularly in the late-phase model. A place for the A<sub>3</sub> receptor in cardioprotection had also been described earlier by Auchampach *et al* (1997), who reported that activation of the A<sub>3</sub> receptor in conscious rabbits gave a level of protection equivalent to that obtained from ischaemic preconditioning. This report measured the effect of A<sub>3</sub> receptor activation on both myocardial stunning and infarct size, and claimed protection in both areas, interestingly without any hemodynamic changes. Activation of the A<sub>1</sub> receptor produces vasodilation, which is undesirable in the clinical setting (Mustafa *et al*, 2009). There are many studies assessing infarct size as a measure of cardioprotection, but fewer that look into myocardial function. One such study found that ischaemic preconditioning did not preserve myocardial function in dogs, but preconditioning with adenosine did (Phillips & Ko, 2007). However, this protection came at a cost as treatment with adenosine lead to an increased energy requirement of the heart and oxygen wasting.

The timing of pharmacological treatment can also affect the extent of protection gained, but findings do vary between models used. For example, infusion of adenosine at the time of reperfusion is effective at reducing infarct size in dogs

(Velasco *et al*, 1991), but no protection was observed in isolated rabbit hearts (Xu *et al*, 2001). It has been reported that activation of the A<sub>2B</sub> receptor at the time of reperfusion is important for ischaemic preconditioning in rabbit hearts (Kuno *et al*, 2007), and also that postconditioning is dependent on activation of the A<sub>2B</sub> receptor, but not A<sub>1</sub> or A<sub>2A</sub> receptors (Philipp *et al*, 2006). These data suggest that the A<sub>2B</sub> receptor is the main mediator of postconditioning, but the protective effect of ischaemic postconditioning is lost in A<sub>1</sub> receptor knock-out mice, suggesting an additional role for the A<sub>1</sub> receptor (Xi *et al*, 2008). Interestingly, the protection afforded by ischaemic preconditioning was absent in A<sub>2B</sub> receptor knock-out mice – but mice lacking the A<sub>1</sub>, A<sub>2A</sub> or A<sub>3</sub> receptor had a preserved response (Eckle *et al*, 2007). It has been proposed that the release of adenosine during ischaemic preconditioning triggers activation of the A<sub>1</sub> and A<sub>3</sub> receptors, which (via a Gi protein and PKC-dependent pathway) activate the A<sub>2B</sub> receptor. The A<sub>2B</sub> receptor then mediates ischaemic preconditioning by targeting effector proteins such as the KATP channel and the mPTP (Cohen & Downey, 2008).

There is a clear role for the adenosine A<sub>1</sub> and possibly A<sub>2B</sub> and A<sub>3</sub> receptors in cardioprotection, however, the role of the A<sub>2A</sub> receptor remains controversial. For example, in anesthetized rabbits there is evidence for and against adenosine A<sub>2A</sub> receptor-mediated protection. Phillip *et al* (2006) described that postconditioning could be blocked with an antagonist at the A<sub>2B</sub> receptor, but not the A<sub>2A</sub> or A<sub>1</sub> receptors. Alternatively, Boucher *et al* (2004) described that activation of the A<sub>2A</sub> receptor 5 minutes prior to (but not 5 minutes after) the onset of reperfusion successfully reduced infarct size.

Understanding the signal transduction mechanisms involved in adenosine receptor-mediated cardioprotection is an area of intense investigation, especially since

adenosine has shown promise in clinical trials (Bolli *et al* 2004). However, further work is needed before further clinical trials are considered. The Acute Myocardial Infarction Study of Adenosine Trials (AMISTAD and AMISTAD II) showed that adenosine was effective at reducing infarct size in humans, but there was no significant improvement of clinical outcome (Mahaffey *et al*, 1999; Ross *et al*, 2005). From the diverse range of data obtained from animal models it was perhaps unwise to invest such a large amount of time and money into clinical trials at this stage.


As mentioned previously, stimulation of the adenosine A<sub>1</sub> receptor has been found to lead to activation of signalling pathways involving several different protein kinases. PKC (Henry *et al*, 1996), ERK1/2 (Germack & Dickenson, 2005) and p38 MAPK (Dana *et al*, 2000) have all been implicated, and another commonly described feature of adenosine A<sub>1</sub> receptor-mediated cardioprotection is the mitochondrial K<sub>ATP</sub> channel (e.g. Van Winkle *et al*, 1994; Heurteaux *et al*, 1995; Baxter & Yellon, 1999). The K<sub>ATP</sub> channel is one of several cytoprotective channels expressed in the inner mitochondrial membrane, and has a well reported role in cardioprotection. More recently, however, a large conductance calcium-activated potassium channel (BK<sub>Ca</sub> channel) located to the inner mitochondrial membrane has also been implicated in cardioprotection.

### 1.7. Large conductance calcium-activated potassium channels


There are two types of BK<sub>Ca</sub> channel, one found on the inner mitochondrial membrane and the other on the cytoplasmic membrane. Mitochondrial BK<sub>Ca</sub> channels are abundant in the brain and cardiac tissue, cytoplasmic BK<sub>Ca</sub> channels are ubiquitously expressed throughout vascular beds in the membranes of smooth muscle cells (Korovkina & England, 2002). The exact structure of the BK<sub>Ca</sub> channel is currently under debate, but it is thought that the channel consists of a tetramer of pore-forming  $\alpha$ -subunits that alone constitute a fully functional channel (see Figure 1.10, page 39), with associated modulatory  $\beta$ -subunits (Yusifov *et al*, 2008). The  $\beta$ 1 subunit is expressed in mammalian cardiac mitochondria (Ohya *et al*, 2005), and the  $\beta$ 4 subunit is highly expressed throughout brain mitochondria (Piwonska *et al*, 2008) – however, although it is predominantly located to the brain, the  $\beta$ 4 subunit has also been detected in cardiac tissue (Poulsen *et al*, 2009).

The  $\alpha$ -subunits are proposed to form a C-terminal Ca<sup>2+</sup> bowl, containing two Ca<sup>2+</sup>-sensing domains (RCK, regulators of the conductance of potassium, domains), with the voltage-sensing domain located on the external side of the channel (Quin *et al*, 2006) (see Figure 1.11, page 39).

Xu *et al* (2002) first discovered the presence of this channel on the inner mitochondrial membrane of guinea pig ventricular cells, and reported that pharmacological activation of this channel provided protection against ischaemic injury. Since then, mitochondrial BK<sub>Ca</sub> channels have been implicated in cardioprotective mechanisms in several different models including anesthetized dogs and isolated murine hearts (Shintani *et al*, 2004; Wang *et al*, 2004).



**Figure 1.10:** The BK<sub>Ca</sub> channel is formed from a tetramer of  $\alpha$ -subunits (dark blue). Each subunit consists of seven membrane spanning domains (see highlighted light blue section).



**Figure 1.11:** Proposed structure of the BKCa channel subunits. Each  $\alpha$ -subunit (dark blue) has an internal Ca<sup>2+</sup> sensing bowl and an external voltage sensing domain, and a pore is formed between the seventh and eighth membrane spanning domains. One auxiliary  $\beta$ -subunit (light blue) can associate with the N terminal of an  $\alpha$ -subunit.

On separate occasions Cao's group used rat ventricular myocytes and isolated perfused rat hearts to elaborate on the role of the mitochondrial BK<sub>Ca</sub> channel, and

reported that this channel is responsible for triggering cardioprotection of ischaemic preconditioning (Cao *et al*, 2005a) and cardioprotection mediated by the  $\kappa$ -opioid receptor (Cao *et al*, 2005). In the latter study it was also deduced that PKC activation occurs upstream of the mitochondrial BK<sub>Ca</sub> channel, and activation of the mitochondrial BK<sub>Ca</sub> channel is proposed to lead to inhibition of the mPTP (Cao *et al*, 2005; Cheng *et al*, 2008). Several other studies have also implicated protein kinases in the signal transduction pathways leading to mitochondrial BK<sub>Ca</sub> channel activation. In 2007, Gao *et al* reported that the cardioprotective isoflavone puerarin provides protection against ischaemia/reperfusion in isolated perfused rat hearts by activation of PKC and the mitochondrial BK<sub>Ca</sub> channel. However, Sato *et al* (2005) claimed that activation of PKA enhanced NS1619 (BK<sub>Ca</sub> channel opener)-induced flavoprotein oxidation, suggesting that a mechanistic link is present between the two signal transducers. However, no such augmentation was observed with PKC and the BK<sub>Ca</sub> channel. Redel *et al* (2008) also found that PKA was involved in signal transduction leading up to BK<sub>Ca</sub> channel activation, in this case in anaesthetic-induced preconditioning with desflurane. Activation of the BK<sub>Ca</sub> channel is involved in preconditioning triggered by a variety of pharmacological agents including tumour necrosis factor- $\alpha$ , estradiol, the phosphodiesterase type 5 inhibitor sildenafil and the phosphodiesterase type 3 inhibitor cilostazol (Gao *et al*, 2005; Ohya *et al*, 2005; Wang *et al*, 2008; Fukasawa *et al*, 2008), and GPCR agonists such as (-)-U-50488 and adrenomedullin (Cao *et al*, 2005; Nishida *et al*, 2008). However, to date, the role of the BK<sub>Ca</sub> channel in adenosine receptor-mediated signalling has yet to be investigated.

Overall, in simple terms, it can be presumed that pre- and postconditioning are triggered by stimulation of GPCRs, which leads to recruitment of cell survival

protein kinases, and culminates in activation of cytoprotective ion channels. However, the precise mechanisms are still under debate. Any information that could lead to elucidation of cardioprotective signalling would help in the search for effective pharmacological targets against ischaemia and ischaemia/reperfusion injury.

#### **1.8. H9c2 cells and rat ventricle strips – models for studies into cardioprotection**

The H9c2 cell line is derived from embryonic rat heart tissue (Kimes & Brandt, 1976), and is increasingly used as an *in vitro* model of cardiac tissue for studies into cardioprotection as these cells display similar morphological, electrophysiological and biochemical properties to primary cardiac cells (Hescheler *et al*, 1991). It has previously been shown that adenosine can protect against simulated ischaemia in H9c2 cells, although the subtype of adenosine receptor involved in such preconditioning and the type of cell death triggered by ischaemia were not reported (Nagarkitti & Sha'afi, 1998).

H9c2 cells are a useful model for investigating cardiac signal transduction, and also for assessing the cardioprotective potential of pharmacological agents from a cell viability perspective. It is always advisable to compare experimental results from more than one model as discrepancies often occur between different cell, tissue and animal models, so a comparison of data from more than one model gives a more rounded perspective and verification of results. To validate the results obtained from H9c2 cells in this report a model using isolated rat right ventricle strips was utilised.

Rat ventricle strips are a more physiologically relevant model for studies into cardioprotection than H9c2 cells, and are reported to exhibit a larger hypoxia-

induced mechanical impairment than strips from guinea pig or frog ventricles (Joseph *et al*, 2000) – therefore they are ideal for assessing the potential of pharmacological agents to protect against hypoxia. It has been shown that adenosine treatment does not provide any benefit to rat ventricle strips during hypoxia (Varela *et al*, 1999), but preconditioning with adenosine and agonists specific to the adenosine A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> receptors significantly increase the return of mechanical function during reperfusion (Button *et al*, 2005). However, the role of the BK<sub>Ca</sub> channel in preconditioning of rat ventricle strips has not been investigated.

### **1.9. Aims of this project**

The main aims of this project were:

- 1) To establish the functional expression of GPCRs on H9c2 cells, and assess the cytoprotective potential of such receptor activation
- 2) To investigate the role of the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> receptor-mediated signalling in H9c2 cells
- 3) To validate the data obtained from H9c2 cells and research the role of the BK<sub>Ca</sub> channel in adenosine receptor-mediated preconditioning in rat ventricle strips



## 2. Methods

### 2.1. Cell Culture

Rat embryonic cardiomyoblast-derived H9c2 cells (European Collection of Animal Cell Cultures, Salisbury, UK) were cultured in 75 cm<sup>2</sup> flasks in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% (v/v) foetal calf serum, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin. Cells were maintained in a humidified incubator (95% air / 5% CO<sub>2</sub>, 37°C) and grown to 70-80% confluency to avoid differentiation and formation of myotubes. Typically, cells were sub-cultured with a 1:5 split using trypsin (0.05% w/v)/EDTA (0.02% w/v). Cells for functional receptor expression assays were grown in 24 well plates (Sarstedt), cells for LDH assay were grown in 96 well plates (Sarstedt) and cells for caspase-3 analysis and western blot were grown in 60mm culture dishes (Greiner Bio-One).

### 2.2. Functional Expression of GPCRs:

#### i) Measurement of cAMP accumulation

Confluent H9c2 cells were incubated with 500 µl serum-free DMEM and 2 µCi [<sup>3</sup>H]-adenine for 2 hours, then washed twice with Hank's Balanced Salt Solution (HBSS) to remove excess radioactivity. Cells were treated with the phosphodiesterase inhibitor rolipram (10 µM in 500 µl serum-free DMEM) and incubated for 15 minutes in a humidified incubator (95% air / 5% CO<sub>2</sub>, 37°C). Agonists were then added (1:10 dilution) and incubated for a further 15 minutes. When assessing G<sub>i</sub>-coupled receptor activity, the agonists were added 5 minutes prior to a 10 minute incubation period with forskolin (10 µM). If required, cells were pre-treated with antagonists for 15 minutes prior to addition of rolipram. The experiments were

terminated by exchanging the media for 500  $\mu$ l trichloroacetic acid (5% w/v) then plates were wrapped in foil and stored at  $-20^{\circ}\text{C}$ .

Samples were purified by gravitational column chromatography. Dowex columns were pre-washed with 5 ml HCl (1 M) and 20 ml distilled water, alumina columns were pre-washed with 20 ml imidazole (0.1 M). Well content was transferred to the dowex columns and washed through with 3 ml distilled water. The dowex columns were then placed on top of the alumina columns and 4 ml distilled water washed through both sets. 5 ml HCl (1 M) and 20 ml distilled water was then used to wash the dowex columns only, while 5 ml imidazole (0.1 M) was drained through the alumina columns and collected in scintillation vials. The cAMP had now been eluted from the alumina columns so they were washed with 20 ml imidazole (0.1 M). To the vials, 0.5 ml HCl (1 M) and 10 ml liquid scintillant was added (Packard Biosciences). Vials were shaken and activity read using a liquid scintillation counter (Packard Tri-Carb Liquid Scintillation Analyser). For reference, see Cordeaux *et al* (2000).

#### ii) **Inositol trisphosphate Assay**

Confluent H9c2 cells were pre-labelled with 3  $\mu\text{Ci}$  [ $^3\text{H}$ ] *myo*-inositol in 500  $\mu$ l serum-free DMEM for 24 hours. Excess radioactivity was then removed by two washes with HBSS, and then cells were incubated with LiCl (20 mM) in 500  $\mu$ l serum-free DMEM for 30 minutes in a humidified incubator (95% air / 5%  $\text{CO}_2$ ,  $37^{\circ}\text{C}$ ). Without removing the LiCl the cells were further incubated with  $G_q$  agonist for 30 minutes (1:10 dilution). Reactions were stopped by replacing the media with 1 ml termination mix (6 ml concentrated HCl in 500 ml  $\text{dH}_2\text{O}$  added to 500 ml methanol; pH 2-3).

Samples were purified by anion-exchange chromatography. HCl (10 ml; 1 M) was washed through the columns followed by 20 ml distilled water. Samples were then added to 4 ml neutralising solution (0.5 M NaOH, 25 mM Tris; pH 7) and run through the columns; 20 ml distilled water followed. 10 ml of ammonium formate (25 mM) was drained through then the columns were placed above scintillation vials. 3 ml HCl (1 M) was run through into the vials then 10 ml liquid scintillant was added before reading the radioactivity using a liquid scintillation counter (Packard Tri-Carb Liquid Scintillation Analyser). For reference, see White *et al* (1992).

### **2.3. Protection against hypoxia- and hypoxia/reoxygenation-induced cell death: Experimental protocol**

80% confluent H9c2 cells in glucose and serum-free DMEM were exposed to hypoxia (5% CO<sub>2</sub>/0.5% O<sub>2</sub>; 37°C) for 6 hours (NB. this time varied for time-course experiments) before performance of the appropriate cell viability assay. Normoxic incubation was used for controls.

Where pharmacological preconditioning was required, cells were incubated with GPCR agonist or potassium channel opener in 200 µl (when using microplates) / 2 ml (when using culture dishes) serum-free DMEM for 30 minutes; this medium was then discarded and replaced with 200 µl / 3 ml glucose and serum-free DMEM for the hypoxic/normoxic incubation. When required, cells were also treated with antagonist or potassium channel blocker for 15 minutes prior to the addition of agonist or channel opener.


For hypoxia-reoxygenation experiments, cells were exposed to hypoxia for 6 hours as before, and then reoxygenated for 18 hours in 200  $\mu$ l / 3 ml DMEM containing glucose and 1% serum. Preconditioning occurred prior to hypoxia, postconditioning occurred at the start of reoxygenation – treatment protocol as before (see Figure 2.1 for summary)

### Hypoxia



### Hypoxia/Reoxygenation

#### Pre-conditioning



#### Post-conditioning




Figure 2.1: Protocol for hypoxia and hypoxia/reoxygenation experiments

**i) MTT Assay**

H9c2 cells were cultured in 96 well flat bottom plates, at a density of 5000 cells/well, for 24 hours in fully supplemented DMEM. Incubations were performed in 200ul glucose/serum-free DMEM, then cell viability measured by colorimetric assessment of the mitochondrial reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to a coloured formazan product. Cells were incubated for 1 hour (37°C) in 0.5 mg/ml MTT. Solution was then aspirated away and replaced with 100 µl DMSO. Plates were shaken to solubilise the formazan product then absorbance read at 570nm using a standard plate reader (Model 680, Bio-Rad). Results expressed as percentage of basal MTT reduction.

**ii) Lactate dehydrogenase (LDH) Assay**

H9c2 cells were cultured in 96 well flat bottom plates, at a density of 5000 cells/well, for 24 hours in fully supplemented DMEM. Incubations were performed in 200 µl of the appropriate medium then cell death measured using the colorimetric CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). This kit allows LDH release to be measured via a coupled chemical reaction that leads to formation of a coloured formazan product. Firstly, LDH released from the cells catalyses the formation of pyruvate and NADH from lactate and NAD<sup>+</sup>. The secondary reaction is catalysed by the dehydrogenase enzyme diaphorase (present in the substrate mix), and involves the formation of NAD<sup>+</sup> and a red formazan product from NADH and a tetrazolium salt. LDH release is proportional to the red formazan product, which is measured using a standard plate reader (Model 680, Bio-Rad).

Plates were centrifuged to compact any cell debris to the bottom of the wells (5 minutes at 300 g), and then 50  $\mu$ l of supernatant was transferred to a non-sterile 96 well plate ("assay plate"; Greiner Bio-One). A further 60  $\mu$ l of the supernatant was discarded before 10  $\mu$ l of 10x lysis buffer (9% v/v Triton<sup>®</sup> X-100, provided with kit) was added to the remaining 90  $\mu$ l. Following 45 minutes incubation at 37°C, the plates were centrifuged for 5 minutes at 300 g. As before, 50  $\mu$ l of supernatant was added to the assay plate. Reconstituted assay buffer (50  $\mu$ l; provided in the kit) was added to each well, and then the assay plates were wrapped in foil and agitated for 30 minutes at room temperature. To terminate the reactions, 50  $\mu$ l of stop solution (1 M acetic acid, provided with kit) was dispensed into each well; absorbance was then read at 490nm.

LDH release was calculated as a percentage of total LDH, and results are presented as LDH release as a percentage of basal release (acquired from untreated controls).

### **iii) Caspase-3 Assay**

Cells were cultured in 60 mm dishes, until confluent, in fully supplemented DMEM. Where appropriate, treatments were performed in 2 ml serum-free DMEM, this was replaced with 3 ml glucose/serum-free DMEM for the 6 hours incubation in hypoxia or normoxia. When the incubation period was over phosphate buffered saline (PBS) was used to wash the cells which were then trypsinised and centrifuged for 10 minutes at 300 g to obtain a cell pellet. Supernatant was discarded and pellets were stored at -20°C until required for the caspase-3 assay.

Cell pellets were resuspended in 120  $\mu$ l lysis buffer (25 mM HEPES, 2.5 mM CHAPS, 2.5 mM DTT, pH 7.4) and incubated on ice for 20 minutes. Lysate was



then centrifuged for 10 minutes (4°C, 14000 rcf) and supernatant collected and stored on ice. Supernatant (30 µl) was added to a black microplate (Greiner Bio-One) along with 50 µl assay buffer (20 mM HEPES, 5 mM DTT, 0.1% CHAPS, 2 mM EDTA, pH 7.4) and 20 µl substrate (0.5 mM, Acetyl-Asp-Glu-Val-Asp-7-Amido-Methyl Coumarin). For blanks, assay buffer replaced supernatant.

Fluorescence was read over a 2 hour period resulting in a linear relationship between time and caspase-3 activity (FLUOstar Optima, BMG Labtech). In combination with the protein assay, caspase-3 activity per minute per µg protein (Ufluo/min/µg) was calculated and expressed as percentage of basal activity.

#### iv) DC Lowry Protocol – Protein Assay

Protein content of samples was measured using the DC Lowry Protocol (reagents from the Bio-Rad DC Protein Assay range) using bovine serum albumin standards (BSA). Standards were prepared with 2 mg/ml BSA to produce a calibration curve as below (table 2.1), to ensure that the relationship between protein content and absorbance was linear.

**Table 2.1: BSA standard curve**

Protein mg/ml	µl protein standard	µl dH2O
0.0	0	>10
0.2	20	180
0.4	40	160
0.5	50	150
0.8	80	120
1.0	100	100
1.5	150	50
2.0	>10	0

5 µl of standards and samples were added to a 96-well flat bottom plate in duplicate. 25 µl of reagent A' (comprising of 20 µl Reagent S to 1 ml Reagent A; BioRad) and 200 µl of Reagent B (BioRad) was added to each well and then plates were covered in foil and agitated for 15 minutes. Absorbance was read at 750nm using a standard plate reader (Model 680, Bio-Rad).

Protein content of the samples was obtained by manipulation of the equation of the standard curve; results expressed as µg protein/µl.

#### **2.4. Western blot analysis of BK<sub>Ca</sub> channel subunit expression and protein kinase phosphorylation**

For the determination of BK<sub>Ca</sub> channel subunit expression isolated mitochondrial, cytoplasmic and whole cell protein fractions (isolated by subcellular fractionation, see section 2.9) were mixed two parts to one part sample buffer (Cell Signalling Technology). For the assessment of protein kinase activation H9c2 cells were exposed to the conditions and treatments described previously and stated in the figure legends. Following stimulation cell supernatants were removed and the cells washed twice with ice-cold PBS and lysed in ice-cold lysis buffer (100 µl; 150 mM NaCl, 50 mM Tris.HCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS (sodium dodecyl sulphate), 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM NaF, 1 mM benzamide, 0.1 mM phenylmethylsulphonylfluoride (PMSF), 10 µg/ml aprotinin and 5 µg/ml leupeptin). Cell lysates were cleared by centrifugation (5 minutes; 12,000 g; 4°C), the supernatant collected and mixed two parts to one part sample buffer – with an aliquot of the supernatant taken for analysis of protein content. Samples were boiled at 95°C for 5 minutes and thoroughly vortexed to

ensure protein denaturation, and then stored at  $-20^{\circ}\text{C}$ . Protein concentration was determined using Bio-Rad *DC* Protein assay as described above and protein samples separated by Sodium Dodecyl Sulphate/Polyacrylamide Gel Electrophoresis (SDS/PAGE) using a Bio-Rad Mini-Protean II system.

Equipment was set up according to the manufacturers' instructions and 20 ml of 12% acrylamide solution made per two gels (6.6 ml  $\text{dH}_2\text{O}$ , 8.0 ml 30% Acrylamide mix, 5.0 ml 1.5 M Tris buffer, 200  $\mu\text{l}$  10% SDS solution, 200  $\mu\text{l}$  10% ammonium persulphate (APS) solution, 20  $\mu\text{l}$  TEMED) – APS and TEMED are responsible for initiating gel polymerisation so were added last. The unpolymerised acrylamide gel solution was pipetted between two glass plates held together in the BioRad equipment, with a gap at the top being left for  $\text{dH}_2\text{O}$  to ensure level setting of the gel. Once the gel had set, the water was poured off and replaced with stacking gel (for two gels: 4.1 ml  $\text{dH}_2\text{O}$ , 1.0 ml 30% Acrylamide mix, 750  $\mu\text{l}$  1.5 M Tris buffer, 60  $\mu\text{l}$  SDS solution, 60  $\mu\text{l}$  APS, 6  $\mu\text{l}$  TEMED) and a plastic comb to form wells. The equipment was placed into the lower buffer chamber with electrophoresis buffer (24.8 mM Tris base, 192 mM Glycine, 3.5 mM SDS), ensuring that the buffer did not leak from between the two gels. Once the stacking gels had set the combs were removed and samples were loaded into the wells (20-30  $\mu\text{g}$ /well depending on target protein). The circuit was then run for 45 minutes at 200 V.

Separated proteins were transferred to nitrocellulose membranes using a Bio-Rad Trans-Blot system (1 hour at 100 V in 25 mM Tris base, 192 mM glycine and 20% MeOH). Following transfer, nitrocellulose membranes were stained with Poncea S (Sigma) and the appropriate band size identified and cut from the rest of the membrane. The desired strips of membrane were washed with the pH buffer Tris-

buffered saline (TBS) and blocked for 1 hour at room temperature in blocking buffer (TBS, 5% (w/v) skimmed milk powder, 0.1% Tween-20). Membranes were then incubated overnight at 4°C in blocking buffer with the following primary antibodies: cytochrome *c* (Santa Cruz Biotechnology; 1:500); BK<sub>Ca</sub> channel  $\alpha$  subunit (Becton Dickinson; 1:250), BK<sub>Ca</sub> channel  $\beta$ 4 subunit (Sigma-Aldrich; 1:250), phospho-specific ERK1/2 (Thr<sup>202</sup>/Tyr<sup>204</sup>; Sigma Aldrich; 1:1000), and phospho-specific PKB (Ser<sup>473</sup>; New England Biolabs (U.K.) Ltd; 1:500). The next day the primary antibody was removed and the membrane extensively washed three times for 10 minutes in TBS/Tween 20. Blots were then incubated for 1 hour at room temperature with the appropriate secondary antibody (1:1000) coupled to horseradish peroxidase (DAKO Ltd, Cambridge, UK) in blocking buffer. Following removal of the secondary antibody, blots were extensively washed as above and developed using the Enhanced Chemiluminescence Detection System (Amersham Pharmacia Biotech, Little Chalfont, UK) and quantified by densitometry using GeneGenius BioImaging System (Syngene, Synoptics Ltd, UK). Replicate samples from each experiment were analysed on separate blots using total unphosphorylated ERK1/2 (New England Biolabs (U.K.) Ltd; 1:1000) and PKB (New England Biolabs (U.K.) Ltd; 1:1000) primary antibodies in order to confirm the uniformity of protein loading.

## **2.5. Subcellular fractionation**

H9c2 cells were grown in 125 cm<sup>2</sup> culture flasks; to obtain enough protein 3 flasks were used per experiment. Once confluent cells were detached using trypsin and then centrifuged for 5 minutes at 300 g. The supernatant was discarded and the cell pellet resuspended in 1 ml PBS and centrifuged again (5 minutes, 300 g). This process was repeated, then the cell pellet was transferred to a Dounce tissue grinder

tube (Sigma) kept on ice using a Pasteur pipette and homogenised 10 times with grinder A and 10 times with grinder B (Sigma; each time consisting of one clockwise rotation of the grinder). The cell homogenate was resuspended in 500  $\mu$ l of extraction buffer (10 mM HEPES, 1 mM EGTA, 200 mM mannitol, 1 mM sucrose) and transferred to a 2 ml centrifuge tube labelled "nucleus", then centrifuged for 5 minutes at 300 g (4°C). The supernatant was transferred to a 2 ml centrifuge tube labelled "mitochondria", with 100  $\mu$ l being saved as total extract. The nuclear pellet was resuspended in 500  $\mu$ l of extraction buffer and centrifuged for 10 minutes at 1000 g (4°C). The supernatant was again transferred to the mitochondria tube, and then the nuclear pellet was discarded. The mitochondrial fraction was centrifuged for 15 minutes at 10,000 g (4°C) then the supernatant was transferred to a 2 ml centrifuge labelled "cytoplasm". The mitochondrial pellet was resuspended in 500  $\mu$ l extraction buffer and centrifuged for 10 minutes at 10,000 g (4°C). The supernatant was again transferred to the cytoplasmic extract tube and the mitochondrial pellet resuspended in 100  $\mu$ l extraction buffer. All fractions were then stored at -20°C until required.

## **2.6. Right Ventricle Strip Preparation**

All experiments were performed on adult Wistar rats of either sex which were executed by cervical dislocation in accordance with the Animals (Scientific Procedures) Act 1986. Hearts were rapidly removed and placed in ice-cold Krebs solution (119 mM NaCl, 25 mM NaHCO<sub>3</sub>, 11.1 mM D-glucose, 4.7 mM KCl, 2.5 mM CaCl<sub>2</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 1.0 mM MgSO<sub>4</sub>). One strip from the right ventricle wall (approximately 2 mm x 10 mm) was isolated per heart and then longitudinally attached to platinum electrodes and isometric force transducers. The strips were

placed under 2 g tension in a tissue bath (Harvard Single Heated Tissue Bath) containing 40 ml gassed Krebs (95% O<sub>2</sub>-5%-CO<sub>2</sub>, 37°C) and electrically stimulated at a frequency of 1 Hz (Ealing Dual Pulse Student Stimulator). Contractions were measured on a chart recorder (Harvard Student Oscillograph). All strips were equilibrated for 40 minutes in gassed Krebs (95% O<sub>2</sub>-5% CO<sub>2</sub>, 37°C) before drug challenge. Hypoxia was simulated by replacing the medium with gassed glucose-free Krebs (95% N<sub>2</sub>-5% CO<sub>2</sub>, 37°C). Normalisation of data controlled for variation of data due to ventricle thickness.

### **Experimental protocol:**

Following the equilibration period, control strips were exposed to 30 minutes oxygenation followed by 30 minutes hypoxia and finally 30 minutes reoxygenation – this treatment protocol was previously established by members of my research group, therefore deemed appropriate for use with this current project (Button *et al*, 2005).

If appropriate, CPA or NS1619 was added to the medium for the final 2 minutes of oxygenation. When using DPCPX, Paxilline or Iberitoxin the required drug was added at the start of oxygenation and remained there for the 30 minutes duration.

For hypoxic preconditioning, ventricle strips were equilibrated for 40 minutes as usual, and then exposed to a 10 minute preconditioning period of hypoxia followed by 20 minutes oxygenation, 30 minutes hypoxia and finally 30 minutes reoxygenation. When using iberitoxin the drug was added after for the final 30 minutes of the equilibration. All drugs were washed out following treatment and no drugs were present during hypoxia or reoxygenation. See figure 2.2 for summary.




Figure 2.2: Protocol for rat ventricle hypoxia/reoxygenation experiments



## 2.7. Data analysis

GraphPad Prism 5 was used for all statistical analysis. The one-way ANOVA (analysis of variance) test was used to compare two or more sets of data, with the two-way ANOVA being used to compare grouped sets of data. Tukey's Multiple Comparison Post Test was used to further analyse the data to uncover where any significance lay. Significance was classed as  $p < 0.05$  and highlighted with an asterix; all data is presented as mean  $\pm$  S.E.M.

## 2.8. Materials

Acetyl-Asp-Glu-Val-Asp-7-Amido-Methyl Coumarin, acetylcholine, 30% acrylamide mix, adenosine, ATP (adenosine triphosphate), baclofen, BSA (bovine serum albumin), D-glucose, DPCPX (8-Cyclopentyl-1,3-dipropylxanthine), forskolin, histamine, imidazole, isoprenaline, lithium chloride, MRS1220 (N-[9-Chloro-2-(2-furanyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-yl]benzene acetamide), noradrenaline, NS1619 (1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one), PTX (pertussis toxic), rolipram, SDS (sodium dodecyl sulphate), TEMED (N,N,N',N'-Tetramethylethylenediamine), TCA (trichloroacetic acid), staurosporine, and UTP (uridine triphosphate) were all obtained from Sigma-Alrich.

(-)-U-50488 (( $\pm$ )-U-50488 hydrochloride; trans-( $\pm$ )-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride), CGS (CGS 21680 hydrochloride; 4-[2-[[6-Amino-9-(N-ethyl-b-D-ribofuranuronamidoyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride), CI-IB-MECA (2-CI-IB-MECA; 1-[2-Chloro-6-[[3-iodophenyl]methyl]amino]-9H-purin-9-yl]-1-deoxy-N-

methyl-b-D-ribofuranuronamide), CPA (*N*<sup>6</sup>-Cyclopentyladenosine), dobutamine (dobutamine hydrochloride; 4-[2-[[3-(4-Hydroxyphenyl)-1-methylpropyl]aminoethyl-1, 2-benzenediol hydrochloride], iberiotoxin, *nor*-BNI (*nor*-Binaltorphimine dihydrochloride; 17,17'-(Dicyclopropylmethyl)-6,6',7,7'-6,6'-imino-7,7'-binorphan-3,4',14,14'-tetrol dihydrochloride), paxilline, procaterol and SNC 80 ((+)-4-[(aR)-a-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) were all obtained from Tocris Biosciences.

All cell culture agents, unless stated, were obtained from Cambrex. Glucose-free DMEM was obtained from Invitrogen, and FBS (foetal bovine serum) was obtained from BioSera.

[<sup>3</sup>H]-adenine was obtained from Amersham Biosciences; [3H]-myo-inositol was obtained from M.P Biomedicals.

Antibodies were obtained from the following suppliers: monoclonal BK<sub>Ca</sub> channel  $\alpha$  subunit from Beckon-Dickinson; polyclonal BK<sub>Ca</sub> channel  $\beta$ 4 subunit and monoclonal phospho-specific ERK1/2 (Thr<sup>202</sup>/Tyr<sup>204</sup>) from Sigma-Aldrich; polyclonal phospho-specific PKB (Ser<sup>473</sup>), monoclonal total unphosphorylated ERK1/2 and polyclonal total unphosphorylated PKB from New England Biolabs (U.K.) Ltd; and monoclonal cytochrome *c* from Santa Cruz Biotechnology. All other chemicals were of analytical grade.

### 3. Functional GPCR studies

#### 3.1. Functional expression of adenosine receptors on H9c2 cells

Adenosine is released from myocardial tissue during ischaemia or ischaemia/reperfusion (I/R), exerting cardioprotective effects against ischaemic injury/damage caused by reperfusion (Mubagwa & Flameng 2001; Fryer *et al*, 2002). Cardiomyocytes have been shown to express the adenosine A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> receptor subtypes (Germack & Dickenson, 2004; for review see Peart & Headrick, 2007), but the presence of functional adenosine receptors on H9c2 cells has not been reported. In this study GPCR expression on H9c2 cells has been investigated by measuring the effects of selective receptor agonists and antagonists on [<sup>3</sup>H]-cAMP accumulation.


CPA, the selective A<sub>1</sub> receptor agonist, gave a modest inhibition of forskolin-induced cAMP accumulation (maximum inhibition occurring at 100 nM; 22.0 ± 4.2%; n=6; see Fig.3.1) but at higher concentrations produced a significant augmentation of cAMP-accumulation (maximum effect at 10 μM, 288 ± 56%, n=5, p<0.01). CGS 21680, the adenosine A<sub>2A</sub> receptor agonist, did not increase cAMP accumulation (see Fig.3.2). CI-IB-MECA, the G<sub>i</sub>-coupled A<sub>3</sub> receptor agonist (up to 1 μM), had no effect on forskolin-stimulated cAMP accumulation. However, 10 μM CI-IB-MECA induced a significant increase in cAMP accumulation (179.6 ± 15% compared to forskolin response alone = 100%, n=5, p<0.05, see Fig.3.3).

The inhibition afforded by CPA was reversed by pertussis toxin (PTX), a specific blocker of G<sub>i</sub> protein (119.1 ± 4% of forskolin response in the presence of PTX; n=6; see Fig.3.4), and by the adenosine A<sub>1</sub> receptor antagonist DPCPX (107.4 ± 7% of forskolin response in the presence of DPCPX; n=4; see Fig.3.4).


The augmentation of cAMP accumulation induced by CI-IB-MECA was blocked by the adenosine A<sub>1</sub> receptor antagonist DPCPX (112.2 ± 7% of forskolin response in the presence of DPCPX; n=4; see Fig.3.5) but not significantly by the adenosine A<sub>3</sub> receptor antagonist MRS 1220 (130.8 ± 11% of forskolin response in the presence of MRS 1220; n=4; see Fig.3.5).

These data suggest that H9c2 cells functionally express G<sub>i</sub>-coupled adenosine A<sub>1</sub> receptors, but not adenosine A<sub>2A</sub> or A<sub>3</sub> receptors, and that at high agonist concentrations the adenosine A<sub>1</sub> receptor can also couple to G<sub>s</sub> protein.


(a)




(b)



**Figure 3.1: CPA-mediated effects on forskolin-induced cAMP accumulation in H9c2 cells.** Cells were pre-treated with the indicated concentrations of the selective adenosine A<sub>1</sub> receptor agonist CPA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin response (=100%). Each point represents mean  $\pm$  S.E.M. of 5 separate experiments each performed in triplicate. (b) is an enlargement of the frame in (a). \*  $p < 0.05$  vs. forskolin alone response; \*\*  $p < 0.01$  vs. forskolin alone response.




**Figure 3.2: CGS 21680-mediated cAMP accumulation in H9c2 cells.** Cells were treated with the indicated concentrations of the selective adenosine  $A_{2A}$  receptor agonist CGS 21680 hydrochloride for 15 minutes. Data expressed as percentage of basal cAMP accumulation (=100%). Each point represents mean  $\pm$  S.E.M of 6 separate experiments each performed in triplicate.




**Figure 3.3: CI-IB-MECA-mediated effects on forskolin-induced cAMP accumulation in H9c2 cells.** Cells were pre-treated with the indicated concentrations of the adenosine A<sub>3</sub> receptor agonist CI-IB-MECA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin response (=100%). Each point represents mean  $\pm$  S.E.M. of 5 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. forskolin alone response.



(a)




(b)




**Figure 3.4: The effect of pertussis toxin (PTX) and DPCPX on CPA-induced inhibition of forskolin-mediated cAMP accumulation in H9c2 cells.** (a) Control and PTX-treated cells (100 ng/ml; 16 hours) were pre-treated with 100 nM CPA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. (b) Control and DPCPX-treated cells (10  $\mu$ M) were pre-treated with 100 nM CPA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin control response (=100%). Each point represents mean  $\pm$  S.E.M. of 4 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. forskolin alone response.

(a)



(b)



**Figure 3.5: The effect of MRS 1220 and DPCPX on CI-IB-MECA-induced augmentation of forskolin-mediated cAMP accumulation.** (a) Control and MRS 1220-treated cells (10  $\mu$ M) were pre-treated with 10  $\mu$ M CI-IB-MECA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. (b) Control and DPCPX-treated cells (10  $\mu$ M) were pre-treated with 10  $\mu$ M CI-IB-MECA for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin control response (=100%). Each point represents mean  $\pm$  S.E.M. of 4 separate experiments each performed in triplicate. \*\*\*  $p < 0.001$  vs. forskolin alone response.


### 3.2. Functional expression of opioid receptors on H9c2 cells

It has been shown that during periods of stress (e.g. cardiac ischaemia) the synthesis and release of some opioid peptides are increased, leading to modulation of response and cytoprotection (Clement-Jones *et al* 1980; Falcone *et al* 1993). The receptors are widely distributed throughout the central nervous system and periphery; it has been reported that the  $\kappa$ - and  $\delta$ -opioid receptors are the dominant subtypes present in rat heart (Zimlichman *et al*, 1996), and there is supporting data for the involvement of both receptors in cardioprotection (Valtchanova-Matchouganska & Ojewole, 2003). The presence of functional  $\kappa$ - and  $\delta$ -opioid receptors on H9c2 cells has not been reported, so this study investigated this by measuring the effects of selective receptor agonists and antagonists on [<sup>3</sup>H] - cAMP accumulation.

The  $\delta$ -opioid receptor agonist SNC 80 had no effect on forskolin-induced cAMP accumulation (see Fig.3.6), whereas the  $\kappa$ -opioid agonist (-)-U-50488 induced a robust inhibition (maximal inhibition occurring at 1  $\mu$ M,  $25.5 \pm 7.4\%$ ,  $n=4$ ,  $p<0.05$ , see Fig.3.7). The G<sub>i</sub>-protein blocker PTX attenuated (-)-U-50488-mediated inhibition of cAMP accumulation ( $15 \pm 2.6\%$  reduction of forskolin response in the presence of PTX compared to  $27.5 \pm 4.1\%$  reduction of forskolin response seen in controls,  $n=4$ , see Fig.3.8a) and the selective kappa-opioid receptor antagonist *nor*-Binaltorphimine completely reversed (-)-U-50488-mediated inhibition of cAMP accumulation ( $112.4 \pm 11.4\%$  of forskolin response in the presence of *nor*-BIN,  $n=4$ , see Fig.3.8b).

Overall, these data suggest that H9c2 cells functionally express G<sub>i</sub>-coupled  $\kappa$ -opioid receptors, but not  $\delta$ -opioid receptors.





**Figure 3.6: SNC 80-mediated effect on forskolin-induced cAMP accumulation in H9c2 cells.** Cells were pre-treated with the indicated concentrations of the selective  $\delta$ -opioid receptor agonist SNC 80 for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin response (=100%). Each point represents mean  $\pm$  S.E.M. of 4-6 separate experiments each performed in triplicate.






Figure 3.7: (-)-U-50488-mediated effect on forskolin-induced cAMP accumulation in H9c2 cells. Cells were pre-treated with the stated concentrations of the selective  $\kappa$ -opioid receptors agonist for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin response (=100%). Each point represents mean  $\pm$  S.E.M of 5 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. forskolin alone response.

(a)



(b)




**Figure 3.8: The effects of PTX and nor-BIN on (-)-U-50488-mediated inhibition of forskolin-induced cAMP accumulation in H9c2 cells.** (a) Control and PTX-treated cells (100 ng/ml; 16 hours) were pre-treated with 1  $\mu$ M (-)-U-50488 for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. (b) Control and nor-BIN-treated cells (10  $\mu$ M) were pre-treated with 1  $\mu$ M (-)-U-50488 for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin control response (=100%). Each point represents mean  $\pm$  S.E.M. of 5 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. forskolin alone response.

### 3.3. Functional expression of beta-adrenergic receptors on H9c2 cells

During ischaemia it is well accepted that catecholamines, such as noradrenaline, are released and consequential activation of G protein-coupled adrenergic receptors occurs. The presence of both the  $\beta_1$  and  $\beta_2$  subtypes has been demonstrated on H9c2 cells using radioligand binding studies (Dangel *et al*, 1996) and using antibody imaging (Ianoul *et al*, 2005). In this study, the presence of functional beta-adrenergic receptors on H9c2 cells was investigated by measuring the effects of selective receptor agonists and on [ $^3$ H]-cAMP accumulation.


The non-selective  $\beta$ -adrenergic receptor agonist isoprenaline stimulated a concentration-dependent increase in cAMP accumulation (maximal effect occurring at 100 nM;  $622 \pm 117\%$  basal response;  $n = 4$ ; see Fig.3.9). The selective  $\beta_1$  agonist dobutamine stimulated cAMP accumulation to an extent (10  $\mu$ M induced  $174 \pm 57\%$  basal response;  $n=4$ ; see Fig.3.10), however, a larger response was seen from the selective  $\beta_2$  agonist procaterol (1  $\mu$ M induced  $203 \pm 29\%$  basal response,  $n=4$ ; 10  $\mu$ M induced  $598 \pm 150\%$  basal response;  $n=4$ ; see Fig.3.11).

These data suggest that the  $G_s$ -coupled  $\beta_2$  adrenergic receptor could be present on H9c2 cells, but the presence of a functional  $\beta_1$  adrenergic receptor is less clear.




**Figure 3.9: The effect of isoprenaline on cAMP accumulation in H9c2 cells.** Cells were treated with the indicated concentrations of isoprenaline for 10 minutes. Data expressed as the percentage of basal response (=100%). Each point represents mean  $\pm$  S.E.M of 4 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. basal response, \*\*  $p < 0.01$  vs. basal response.





**Figure 3.10: The effect of dobutamine on cAMP accumulation in H9c2 cells.** Cells were treated with the indicated concentrations of the  $\beta_1$  receptor agonist dobutamine for 10 minutes. Data expressed as the percentage of basal response (=100%). Each point represents mean  $\pm$  S.E.M of 4 separate experiments each performed in triplicate.



**Figure 3.11:** The effect of procaterol on cAMP accumulation in H9c2 cells. Cells were treated with the indicated concentrations of the  $\beta_2$  receptor agonist procaterol for 10 minutes. Data expressed as the percentage of basal response (=100%). Each point represents mean  $\pm$  S.E.M of 4 separate experiments each performed in triplicate. \*  $p < 0.05$  vs. basal response.

### 3.4: Functional expression of other G<sub>i</sub> and G<sub>q</sub> protein-coupled receptors on H9c2 cells

The presence of a selection of other GPCRs on H9c2 cells was also investigated as, to date, an extensive functional study has not been reported.

Firstly, the effects of baclofen and acetylcholine on forskolin-induced cAMP accumulation were tested. Baclofen is an agonist at the G<sub>i</sub>-coupled GABA<sub>B</sub> receptor, which has been found to be expressed in mammalian heart and exert a cardioprotective effect during ischaemia (Lorente *et al*, 2000). In H9c2 cells this agent provided some inhibition of cAMP accumulation, but not to a statistically significant level (maximal inhibition occurring at 10 nM,  $83 \pm 9\%$  of forskolin response = 100%, n=4, p>0.05, see fig.3.12a). Therefore, functional expression of this receptor on H9c2 cells is debatable.

There are several subtypes of acetylcholine receptor, and the G<sub>i</sub>-coupled muscarinic M<sub>2</sub> subtype is known to have parasympathetic effects in the heart. However, no significant effect on cAMP accumulation was observed from acetylcholine suggesting that the muscarinic M<sub>2</sub> receptor is not functionally expressed on H9c2 cells (see fig.3.12).

It was also decided to test a range of agonists at G<sub>q</sub>-coupled receptors by measuring the accumulation of radiolabelled inositol trisphosphate (IP<sub>3</sub>) following receptor stimulation. As previously mentioned, mammalian cardiomyocytes express G<sub>i</sub>-coupled M<sub>2</sub> receptors, but there is also evidence supporting the expression of G<sub>q</sub>-coupled M<sub>1</sub> receptors (Sharma *et al*, 1997). Acetylcholine did stimulate an increase in IP<sub>3</sub> accumulation in H9c2 cells, but not significantly implying that the G<sub>q</sub>-coupled

muscarinic receptors may not be functionally expressed (100  $\mu$ M, 132  $\pm$  12% of control = 100%, n=6, p>0.05, see fig.3.13).

Histamine H<sub>1</sub> receptors predominantly couple to G<sub>q</sub> protein, but there is evidence stating that the H<sub>2</sub> receptor can also bind G<sub>q</sub> protein (Kühn *et al*, 1996). Both of these subtypes have been found to have a role in the mediation of the effects of histamine in the heart (Flynn *et al*, 1979), but this study found no evidence for functional expression of a histamine receptor on H9c2 cells (100  $\mu$ M, 94  $\pm$  8% of control = 100%, n=6, p>0.05, see fig. 3.13).


As mentioned previously, catecholamines such as noradrenaline are released from cardiac tissue during ischaemia; it has been found that G<sub>q</sub>-coupled  $\alpha_{1A}$ ,  $\alpha_{1B}$  and  $\alpha_{1D}$ -adrenergic receptors are all expressed in rat heart, with the  $\alpha_{1B}$  receptor being the predominant subtype and mainly responsible for the cardioprotective effects of  $\alpha$ -adrenergic receptor agonism (Gao *et al*, 2007). Treatment of H9c2 cells with noradrenaline did result in a sizeable increase in IP<sub>3</sub> accumulation – but this was not statistically significant (100  $\mu$ M, 150  $\pm$  15% of control = 100%, n=4, p>0.05, see fig. 3.13).

Cardiac ischaemia stimulates the release of ATP and UTP, which then activate purinergic P2Y receptors. The expression of P2Y<sub>4</sub> receptors, which preferentially bind UTP, is low in the heart but the expression of P2Y<sub>2</sub> (equal affinity for ATP and UTP) and P2Y<sub>11</sub> (preferentially bind ATP) is high (Erlinge & Burnstock, 2008). Although ATP did not elicit an increase in IP<sub>3</sub> accumulation in H9c2 cells (100  $\mu$ M, 103  $\pm$  15% of control = 100%, n=6, p>0.05, see fig.3.13), UTP gave a sizeable response (100  $\mu$ M, 199  $\pm$  15% of control = 100%, n=4, p<0.01, see fig.3.13). This


suggests that one or more of the UTP-binding receptors are functionally expressed on H9c2 cells.

In conclusion, these data provide evidence for the functional expression of  $G_i$ -coupled adenosine  $A_1$  and  $\kappa$ -opioid receptors,  $G_s$ -coupled  $\beta_2$  adrenergic receptors and  $G_q$ -coupled UTP-binding P2Y purinergic receptors on H9c2 cells.


(a)



(b)



**Figure 3.12: The effects of baclofen and acetylcholine of forskolin-induced cAMP accumulation in H9c2 cells.** Cells were pre-treated with the indicated concentrations of (a) the GABA<sub>B</sub> receptor agonist baclofen or (b) the muscarinic receptor agonist ACh for 5 minutes prior to the addition of 10  $\mu$ M forskolin for a further 10 minutes. Data expressed as the percentage of forskolin response (=100%). Each point represents mean  $\pm$  S.E.M. of 4 separate experiments each performed in triplicate.



**Figure 3.13: The effects of selected agonists on inositol phosphate accumulation in H9c2 cells.** Cells were incubated with the selected agonists (noradrenaline (NA), ATP, UTP, histamine (HA), ACh all at 100  $\mu$ M) for 30 minutes. Data expressed as the percentage of basal response (=100%). Each point represents mean  $\pm$  S.E.M. of 4 separate experiments each performed in triplicate.

## 4. Cardioprotective potential of functionally expressed receptors on H9c2 cells

### 4.1. Determining the effects of GPCR agonists against hypoxia-induced cell death in H9c2 cells

As mentioned in the previous chapter, all of the GPCRs found to be functionally expressed on H9c2 cells have been implicated in cardioprotective mechanisms so it was important to assess such properties in this cell line. Initially it was necessary to investigate the effect of hypoxia upon H9c2 cells, allowing the ideal length of time in hypoxia to be chosen for further experiments involving pharmacological preconditioning.

Cell death was measured following 1, 2, 4, 6, 8 and 24 hours in hypoxia (0.5% O<sub>2</sub>) using assays to measure MTT reduction, LDH release and caspase-3 activity (see fig.4.1). 6 hours of hypoxia was chosen for further experiments as it produced a large response in all of the assays (MTT reduction was decreased to  $33 \pm 8\%$  of control,  $n=4$ ,  $p<0.01$ ; LDH release was increased to  $352 \pm 101\%$  of control,  $n=4$ ; caspase-3 activity was increased to  $235 \pm 19\%$  of control,  $n=4$ ,  $p<0.05$ ) and allowed a whole experiment with preconditioning and viability assay to be completed in a working day.

The adenosine A<sub>1</sub> receptor agonist CPA (100 nM) was the only drug to increase MTT reduction during hypoxia ( $123 \pm 24\%$  compared to  $65 \pm 13\%$  = hypoxic control,  $n=4$ ,  $p<0.05$ , see fig.4.2a). Interestingly, the  $\beta_2$  adrenergic receptor agonist procaterol (10  $\mu$ M) significantly increased MTT reduction during normoxia ( $164 \pm 34\%$  compared to normoxic control = 100%,  $n=4$ ,  $p<0.01$ ).




LDH release during hypoxia was significantly reduced by CPA (100 nM,  $102 \pm 10\%$  compared to  $161 \pm 10\%$  = hypoxic control,  $n=7$ ,  $p<0.01$ , see fig.4.2b) and the  $\kappa$ -opioid receptor agonist (-)-U-50488 (100 nM,  $112 \pm 9\%$  compared to  $161 \pm 10\%$  = hypoxic control,  $n=7$ ,  $p<0.05$ ). None of the drugs had a significant effect during normoxia.


CPA also significantly reduced hypoxia-induced caspase-3 activity (100 nM,  $103 \pm 14\%$  compared to  $174 \pm 11\%$  = hypoxic control,  $n=5$ ,  $p<0.05$ , see fig.4.2c), as did the non-selective beta-adrenergic receptor agonist isoprenaline (10  $\mu$ M,  $99 \pm 15\%$  compared to  $174 \pm 11\%$  = hypoxic control,  $n=5$ ,  $p<0.05$ ). As before, none of the drugs had a significant effect during normoxia.

Overall, the most promising target for protection against hypoxia-induced cell death in H9c2 cells was the adenosine A<sub>1</sub> receptor, which attenuated cell death according to all three parameters measured. Stimulation of the beta-adrenergic receptors also appeared to be beneficial, as did activation of the  $\kappa$ -opioid receptor. Importantly, these data show that i) it is possible to stimulate a preconditioning response in H9c2 cells, and ii) the protective properties of activation of the adenosine A<sub>1</sub> receptor observed in cardiac myocytes (Safran *et al*, 2001) can be reproduced in H9c2 cells.


(a)



(b)




(c)




**Figure 4.1: Effect of hypoxia on H9c2 cell viability over time.** Cells were exposed to hypoxia for the stated times then cell viability was assessed via (a) MTT reduction, (b) LDH release and (c) caspase-3 activity. Data expressed as the percentage of control response (=100%). Each point represents mean  $\pm$  S.E.M. of 4-6 separate experiments; for each experiment the mean was taken from 2 (caspase-3) or 6 (MTT and LDH) replicates. \*  $p < 0.05$  vs. control; \*\*  $p < 0.01$  vs. control; \*\*\*  $p < 0.001$  vs. control.


(a)



(b)



(c)



**Figure 4.2: Effects of GPCR agonists on hypoxia-induced cell death in H9c2 cells.** Cells were exposed to the stated agonist (Concentrations as follows: 10  $\mu$ M isoprenaline, 10  $\mu$ M dobutamine, 10  $\mu$ M procaterol, 100 nM CPA, 100 nM (-)-U-50488) for 30 minutes prior to 6 hours hypoxia. Cell viability was measured by (a) MTT reduction, (b) LDH release and (c) caspase-3 activity. Data expressed as the percentage of Normoxic control response (=100%). Each point represents mean  $\pm$  S.E.M. of 4-6 separate experiments; for each experiment the mean was taken from 2 (caspase-3) or 6 (MTT and LDH) replicates. ##  $p < 0.01$  vs. normoxic control; \*  $p < 0.05$  vs. hypoxic control; \*\*  $p < 0.01$  vs. hypoxic control.

#### 4.2: Establishing a role for the ATP-sensitive potassium channel ( $K_{ATP}$ ) and the large-conductance calcium-activated potassium channel ( $BK_{Ca}$ channel)

$K_{ATP}$  channels have a widely accepted role in cardioprotection and ischaemic preconditioning (for review see Gross & Peart, 2003). Sarcolemmal  $K_{ATP}$  (sarco $K_{ATP}$ ) channels were the first to be described, with evidence for a mitochondrial  $K_{ATP}$  (mito $K_{ATP}$ ) emerging at a later date. Garlid *et al* (1997) were the first to publish data showing a link between the mito $K_{ATP}$  channel and cardioprotection using diazoxide and rat hearts; therefore this study postulated that diazoxide would have a protective effect against hypoxia in the cardiac H9c2 cell line.

Diazoxide significantly reduced hypoxia-induced LDH release ( $123 \pm 3\%$  compared to  $156 \pm 9\%$  = hypoxic control,  $n=5$ ,  $p<0.01$ , see fig.4.3), and this effect was reversed by co-treatment with the  $K_{ATP}$  channel blocker 5-HD ( $153 \pm 6\%$  compared to  $156 \pm 9\%$  = hypoxic control,  $n=5$ , see fig.4.3). This data supports the presence of a  $K_{ATP}$  channel in H9c2 cells, and as diazoxide is a potent opener of cardiac mito $K_{ATP}$  channels but a weak sarco $K_{ATP}$  opener it is highly likely that the channel in question is located to the mitochondria. However, as much evidence already exists regarding the role of the  $K_{ATP}$  channel in cardioprotection and its link with GPCRs, for the remainder of this study it was decided to proceed purely with research in to the  $Ca^{2+}$ -activated  $K^+$  channel.

Siemen *et al* (1999) first described the presence of a  $Ca^{2+}$ -activated  $K^+$  channel on the inner mitochondrial membrane of human glioma LN229 cells, and since this discovery the activation of mito $BK_{Ca}$  channels has been implicated in


cardioprotection against ischemia and reperfusion injury in various models including isolated perfused guinea pig hearts (Xu *et al*, 2002), anesthetised dogs (Shintani *et al*, 2004) and isolated guinea pig ventricular myocytes (Sato *et al*, 2005). It was, therefore, postulated that activation of these channels would also elicit a protective effect against hypoxia-induced cell death in H9c2 cells.

The BK<sub>Ca</sub> channel activator, NS1619 (10  $\mu$ M), significantly decreased LDH release during hypoxia ( $111 \pm 10\%$  compared to  $161 \pm 12\%$  = hypoxic control, n=7, p<0.05, see fig.4.4) and this was attenuated by the selective BK<sub>Ca</sub> channel blockers paxilline (1  $\mu$ M,  $151 \pm 15\%$  compared to  $161 \pm 12\%$  = hypoxic control, n=7) and iberiotoxin (10 nM,  $141 \pm 13\%$  compared to  $161 \pm 12\%$  = hypoxic control, n=5). NS1619 (10  $\mu$ M) also considerably reduced caspase-3 activity during hypoxia ( $126 \pm 11\%$  compared to  $195 \pm 16\%$  = hypoxia control, n=5, p<0.05, see fig.4.5), and this was completely reversed by both paxilline ( $207 \pm 26\%$  compared to  $195 \pm 16\%$  = hypoxia control, n=5) and iberiotoxin ( $196 \pm 59\%$  compared to  $195 \pm 16\%$  = hypoxia control, n=5).

To confirm that the channel in question was the mitochondrial BK<sub>Ca</sub> channel, mitochondria from H9c2 cells were collected and probed with antibodies for the BK<sub>Ca</sub>- $\alpha$  and  $\beta$ 4 subunits and the mitochondrial marker cytochrome *c* (see fig.4.6). Bands for the BK<sub>Ca</sub>- $\alpha$  and  $\beta$ 4 subunits were clearly observed in the mitochondrial fraction, but not in the cytoplasmic fraction or total extract. Cytochrome *c* was abundant in the mitochondrial fraction but absent from the cytoplasmic fraction, confirming the purity of the fractions.


In conclusion, these data show that NS1619 is activating the mitochondrial BK<sub>Ca</sub> channel, and that this channel has cytoprotective potential in H9c2 cells.






**Figure 4.3: Establishing a role for the  $K_{ATP}$  channel in protection against hypoxia-induced cell death in H9c2 cells.** Cells were exposed to the channel blocker 5-HD (100  $\mu$ M) for 45 minutes, with the addition of diazoxide (30  $\mu$ M) for the final 30 minutes, prior to 6 hours hypoxia. Cell viability was assessed via LDH release. Data expressed as the percentage of normoxic control response (=100%). Each point represents mean  $\pm$  S.E.M. of 5 separate experiments; for each experiment the mean was taken from 6 replicates. \*\*  $p < 0.01$  vs. normoxic control.






**Figure 4.4: Establishing a role for the BK<sub>Ca</sub> channel in protection against hypoxia-induced LDH release in H9c2 cells.** Cells were exposed to the channel blockers paxilline (1  $\mu$ M) or iberiotoxin (10 nM) for 45 minutes, with the addition of NS1619 (10  $\mu$ M) for the final 30 minutes, prior to 6 hours hypoxia. Cell viability was assessed via LDH release. Data expressed as the percentage of normoxic control response (=100%). Each point represents mean  $\pm$  S.E.M. of 5-7 separate experiments; for each experiment the mean was taken from 6 replicates. \*  $p < 0.05$  vs. normoxic control.



**Figure 4.5: Establishing a role for the BK<sub>Ca</sub> channel in protection against hypoxia-induced caspase-3 activation in H9c2 cells.** Cells were exposed to the channel blockers paxilline (1  $\mu$ M) or iberiotoxin (10 nM) for 45 minutes, with the addition of NS1619 (10  $\mu$ M) for the final 30 minutes, prior to 6 hours hypoxia. Cell viability was assessed via caspase-3 activity. Data expressed as the percentage of normoxic control response (=100%). Each point represents mean  $\pm$  S.E.M. of 5-7 separate experiments; for each experiment the mean was taken from 2 replicates. \*  $p < 0.05$  vs. normoxic control.



**Figure 4.6: Establishing the presence of the mitochondrial BK<sub>Ca</sub> channel subunits in H9c2 cells.** Mitochondria were extracted from H9c2 cells by differential centrifugation and probed with antibodies specific to the BK<sub>Ca</sub>-α and BK<sub>Ca</sub>-β4 subunits (30 μg protein was loaded per lane). Cyto represents the cytoplasmic fraction; TE represents total extract. Cytochrome *c* was used to confirm purity of the mitochondrial fraction. Blots are representative of 4 separate experiments.

#### 4.3: Determining a link between the adenosine A<sub>1</sub> receptor and the BK<sub>Ca</sub> channel

There is some evidence that BK<sub>Ca</sub> channels have a role in cardioprotection induced by some GPCR agonists including the  $\kappa$ -opioid receptor agonist (-)-U-50488 (Cao *et al*, 2005). However, to date, the role of the BK<sub>Ca</sub> channel in adenosine receptor-induced cardioprotection has yet to be investigated. The adenosine A<sub>1</sub> receptor activates similar G<sub>i</sub> protein-modulated pathways to the  $\kappa$ -opioid receptor, so it was hypothesized that the BK<sub>Ca</sub> channel may also feature in cardioprotection induced by this receptor.


As before, activation of the adenosine A<sub>1</sub> receptor with CPA reduced LDH release during hypoxia (100 nM, 135  $\pm$  10% compared to 191  $\pm$  8% = hypoxic control, n=6, p<0.05, see fig.4.7a). This effect was attenuated by the A<sub>1</sub> receptor antagonist DPCPX (10  $\mu$ M, 171  $\pm$  5% compared to 191  $\pm$  8% = hypoxic control, n=6), and interestingly, also by the BK<sub>Ca</sub> channel blockers paxilline (1  $\mu$ M, 177  $\pm$  9% compared to 191  $\pm$  8% = hypoxic control, n=6) and iberiotoxin (10 nM, 173  $\pm$  7% compared to 191  $\pm$  8% = hypoxic control, n=6).

This was also the case when assessing caspase-3 activity. CPA reduced caspase-3 activity during hypoxia (128  $\pm$  12% compared to 184  $\pm$  16% = hypoxic control, n=5, p<0.05, see fig.4.7b), and this was prevented by both paxilline (174  $\pm$  17% compared to 184  $\pm$  16% = hypoxic control, n=5) and iberiotoxin (181  $\pm$  30% compared to 184  $\pm$  16% = hypoxic control, n=5).


None of the blockers affected LDH release or caspase-3 activity when used alone (data not shown). These data have, for the first time, uncovered a role for the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> receptor-induced protection against hypoxia.



(a)



(b)



**Figure 4.7: The effect of BKCa channel blockers on CPA-mediated protection against hypoxia-induced cell death in H9c2 cells.** Cells were exposed to paxilline (1  $\mu$ M) or iberiotoxin (10 nM) for 45 minutes, with the addition of CPA (100 nM) for the final 30 minutes prior to 6 hours hypoxia. Cell viability was assessed via (a) LDH release or (b) caspase-3 activity. Data expressed as the percentage of normoxic control response (=100%). Each point represents mean  $\pm$  S.E.M. of 5-6 separate experiments; for each experiment the mean was taken from 2 (caspase-3) or 6 (LDH) replicates. \*  $p < 0.05$  vs. hypoxic control.

## 5. The role of protein kinases ERK1/2 and PKB in adenosine A<sub>1</sub> receptor and BK<sub>Ca</sub> channel-mediated cytoprotection

Several protein kinases have been implicated in ischaemic pre- and postconditioning, including ERK1/2 and PKB. Both of these are pro-survival kinases included in the RISK pathway (Reperfusion Injury Salvage Kinase), and have been associated with the cardioprotective effects of K<sub>ATP</sub> channels (de Toit *et al*, 2008; Grossini *et al*, 2009; for extensive review see Hausenloy & Yellon, 2007). In addition, there is existing data stating that PKB can be activated by the BK<sub>Ca</sub> channel opener NS1619 (100 µM) in neurones (Gáspár *et al*, 2008). Both kinases have been documented to form part of the cardioprotective signalling cascades initiated by activation of adenosine receptors (Germack *et al*, 2004; Downey *et al*, 2008), so when taking this knowledge into account it was postulated that ERK1/2 and PKB are involved in signal transduction mediated by the adenosine A<sub>1</sub> receptor and BK<sub>Ca</sub> channel.

However, in this study it was found that 10 µM NS1619 did not induce phosphorylation of ERK1/2 (see fig.5.1) or PKB (see fig.5.2) in H9c2 cells; conversely, 100 µM significantly inhibited the activation of both protein kinases. ERK1/2 was maximally inhibited following 15 minutes treatment (39 ± 9% of control; n=5; p<0.05; see fig.5.3), after which levels increased over time and phosphorylation was actually raised above control following 180 minutes treatment (144 ± 25% of control; n=5; p>0.05). Maximum inhibition of PKB phosphorylation occurred following 60 minutes treatment with 100 µM NS1619 (32 ± 15% of control; n=4; p<0.05; see fig.5.4), after which the level of activation gradually increased but did not reach that of the control.

It was postulated that NS1619 may activate ERK1/2 and PKB during periods of stress, such as hypoxia. However, when H9c2 cells were pre-treated with NS1619 (10  $\mu$ M) then subjected to hypoxia for 1, 2, 4, or 6 hours no phosphorylation of either protein was observed (see figs.5.5 and 5.6).

It has previously been shown that CPA can activate ERK1/2 and PKB in both cardiomyocytes and the DDT<sub>(1)</sub>MF-2 hamster vas deferens smooth muscle cell line (Germack & Dickenson, 2000; Germack *et al*, 2004). In this study it was also found that CPA activated ERK1/2 in H9c2 cells in a transient manner, with maximal phosphorylation occurring with 5 minutes treatment ( $264 \pm 26\%$  of control;  $n=4$ ;  $p<0.001$ ; see fig.5.7). However, activation of PKB was not observed (see fig.5.8).

Earlier results have shown that by blocking the BK<sub>Ca</sub> channel CPA-mediated protection against hypoxia-induced cell death in H9c2 cells can be attenuated. It was decided to investigate whether ERK1/2 or PKB are involved in this process as it has been shown that ERK1/2 is phosphorylated following activation of the adenosine A<sub>1</sub> receptor, and is well documented that both ERK1/2 and PKB are implicated in cytoprotective pathways. However, in this model CPA (100 nM)-induced ERK1/2 phosphorylation was not blocked by paxilline (1  $\mu$ M;  $277 \pm 75\%$  of control compared to  $227 \pm 48\%$  of control for CPA alone;  $n=4$ ; see fig.5.9) or iberiotoxin (10 nM;  $223 \pm 26\%$  of control compared to  $227 \pm 48\%$  of control for CPA alone;  $n=4$ ; see fig.5.9). No phosphorylation of PKB was observed (see fig.5.10).


From these data it appears that ERK1/2 and PKB are not activated upstream of BK<sub>Ca</sub> channel-mediated signal transduction since no phosphorylation of either protein kinase was detected. It is important to note, however, that compartmentalisation of these activated proteins has been described (Chuderland *et al*, 2008; Gonzalez &




McGraw, 2009). It is therefore possible that if this is the case in H9c2 cells, by using whole cell lysates the phosphorylated proteins may have been diluted to a level undetectable by the method used.

The sizeable phosphorylation of ERK1/2 by stimulation of the adenosine A<sub>1</sub> receptor further confirms earlier data relating to the functional expression of this receptor on H9c2 cells – and although ERK1/2 does not seem to be activated upstream of adenosine A<sub>1</sub> receptor/BK<sub>Ca</sub> channel signalling it is possible that it is an intermediate step in this pathway.

(a)




(b)




**Figure 5.1: The effect of 10  $\mu$ M NS1619 on phosphorylation of ERK1/2 in H9c2 cells.** Cells were exposed to NS1619 for the indicated periods of time then cell lysates were collected and probed for phosphorylated ERK1/2 and total ERK1/2. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 6 separate experiments.

(a)




(b)




**Figure 5.2: The effect of 10  $\mu$ M NS1619 on phosphorylation of PKB in H9c2 cells.** Cells were exposed to NS1619 for the indicated periods of time then cell lysates were collected and probed for phosphorylated PKB (Ser 473) and total PKB. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 6 separate experiments.



(a)




(b)




**Figure 5.3: The effect of 100  $\mu$ M NS1619 on phosphorylation of ERK1/2 in H9c2 cells.** Cells were exposed to NS1619 for the indicated periods of time then cell lysates were collected and probed for phosphorylated ERK1/2 and total ERK1/2. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 5 separate experiments. \*  $p < 0.05$  vs. untreated pERK1/2 control.

(a)




(b)




**Figure 5.4: The effect of 100  $\mu$ M NS1619 on phosphorylation of PKB in H9c2 cells.**

Cells were exposed to NS1619 for the indicated periods of time then cell lysates were collected and probed for phosphorylated PKB (Ser 473) and total PKB. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 4 separate experiments. \* $p < 0.05$  vs. untreated pPKB control.

(a)




(b)






(c)




**Figure 5.5: The effect of NS1619 on ERK1/2 phosphorylation during hypoxia.** H9c2 cells were treated with 10  $\mu$ M NS1619 (or serum-free DMEM for controls) for 30 minutes prior to hypoxic/normoxic incubation for the indicated amount of time (hours; see graph). Cell lysates were then collected and probed for phosphorylated ERK1/2 and total ERK1/2. (a) Representative blot for phosphorylated ERK1/2 (b) Representative blot for total ERK1/2 (c) Data expressed as percentage of 1 hour untreated normoxic control, total ERK1/2 not shown. Each bar represents mean  $\pm$  S.E.M. of 6 separate experiments.

(a)




(b)






(c)




**Figure 5.6: The effect of NS1619 on PKB phosphorylation during hypoxia.** H9c2 cells were treated with 10  $\mu$ M NS1619 (or serum-free DMEM for controls) for 30 minutes prior to hypoxic/normoxic incubation for the indicated amount of time (hours; see graph). Cell lysates were then collected and probed for phosphorylated PKB (Ser 473) and total PKB. (a) Representative blot for phosphorylated PKB (b) Representative blot for total PKB (c) Data expressed as percentage of 1 hour untreated normoxic control, total PKB not shown. Each bar represents mean  $\pm$  S.E.M. of 6 separate experiments.

(a)




(b)




**Figure 5.7: CPA-induced phosphorylation of ERK1/2 in H9c2 cells.** Cells were treated with 100 nM CPA for the indicated amounts of time then cell lysates were collected and probed for phosphorylated ERK1/2 and total ERK1/2. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 4 separate experiments. \*\*\*  $p < 0.001$  vs. untreated pERK1/2 control.

(a)



(b)



**Figure 5.8: The effect of CPA on PKB phosphorylation in H9c2 cells.** Cells were treated with 100 nM CPA for the indicated amounts of time then cell lysates were collected and probed for phosphorylated PKB and total PKB. (a) Representative blot with exposure time (in minutes) underneath. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 4 separate experiments.




(a)


**Phosphorylated ERK1/2**



**Total ERK1/2**




(b)




**Figure 5.9: The effect of blocking the BKCa channel on CPA-induced ERK1/2 phosphorylation in H9c2 cells.** Cells were exposed to paxilline (1  $\mu$ M) or iberiotoxin (10 nM) for 45 minutes, with the addition of CPA (100 nM) for the final 30 minutes. Cell lysates were then collected and probed for phosphorylated ERK1/2 and total ERK1/2. (a) Representative blot. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 4 separate experiments. \*  $p < 0.05$  vs. untreated pERK1/2 control.

(a)



(b)



**Figure 5.10: The effect of blocking the  $BK_{Ca}$  channel on CPA-induced PKB phosphorylation in H9c2 cells.** Cells were exposed to paxilline ( $1 \mu\text{M}$ ) or iberiotoxin ( $10 \text{ nM}$ ) for 45 minutes, with the addition of CPA ( $100 \text{ nM}$ ) for the final 30 minutes. Cell lysates were then collected and probed for phosphorylated PKB and total PKB. (a) Representative blot. (b) Data expressed as percentage of untreated controls. Each bar represents mean  $\pm$  S.E.M. of 5 separate experiments.

## 6. The role of the BK<sub>Ca</sub> channel in adenosine receptor-mediated protection against hypoxia-reoxygenation

### 6.1. A model for hypoxia-reoxygenation in H9c2 cells

Models using hypoxia-reoxygenation allow us to gain a more realistic insight into the damage caused by ischaemia/reperfusion and discovery of potential therapeutic agents. This study utilised a model for hypoxia-reoxygenation in H9c2 cells consisting of 6 hours hypoxia as used for previous experiments, followed by 18 hours of reoxygenation – a time point which had previously been used (Germack & Dickenson, 2005). Preliminary data showed that this model was sufficient for initiating cell death in H9c2 cells as measured by LDH release ( $363 \pm 70\%$  compared to normoxic control = 100%,  $n=6$ ,  $p<0.06$ , see fig.6.1a), but caspase-3 activity was not increased suggesting that apoptosis had not occurred ( $100.5 \pm 11\%$  compared to normoxic control = 100%,  $n=6$ , see fig.6.1b).

For preconditioning, H9c2 cells were treated with pharmacological agents for 30 minutes before the onset of the hypoxic incubation. Activation of the adenosine A<sub>1</sub> receptor with CPA (100 nM) did not provide any protection against hypoxia-reoxygenation induced cell death as measured by LDH release ( $100 \pm 13\%$  compared to untreated control = 100%,  $n=7$ , see fig.6.2). Unexpectedly, treatment with the BK<sub>Ca</sub> channel opener NS1619 (10  $\mu$ M) raised LDH release ( $148 \pm 8\%$  of untreated control = 100%,  $n=11$ ,  $p<0.01$  vs. control, see fig.6.2). This augmentation was reversed by co-treatment with paxilline (1  $\mu$ M,  $110 \pm 6\%$  of untreated control = 100%,  $n=5$ ,  $p<0.05$  vs. NS1619 alone, see fig.6.3) and iberiotoxin (10 nM,  $116 \pm 7\%$


of untreated control = 100%, n=5,  $p < 0.05$  vs. NS1619 alone, see fig.6.3), confirming the involvement of the BK<sub>Ca</sub> channel.

To assess the postconditioning potential of pharmacological agents, treatment occurred after hypoxia at the start of reoxygenation. Postconditioning is a more valid method for protection against myocardial infarction in a clinical setting as the stimulus is applied following a bout of ischaemia – with preconditioning it would be difficult to predict when treatment should occur. NS1619- and CPA-mediated postconditioning both proved to be beneficial in the H9c2 model specified earlier (NS1619: 10  $\mu$ M,  $64 \pm 4\%$  of untreated control = 100%, n=7,  $p < 0.001$ ; CPA: 100 nM,  $59 \pm 6\%$  of untreated control = 100%, n=7,  $p < 0.001$ , see fig. 6.4). The protection afforded by NS1619 was reversed by paxilline (1  $\mu$ M,  $101 \pm 11\%$  of untreated control = 100%, n=5,  $p < 0.05$  vs. NS1619) and iberiotoxin (10 nM,  $103 \pm 8\%$  of untreated control = 100%, n=5,  $p < 0.05$  vs. NS1619, see fig. 6.5), confirming that it is mediated by the BK<sub>Ca</sub> channel.


CPA-mediated protection was reversed by the adenosine A<sub>1</sub> receptor antagonist DPCPX (10  $\mu$ M,  $92 \pm 7\%$  of untreated control = 100%, n=6,  $p < 0.01$  vs. CPA, see fig. 6.6). Interestingly, the BK<sub>Ca</sub> channel blockers paxilline and iberiotoxin also significantly attenuated the CPA-mediated response suggesting a role for the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> receptor-mediated postconditioning in H9c2 cells (paxilline: 1  $\mu$ M,  $83 \pm 5\%$  of untreated control = 100%, n=6,  $p < 0.05$  vs. CPA; iberiotoxin: 10 nM,  $84 \pm 4\%$  of untreated control = 100%, n=6,  $p < 0.05$  vs. CPA).




(a)




(b)



**Figure 6.1: Cell death induced by hypoxia-reoxygenation in H9ce cells.** Cells were exposed to 6 hours normoxia (control), 6 hours hypoxia (HX) or 6 hours hypoxia followed by 18 hours reoxygenation (HX/Reox) then cell death was assessed by (a) LDH release or (b) caspase-3 activity. Data expressed as percentage of control. Each bar represents mean  $\pm$  S.E.M from 6 separate experiments; for each experiment the mean was taken from 2 (caspase-3) or 6 (LDH) replicates. \*\*  $p < 0.01$  vs. control.




**Figure 6.2: Preliminary data investigating the potential cardioprotective effects of preconditioning with CPA and NS1619.** H9c2 cells were exposed to NS1619 (10  $\mu$ M) or CPA (100 nM) for 30 minutes prior to 6 hours of hypoxia followed by 18 hours of reoxygenation. Data expressed as percentage of untreated controls exposed to hypoxia/reoxygenation (HX/Reox = 100%). Each bar represents mean  $\pm$  S.E.M. of 7-11 separate experiments, for each experiment the mean was taken from 6 replicates. \*\*  $p < 0.01$  vs. HX/Reox.




**Figure 6.3: The role of the BKCa channel in NS1619-mediated preconditioning in H9c2 cells.** Cells were treated with paxilline (Pax, 1  $\mu$ M) or iberiotoxin (IbTx, 10 nM) for 45 minutes, with the addition of NS1619 (10  $\mu$ M) for the final 30 minutes. This preceded 6 hours hypoxia followed by 18 hours reoxygenation. Data expressed as percentage of untreated controls exposed to hypoxia/reoxygenation (HX/Reox = 100%). Each bar represents mean  $\pm$  S.E.M. of 5-11 separate experiments, for each experiment the mean was taken from 6 replicates. \*\*  $p < 0.01$  vs. HX/Reox; #  $p < 0.05$  vs. NS1619.






**Figure 6.4: Preliminary data investigating the potential cardioprotective effects of postconditioning with CPA and NS1619.** H9c2 cells were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation. For the first 30 minutes of reoxygenation, cells were exposed to NS1619 (10  $\mu$ M) or CPA (100 nM) which was then removed for the remainder of reoxygenation. Data expressed as percentage of untreated controls exposed to hypoxia/reoxygenation (HX/Reox = 100%). Each bar represents mean  $\pm$  S.E.M. of 7 separate experiments, for each experiment the mean was taken from 6 replicates. \*\*\*  $p < 0.001$  vs. HX/Reox.



**Figure 6.5: The role of the BK<sub>Ca</sub> channel in NS1619-mediated postconditioning in H9c2 cells.** Cells were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation. For the first 45 minutes of reoxygenation the cells were treated with paxilline (Pax, 1  $\mu$ M) or iberiotoxin (IbTx, 10 nM) with the addition of NS1619 (NS, 10  $\mu$ M) for the final 30 minutes of treatment. Data expressed as percentage of untreated controls exposed to hypoxia/reoxygenation (HX/Reox = 100%). Each bar represents mean  $\pm$  S.E.M. of 5 separate experiments, for each experiment the mean was taken from 6 replicates. \*  $p < 0.05$  vs. HX/Reox; #  $p < 0.05$  vs. NS1619.



**Figure 6.6: The role of the BKCa channel in CPA-mediated postconditioning in H9c2 cells.** Cells were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation. For the first 45 minutes of reoxygenation the cells were treated with DPCPX (10  $\mu$ M), paxilline (Pax, 1  $\mu$ M) or iberiotoxin (IbTx, 10 nM) with the addition of CPA (100 nM) for the final 30 minutes of treatment. Data expressed as percentage of untreated control (=100%). Each bar represents mean  $\pm$  S.E.M. of 5 separate experiments, for each experiment the mean was taken from 6 replicates. \*\*\*  $p < 0.001$  vs. control; ##  $p < 0.01$  vs. NS1619; #  $p < 0.05$  vs. NS1619.



## 6.2. A model for hypoxia-reoxygenation in rat ventricle strips

The previous experiments assessed the cytoprotective effects of activation of the adenosine A<sub>1</sub> receptor and the BK<sub>Ca</sub> channel in H9c2 cells. To test the hypothesis that the BK<sub>Ca</sub> channel is involved in A<sub>1</sub> receptor-mediated signal transduction in a more physiologically relevant model the contractile function of rat ventricle strips following hypoxia with/without pharmacological preconditioning was assessed. One strip per heart was taken from the right ventricle wall and set up in an organ bath. Control strips were exposed to 40 minutes of oxygenation to allow for equilibration, a further 30 minutes oxygenation, 30 minutes hypoxia and then 30 minutes reoxygenation – this led to a  $5 \pm 2\%$  recovery of function during reoxygenation, compared to the loss of function during hypoxia. The loss of contractile function during hypoxia and reoxygenation was measured, and the recovery of function during reoxygenation expressed as a percentage of original function compared to the loss observed during hypoxia. For pharmacological preconditioning the agents were added for the final 2 minutes of oxygenation then washed out before the onset of hypoxia. Where appropriate, blockers were added for the whole 30 minutes of oxygenation. For hypoxic preconditioning strips were exposed to 40 minutes of oxygenation to allow for equilibration, 10 minutes preconditioning hypoxia, 20 minutes oxygenation, 30 minutes hypoxia and then 30 minutes reoxygenation. When appropriate, strips were exposed to iberiotoxin for 30 minutes prior to the preconditioning period of hypoxia.

Firstly, it was verified that activation of the BK<sub>Ca</sub> channel has a beneficial effect in this model. Preconditioning with NS1619 significantly increased the return of contractile function of the ventricle strips during the reperfusion stage ( $10 \mu\text{M}$ ,  $36 \pm$



4% contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.01$  vs. control, see fig.6.7). To ensure that the response observed was due to the  $BK_{Ca}$  channel ventricle strips were then co-treated with NS1619 and the channel blockers paxilline and iberiotoxin. Preliminary data with  $1 \mu\text{M}$  paxilline did not reveal any effect upon the NS1619-mediated return of contractile function ( $38 \pm 4\%$  contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.001$  vs. control, see fig.6.7),  $10 \mu\text{M}$  paxilline slightly attenuated the return of response ( $29 \pm 6\%$  contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.01$  vs. control, see fig.6.7); it is possible that the concentrations of paxilline tested were insufficient in this model, however, to reduce the number of animals used it was decided to continue using solely iberiotoxin to block the  $BK_{Ca}$  channel. Iberiotoxin considerably decreased the NS1619-mediated effect ( $50 \text{ nM}$ ,  $14 \pm 6\%$  contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.05$  vs. NS1619, see fig.6.7), confirming that it was due to activation of the  $BK_{Ca}$  channel.

A brief period of hypoxia has been shown to be beneficial against a subsequent, prolonged period of hypoxia (hypoxia preconditioning) in many clinical setting and models – including the rat ventricle strip (Button *et al*, 2005). This study also observed a large return of contractile function when strips were preconditioned in this manner ( $35 \pm 4\%$  contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.001$  vs. control, see fig.6.8), and found that this could be significantly attenuated by treatment with iberiotoxin ( $50 \text{ nM}$ ,  $18 \pm 6\%$  contractile recovery compared to  $5 \pm 2\%$  observed in control strips,  $n=4$ ,  $p<0.05$  vs. hypoxic preconditioning, see fig.6.8). These data indicate that hypoxic preconditioning in rat ventricle strips involves activation of the  $BK_{Ca}$  channel.


Using specific agonists for the adenosine A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> receptors (CPA, CGS 21680 and 2-CI-IB-MECA respectively) it was found that activation of the A<sub>1</sub> and A<sub>2A</sub> receptors lead to significant return of contractile function (see next paragraphs for details), however, a large response with activation of the A<sub>3</sub> receptor was not observed (1 μM, 13 ± 4% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p>0.05 vs. control, data not shown).

Activation of the A<sub>1</sub> receptor with CPA lead to a robust return of function (1 μM, 39 ± 6% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.001 vs. control, see fig.6.9) and this was considerably decreased by co-treatment with DPCPX (10 μM, 14 ± 5% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. CPA alone, see fig.6.9) – confirming involvement of the A<sub>1</sub> receptor.


Activation of the A<sub>2A</sub> receptor with CGS 21680 also increased return of function (1 μM, 32 ± 3% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.001 vs. control, see fig.6.10) which was attenuated by co-treatment with the A<sub>2A</sub> antagonist ZM 241385 (12 ± 3% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. CGS 21680 alone, see fig.6.10). Furthermore, return of function mediated by both CPA and CGS 21680 was significantly inhibited by co-treatment with 50 nM iberiotoxin (CPA: 14 ± 2% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. CPA alone, see fig.6.9; CGS 21680: 15 ± 3% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. CGS 21680 alone, see fig.6.10).

These data, for the first time, demonstrate a role for the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> and A<sub>2A</sub> receptor-mediated preconditioning – with evidence regarding the A<sub>1</sub>

receptor collected from both *in vitro* cell viability work and experiments using an *ex vivo* model measuring mechanical function.




**Figure 6.7: The role of the  $\text{BK}_{\text{Ca}}$  channel in NS1619-mediated pharmacological preconditioning in rat ventricle strips.** Rat ventricle strips were pretreated with paxiline (Pax; 10  $\mu\text{M}$ ) or iberiotoxin (IbTx, 50 nM) for 30 minutes prior to cardioprotection induced by 10  $\mu\text{M}$  NS1619. Data expressed as a percentage of contractile recovery compared to the level of recovery observed in control strips exposed to 30 minutes hypoxia alone. Each bar represents mean  $\pm$  S.E.M. of 4 experiments. \*\*\*  $p < 0.001$  vs. hypoxia control; \*\*  $p < 0.01$  vs. hypoxia control; #  $p < 0.05$  vs. NS1619 alone.




**Figure 6.8: The role of the BK<sub>Ca</sub> channel in hypoxic preconditioning in rat ventricle strips.** Rat ventricle strips were pretreated with iberiotoxin (IbTx, 50 nM) for 30 minutes prior to cardioprotection induced by hypoxic preconditioning (HPC). Data expressed as a percentage of contractile recovery compared to the level of recovery observed in control strips exposed to 30 minutes hypoxia alone. Each bar represents mean ± S.E.M. of 4 experiments. \*\*\* p<0.001 vs. hypoxia control; # p<0.05 vs. HPC alone.





**Figure 6.9: The role of the  $BK_{Ca}$  channel in pharmacological preconditioning mediated by the adenosine  $A_1$  receptor in rat ventricle strips.** Rat ventricle strips were pretreated with iberitoxin (IbTx; 50 nM) or DPCPX ( $A_1$  antagonist, 10  $\mu$ M) for 30 minutes prior to cardioprotection induced by 1  $\mu$ M CPA. Data expressed as a percentage of contractile recovery compared to the level of recovery observed in control strips exposed to 30 minutes hypoxia alone. Each bar represents mean  $\pm$  S.E.M. of 4 experiments. \*\*\*  $p < 0.001$  vs. hypoxia control; ##  $p < 0.01$  vs. CPA alone.




**Figure 6.10: The role of the BKCa channel in pharmacological preconditioning mediated by the adenosine  $A_{2A}$  receptor in rat ventricle strips.** Rat ventricle strips were pretreated with iberiotoxin (IbTx; 50 nM) or ZM 241385 ( $A_{2A}$  antagonist, 1  $\mu$ M) for 30 minutes prior to cardioprotection induced by 1  $\mu$ M CGS 21680. Data expressed as a percentage of contractile recovery compared to the level of recovery observed in control strips exposed to 30 minutes hypoxia alone. Each bar represents mean  $\pm$  S.E.M. of 4 experiments. \*\*\*  $p < 0.001$  vs. hypoxia control; ##  $p < 0.01$  vs. CGS 21680 alone.

## 7. Discussion


### 7.1. Summary of main findings

#### i) H9c2 myocardial cell model



**Figure 7.1.i) Cytoprotective signal transduction in H9c2 cells.** Activation of the adenosine A<sub>1</sub> receptor leads to protection against hypoxia and hypoxia-reoxygenation-induced cell death, and this involves activation of the BK<sub>Ca</sub> channel and possibly ERK1/2. Black arrow = well documented event; red arrow = possible link; blue arrow = novel pathway.

#### ii) Rat ventricle strip model



**Figure 7.1.ii) The BK<sub>Ca</sub> channel in cardioprotection of rat ventricle strips.** For the first time it has been shown that the BK<sub>Ca</sub> channel mediates cardioprotection triggered by hypoxic preconditioning (HPC) and activation of adenosine A<sub>1</sub> and A<sub>2A</sub> receptors in rat ventricle strips.



Figure 7.1.i) summarizes the main findings from this current project using H9c2 cells. It was shown that pharmacological activation of the adenosine A<sub>1</sub> receptor and the BK<sub>Ca</sub> channel both lead to protection against hypoxia and hypoxia-reoxygenation-induced cell death. Regarding hypoxia-reoxygenation-induced damage, the A<sub>1</sub> receptor agonist CPA was most beneficial as a preconditioning agent, whereas the BK<sub>Ca</sub> channel activator NS1619 was most beneficial as a postconditioning agent. Interestingly, the protection afforded by A<sub>1</sub> receptor activation was abolished by blockade of the BK<sub>Ca</sub> channel – implying that the cytoprotective signal transduction pathway triggered by this receptor involves activation of the BK<sub>Ca</sub> channel. However, the role of ERK1/2 in this pathway remains controversial; more work is required to elucidate whether ERK1/2 activation occurs upstream of BK<sub>Ca</sub> channel activation, or not at all.

Figure 7.1.ii) summarizes the findings from the work with the rat ventricle strip model. Hypoxic preconditioning and pharmacological preconditioning with agonists at the adenosine A<sub>1</sub> receptor (CPA) and the A<sub>2A</sub> receptor (CGS 21680) all led to significantly enhanced contractile recovery following a hypoxic insult. Blockade of the BK<sub>Ca</sub> channel prevented such preconditioning, showing that the this channel has an important role in preconditioning of rat ventricle strips mediated by hypoxia, activation of the adenosine A<sub>1</sub> receptor and activation of the adenosine A<sub>2A</sub> receptor.

For the first time, and in two different models, a role for the BK<sub>Ca</sub> channel in adenosine receptor-mediated cytoprotective signal transduction has been demonstrated.

## 7.2. Characterisation of GPCRs functionally expressed on H9c2 cells

### i) Adenosine receptors

This report provides evidence for the functional expression of G<sub>i</sub>-coupled adenosine A<sub>1</sub> receptors on myocardial H9c2 cells. The specific A<sub>1</sub> receptor agonist CPA provided a robust inhibition of forskolin-stimulated [<sup>3</sup>H]-cAMP accumulation, which was reversed by the G<sub>i</sub>-protein blocker pertussis toxin (PTX) and the specific adenosine A<sub>1</sub> receptor antagonist DPCPX. The adenosine A<sub>3</sub> receptor agonist CI-IB-MECA did not inhibit cAMP accumulation, but at a high concentration actually amplified the forskolin response; interestingly, this was blocked by DPCPX but not the A<sub>3</sub> receptor antagonist MRS 1220. This observation is suggestive of a non-specific action of CI-IB-MECA resulting in A<sub>1</sub> activation, indeed this was reported by Kilpatrick *et al* (2001) who showed that CI-IB-MECA-induced cardioprotection was blocked by DPCPX.

The adenosine A<sub>1</sub> receptor usually couples to G<sub>i</sub> protein, producing an inhibitory effect on adenylyl cyclase, but it has been shown that high agonist concentrations can lead an increase in cAMP production (Cordeaux *et al*, 2004). This biphasic adenylyl cyclase response following A<sub>1</sub> receptor activation is due to direct coupling of the A<sub>1</sub> receptor with both G<sub>i</sub> and G<sub>s</sub> protein; and agonist potency at the G<sub>s</sub>-coupled A<sub>1</sub> receptor was in the micromolar range, compared to nanomolar responses at the G<sub>i</sub>-coupled receptor (Cordeaux *et al*, 2004; Baker & Hill, 2007). This finding is in keeping with the biphasic cAMP response to CPA observed in this current report, and could explain the increase in cAMP measured following treatment with 10 μM CI-IB-MECA.

A previous report showed that stimulation of the A<sub>1</sub> receptor transiently activates ERK1/2 in cardiomyocytes (Germack & Dickenson, 2004). In this current report a robust CPA-induced ERK1/2 phosphorylation was also observed in the H9c2 cell line, further validating a functional role for the A<sub>1</sub> receptor in these cells.

The data presented in this report indicate that adenosine A<sub>2A</sub> receptors are not functionally expressed on H9c2 cells. This is in contrast to a recent study by Urmaliya *et al* (2009), which described cooperation between adenosine A<sub>1</sub> and A<sub>2A</sub> receptors in cardioprotection in H9c2 cells. The latter study exposed H9c2 cells to hypoxia (100% N<sub>2</sub>) for 12 hours, and noticed that protection against necrosis mediated by a selective A<sub>1</sub> receptor agonist could be attenuated with a selective A<sub>2A</sub> receptor antagonist. It was also noticed that co-treatment with the A<sub>1</sub> and A<sub>2A</sub> agonists potentiated the effect of the A<sub>1</sub> agonist alone, but treatment with only the A<sub>2A</sub> agonist had no effect – suggesting that the receptors are working together during hypoxia. The presence of the A<sub>2A</sub> receptor in this H9c2 cell model, but not in the functional study in this current report, could be explained by the experimental conditions. It has been demonstrated that adenosine A<sub>2A</sub> receptor mRNA and protein levels are increased during hypoxia in PC12 cells (Kobayashi & Millhorn, 1999), with a maximum of ~250% increase in mRNA and ~400% increase in protein occurring at 12 hours of hypoxia. It is therefore likely that the expression of A<sub>2A</sub> receptors on H9c2 cells is low during normal conditions (and so not detectable by functional assay), but 12 hours of hypoxic incubation stimulates a substantial increase in receptor expression so the effects of A<sub>2A</sub> receptor signalling reach a detectable level.

## ii) Opioid receptors

$\kappa$ -opioid receptors are the predominant subtype of opioid receptor in the heart; and results suggest that these  $G_i$ -coupled receptors are also expressed on H9c2 cells. However, no evidence was uncovered for functional expression of  $\delta$ -opioid receptors. Research suggests that  $\kappa$ -opioid receptors account for 80% of opioid receptors expressed in immature rat hearts (Zimlichman *et al*, 1996), and expression of  $\delta$ -opioid receptors increases with postnatal development. As H9c2 cells are derived from embryonic rat heart (Kimes & Brandt, 1976) this could explain the lack of functional  $\delta$ -opioid receptors.

During these experiments it was found that treatment with pertussis toxin (PTX) actually decreased forskolin-induced cAMP accumulation. This was also observed by Robinson & Caron (1997), who noticed that this effect only occurred with HEK293 cells expressing adenylyl cyclase type V. It is thought that PTX may increase intracellular  $Ca^{2+}$ , which would inhibit the calcium-sensitive adenylyl cyclase type V – which is the predominant isoform of adenylyl cyclase expressed in the heart, possibly explaining the observed effect in the heart-derived H9c2 cells (Ebina *et al*, 1997).

## iii) $\beta$ -adrenergic receptors

The data in this report regarding  $\beta_2$ -adrenergic receptor expression implies that these receptors are expressed on H9c2 cells, but the data regarding  $\beta_1$  receptor expression is less convincing. A study using receptor mRNA levels and radioligand binding assays to investigate  $\beta$ -adrenergic receptor expression on H9c2 cells reported a 29%:71% ratio in favour of the  $\beta_2$  receptor (Dangel *et al*, 1996), but another study

using antibody imaging reported modest expression of both subtypes (Ianoul *et al*, 2005); it is possible that discrepancies regarding expression of the receptor subtypes on H9c2 cells arise from the different methods utilised. Taking all of these data into account, it can be inferred that  $\beta_2$ -adrenergic receptors are expressed on H9c2 cells.

Evidence has also been presented supporting the functional expression of a UTP-sensitive  $G_q$ -coupled P2Y receptor on H9c2 cells. To date, this is the first study looking into the functional expression of GPCRs on H9c2 cells; if time permitted it would be interesting to expand on this body of information by confirming the results using other techniques (e.g.  $Ca^{2+}$  mobilization for  $G_q$ -coupled receptors) and increasing the selection of receptors tested.

## **7.2. The cardioprotective potential of functionally expressed receptors and $K^+$ channels on H9c2 cells**

### **i) Adenosine $A_1$ receptor**

H9c2 cells are commonly used for studies into cardioprotection, as they display similar biochemical and electrophysiological properties to cardiac tissue (Hescheler *et al*, 1991) but are less demanding to culture (Zordoky & El-Kadi, 2007). Activation of the  $G_i$ -coupled adenosine  $A_1$  receptor has a well-documented role in cardioprotection in many models, including primary rat cardiomyocytes (Safran *et al*, 2001; Fei *et al*, 2009), so it was proposed that this would also be the case in H9c2 cells. Stimulation of the adenosine  $A_1$  receptor with the selective agonist CPA, prior to 6 hours hypoxic incubation, significantly increased mitochondrial reduction of MTT, and decreased LDH release and caspase-3 activity. Loss of mitochondrial

function or cell membrane integrity (as measured by MTT metabolism and LDH leakage, respectively) signifies irreversible cell death (i.e. necrosis), but can also occur at the late stages of apoptosis, so caspase-3 activity (which is specific to apoptosis) was also measured to fully distinguish between necrosis and apoptosis. These findings (that CPA increased mitochondrial reduction of MTT, and decreased LDH release and caspase-3 activity) point to a role for the A<sub>1</sub> receptor in regulation of apoptosis and necrosis during hypoxia - confirming the receptors part in cardioprotection. This role for the A<sub>1</sub> receptor in both apoptosis and necrosis has also been documented in murine hearts; in isolated hearts from transgenic mice over-expressing the cardiac A<sub>1</sub> receptor it was reported that, following ischaemia/reperfusion, less apoptosis and less necrosis occurred compared to wild-type controls (Regan *et al*, 2003).

## **ii)      κ-opioid receptor**

Activation of the G<sub>i</sub>-coupled κ-opioid receptor with (-)-U-50488 conferred a different pattern of protection to the adenosine A<sub>1</sub> receptor. Hypoxia-induced LDH release was attenuated, but neither MTT metabolism or caspase-3 activity were affected. This suggests that activation of the κ-opioid receptor provides some protection against necrotic cell death in H9c2 cells, but does not modulate apoptosis or mitochondrial function. There is great variability regarding the anti-apoptotic nature of the κ-opioid receptor when using different experimental models; one study stated that activation of κ-opioid receptors in a human epithelial tumour cell line increased apoptosis (Diao *et al*, 2000), but more recently activation of this receptor has been reported to attenuate myocardial apoptosis following ischaemia/reperfusion (Rong *et al*, 2009). When measuring different parameters, even the beneficial role of cardiac



$\kappa$ -opioid receptor activation can be questioned, as activation of such receptors can be arrhythmogenic during ischaemia/reperfusion (Wong *et al*, 1990). The role of the  $\kappa$ -opioid receptor may be well documented in cardioprotection, but it is important to note that inconsistencies do arise between different *in vitro* and *in vivo* models.

### iii) $\beta$ -adrenergic receptors

As mentioned previously, the role of  $\beta$ -adrenergic receptor activation in cardioprotection is unclear and appears to differ between various models and experimental procedures. In this current study it was found that the non-selective  $\beta$ -adrenergic receptor agonist isoprenaline significantly attenuated hypoxia-induced caspase-3 activity in H9c2 cells. The functional receptor assays implied that the  $\beta_2$  but not  $\beta_1$  adrenergic receptor was present on these cells; the  $\beta_2$  receptor has a well documented role in cardioprotection (Tong *et al*, 2005), and the  $\beta_1$  receptor reportedly has a role in cardioprotection and ischaemia-reperfusion injury (Spear *et al*, 2007). It is thought that the cardioprotective properties of  $\beta$ -adrenergic receptor activation arise from coupling of  $\beta_2$  receptors with  $G_i$  protein, which is dependent on PKA activity (Tong *et al*, 2005) - PKA phosphorylates the receptor, creating a higher affinity for  $G_i$  protein over  $G_s$  protein, and inhibition of PKA has been shown to block isoprenaline-mediated cardioprotection in mouse hearts (Tong *et al*, 2005). Taking this into account, it could be presumed that the effect observed from isoprenaline is mediated by the  $\beta_2$  receptor. However, in this case it is interesting to note that the selective  $\beta_2$  agonist procaterol did not provide any significant protection against hypoxia-induced cell death (as measured by MTT reduction, LDH release and caspase-3 activity) in H9c2 cells, but did increase MTT reduction in control cells exposed to 6 hours normoxia in glucose and serum-free DMEM. It is possible that

this is mediated by a non- $\beta_2$  adrenergic receptor effect, otherwise it would be expected that isoprenaline would also induce an increase in MTT reduction.

Overall, from the agonists used in this study it can be concluded that stimulation of the adenosine  $A_1$  receptor provided the greatest cardioprotective effect in H9c2 cells.

#### iv) $K_{ATP}$ and $BK_{Ca}$ channels

Activation of mitochondrial  $K_{ATP}$  and  $BK_{Ca}$  channels are reported to protect against ischemic injury (Ardehali, 2005), and this also appears to be the case when H9c2 cells are exposed to a 6 hour hypoxic insult. Both diazoxide ( $K_{ATP}$  activator) and NS1619 ( $BK_{Ca}$  activator) significantly reduced LDH release, which was blocked by specific channel inhibitors (5-HD,  $K_{ATP}$  inhibitor; paxilline and iberiotoxin,  $BK_{Ca}$  inhibitors). NS1619 also significantly inhibited hypoxia-induced caspase-3 activity, suggesting an anti-apoptotic role for the  $BK_{Ca}$  channel in H9c2 cells.

It has been reported that NS1619-induced delayed neuronal preconditioning occurs independently of the  $BK_{Ca}$  channel, and is instead mediated by activation of the PI3K/PKB pathway, generation of reactive oxygen species and inhibition of caspases (Gáspár et al, 2008). Taking this into account two specific  $BK_{Ca}$  channel inhibitors (paxilline and iberiotoxin) were used in this present study to confirm the presence of a  $BK_{Ca}$  channel in H9c2 cells via NS1619-mediated cytoprotection, however, there is doubt surrounding the specificity of diazoxide for  $K_{ATP}$  channels. Kim *et al* (2006) suggest that activation of  $K_{ATP}$  channels by diazoxide is indirect, with diazoxide inducing translocation of PKC which then leads to opening of  $K_{ATP}$  channels. Alternatively, Dröse *et al* (2006) found that diazoxide induced oxidation of a reactive oxygen species indicator in the absence of potassium or ATP, so questioning the

involvement of  $K_{ATP}$  channels. This article also postulated that 5-HD acts as a metabolic substrate rather than an inhibitor of  $K_{ATP}$  channels. Despite these reservations regarding the specific actions of diazoxide, it is still widely accepted that it has a role in cardioprotection.

Due to the large body of work and knowledge regarding mito $K_{ATP}$  channels, it was decided to concentrate on  $BK_{Ca}$  channels for the remainder of the project. However, by finding evidence for functional expression of  $K_{ATP}$  channels the expression profile of receptors and channels on H9c2 cells has been expanded.

Although mitochondrial, not sarcolemmal,  $BK_{Ca}$  channels are reported to be expressed in myocardial cells, the  $BK_{Ca}$  channel opener NS1619 does not discriminate between channels expressed at the two locations so further investigation was required to uncover the location of  $BK_{Ca}$  channels in H9c2 cells. By probing the mitochondrial and cytoplasmic fractions of these cells with antibodies specific to the  $\alpha$  and  $\beta_4$  subunits of the  $BK_{Ca}$  channel it was shown that myocardial H9c2 cells express a  $BK_{Ca}$  channel in the mitochondria, but not cytoplasm (therefore, not in the sarcolemmal membrane). As mentioned previously, mitochondrial  $BK_{Ca}$  channels are reported to be expressed in cardiomyocytes but the presence of a plasma membrane channel is less definite (Ko *et al*, 2009), so this finding is as expected. Interestingly, the  $BK_{Ca}$  channel  $\beta_4$  subunit is believed to be the predominant subunit in the brain, with  $\beta_1$  mainly expressed in the heart (Piwonska *et al*, 2008; Jiang *et al*, 1999) – but the use of a  $\beta_1$ -specific antibody did not provide evidence for protein expression of this subtype in H9c2 cells (data not shown). However, a study using RT-PCR has identified both the  $\beta_1$  and  $\beta_4$  subunits in rat cardiac tissue (Poulsen *et al*, 2009), demonstrating that the  $\beta_4$  subunit is not purely localised to neural tissue.

BK<sub>Ca</sub> channels with associated  $\beta$ 4 subunits are less sensitive to the channel blockers charybdotoxin and iberiotoxin (Meera *et al*, 2000), so the presence of the  $\beta$ 4 subunit in H9c2 cells could explain why iberiotoxin did not block NS1619-mediated cytoprotection as fully as paxilline in this report.

In conclusion, BK<sub>Ca</sub> channels display cytoprotective properties in H9c2 cells, and the channels in question are located to the mitochondria. These mitochondrial BK<sub>Ca</sub> channels have been linked with signalling pathways mediated by GPCR agonists such as (-)-U-50488 (Cao *et al*, 2005) and adrenomedullin (Nishida *et al*, 2008), but for the first time this present study discovered a link between mitochondrial BK<sub>Ca</sub> channels and adenosine A<sub>1</sub> receptor-mediated signal transduction. It was revealed that hypoxia-induced LDH release and caspase-3 activity were attenuated by pre-treatment with CPA, the selective adenosine A<sub>1</sub> receptor agonist, and this effect could be reversed by blockade of the BK<sub>Ca</sub> channel with paxilline and iberiotoxin. This finding demonstrates that BK<sub>Ca</sub> channels (presumably mitochondrial BK<sub>Ca</sub> channels) mediate the cytoprotective and anti-apoptotic effects of the adenosine A<sub>1</sub> receptor against hypoxia-induced cell death in H9c2 cells.

### **7.3. The role of protein kinases ERK1/2 and PKB in adenosine A<sub>1</sub> receptor and BK<sub>Ca</sub> channel-mediated cytoprotection**

Having shown that stimulation of the adenosine A<sub>1</sub> receptor can lead to activation of the BK<sub>Ca</sub> channel it was then postulated that cellular protein kinases mediate some of the intermediate signal transduction pathways. Extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase B (PKB) have well documented roles in the

Reperfusion Injury Salvage Kinase (RISK) pathway (Hausenley *et al*, 2007), and have both been implicated in cardioprotection mediated by adenosine receptors (Germack & Dickenson, 2005; Germack *et al*, 2004) and mitochondrial  $K_{ATP}$  channels (de Toit *et al*, 2008; Grossini *et al*, 2009), so it was postulated that they may be involved in  $A_1$  receptor/ $BK_{Ca}$  channel signalling in H9c2 cells. Initially, cells were treated with 10  $\mu$ M NS1619 for varying amounts of time, but at no point was an increase in ERK1/2 or PKB phosphorylation observed. It was then decided to use 100  $\mu$ M NS1619, as one study reported that this activates PKB in neurones (although by a  $BK_{Ca}$  channel-independent mechanism; Gáspár *et al*, 2008). However, this finding was not replicated in H9c2 cells – in fact 100  $\mu$ M NS1619 significantly inhibited phosphorylation of PKB, and ERK1/2. It is likely that due to the high concentration used, the observed effects of NS1619 on dephosphorylation of ERK1/2 and PKB are independent of the  $BK_{Ca}$  channel – possibly occurring via activation of a phosphatase. It is interesting to note that Quercetin, a flavonoid which is reported to activate  $BK_{Ca}$  channels in coronary arteries (Cogolludo *et al*, 2007), also dephosphorylates ERK1/2 and PKB when used at a high concentration (Spencer *et al*, 2003).

As PKB and ERK1/2 are both cell survival kinases activated during periods of stress, and activation of the  $BK_{Ca}$  channel has an anti-apoptotic effect in H9c2 cells, it was proposed that increased phosphorylation of these kinases may be observed during hypoxia following pre-treatment with NS1619 (10  $\mu$ M); however this was not observed – suggesting that the anti-apoptotic effect of  $BK_{Ca}$  channel-mediated signalling occurs independently of ERK1/2 and PKB, or that  $BK_{Ca}$  channel activation occurs downstream of ERK1/2 or PKB phosphorylation. It is interesting to note that

activation of both of these protein kinases has been reported following pharmacological activation of the mitochondrial  $K_{ATP}$  channel, implying that the anti-apoptotic effects of the mitochondrial  $K_{ATP}$  channel and the  $BK_{Ca}$  channel are differentially mediated (Ahmad *et al*, 2006; Naitohel *et al*, 2006).

An alternative explanation is that compartmentalisation of ERK1/2 and PKB occurs upon activation. During the resting state of a cell ERK1/2 and PKB are distributed throughout the cytoplasm, but both have been reported to localise elsewhere when activated. Despite the lack of a nuclear localisation signal ERK1/2 has been found to accumulate in the nucleus upon activation (Chuderland *et al*, 2008), where it is then able to generate signal responses most effectively. Translocation of PKB to the mitochondria upon activation is reported in rat cardiomyocytes, where it then exerts an anti-apoptotic effect by phosphorylating hexokinase-II which prevents opening of the mPTP (Miyamoto *et al*, 2008). If this was the case, phosphorylation of ERK1/2 or PKB at specific subcellular localities may not be apparent when using whole cell lysates.

Activation of the adenosine  $A_1$  receptor with CPA has been reported to produce an increase in activity of ERK1/2 and PKB in rat cardiomyocytes (Gemack & Dickenson, 2004; Germack *et al*, 2004). In H9c2 cells CPA produced a significant, transient increase in ERK1/2 phosphorylation, but had no effect on PKB – suggesting that in these cells adenosine  $A_1$  receptor signalling is mediated by ERK1/2 but not PKB.

Using the knowledge that adenosine  $A_1$  receptor stimulation leads to activation of ERK1/2 and the  $BK_{Ca}$  channel, it was hypothesised that ERK1/2 forms part of the  $A_1$  receptor/ $BK_{Ca}$  channel signal transduction pathway. However, in H9c2 cells



blockade of the BK<sub>Ca</sub> channel did not affect CPA-mediated ERK1/2 activation – suggesting that these kinases are not phosphorylated downstream of the BK<sub>Ca</sub> channel.

Overall, these data suggest that activation of the BK<sub>Ca</sub> channel, and the signalling pathway between adenosine A<sub>1</sub> receptors and the BK<sub>Ca</sub> channel, are likely to occur independently of ERK1/2 and PKB activation in H9c2 cells.

#### **7.4. The role of the BK<sub>Ca</sub> channel in adenosine receptor-mediated protection against hypoxia-reoxygenation**

##### **i) A model for hypoxia-reoxygenation in H9c2 cells**

Studies into protection against hypoxia-induced cell death are important to help elucidate the mechanisms involved in such phenomena, but models using hypoxia-reoxygenation can provide more clinically relevant data, especially when relating to myocardial infarction. By creating a model for hypoxia-reoxygenation in H9c2 cells it was possible to then test the pre- and postconditioning potential of pharmacological activation the adenosine A<sub>1</sub> receptor and the BK<sub>Ca</sub> channel. It was observed that a protocol of 6 hours hypoxia (0.5% O<sub>2</sub> with glucose/serum-free DMEM to mimic ischaemia) followed by 18 hours reoxygenation (DMEM containing glucose and 1% serum) was sufficient to induce necrotic cell death, as measured by LDH release. No caspase-3 activity was observed though, indicating that apoptosis had not occurred. Nevertheless, it is possible that during the 24 hour long protocol of hypoxia and reoxygenation, any cell death initiated by hypoxia

could have progressed beyond the apoptotic stage – consequentially caspase-3 would not be detected but LDH would be released from the damaged and dying cells.

#### **ii) Pre- and postconditioning in H9c2 cells**

Pre-treating H9c2 cells with CPA prior to the period of hypoxia did not have any effect on LDH release, implying that adenosine A<sub>1</sub> receptor-mediated pharmacological preconditioning is not protective in H9c2 cells. Interestingly, preconditioning with NS1619 augmented LDH release, and this was reversed with paxilline and iberiotoxin – indicating that pharmacological preconditioning via activation of the BK<sub>Ca</sub> channel amplifies cell death in this model. This finding contrasts with the majority of reports regarding BK<sub>Ca</sub> channels in preconditioning, so more work would be required to uncover the mechanisms involved. It is possible that the observed increase in LDH release could be a cell specific effect, or due to the experimental protocol used. It has been shown that the time of agonist/antagonist treatment can greatly affect the experimental outcome. For example, Schröter *et al* (2005) found that excitotoxic NMDA receptor-evoked rises in neuronal intracellular calcium could be attenuated by pre-treatment with nitric oxide, but nitric oxide treatment at the time of NMDA receptor stimulation actually potentiated the toxicity. Therefore it can be expected that the treatment protocol used would affect the end result.

Conversely, activation of the BK<sub>Ca</sub> channel during the first few minutes of reoxygenation (i.e. postconditioning) significantly reduced hypoxia-reoxygenation-induced LDH release. This was also attenuated by co-treatment with paxilline and iberiotoxin, suggesting that the effect was mediated by the BK<sub>Ca</sub> channel. Currently,

this is the first report of postconditioning triggered by direct activation of the BK<sub>Ca</sub> channel.

Despite the lack of efficacy of CPA as a preconditioning agent, activation of the adenosine A<sub>1</sub> receptor created a postconditioning effect in H9c2 cells as LDH release was significantly reduced. Not only was this reversed by antagonism of the A<sub>1</sub> receptor, but also by blockade of the BK<sub>Ca</sub> channel – providing the first evidence of a role for the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> receptor-mediated postconditioning.

### iii) Preconditioning in rat ventricle strips

To validate the use of H9c2 cells as a model for investigating adenosine A<sub>1</sub> receptor and BK<sub>Ca</sub> channel mediated signalling, it was decided to verify the observed results in a more physiologically relevant model. Strips of rat ventricle are often used as a method for measuring mechanical contractile function of the tissue following various treatment protocols (for examples see: Button *et al*, 2005; Bravo *et al*, 2007; Vassallo *et al*, 2008; ). In this case, strips from the right ventricle were used as the right ventricle wall is thinner than the left, allowing for greater penetration of drugs. Following a period of hypoxia (glucose/oxygen-free KREBS solution to mimic ischaemia) contractile function of the ventricle strips returned to approximately 5% of that observed prior to hypoxia, i.e. the control phase. This was important as it conveyed that the tissue was still viable – if there had been no return of function it would be possible that the tissue had died, therefore the beneficial effects of preconditioning would be masked.

Preconditioning with NS1619 significantly enhanced the return of contractile function following hypoxia, and this was blocked by iberiotoxin. This is the first

time that activation of the BK<sub>Ca</sub> channel has been investigated, and indeed shown to be beneficial, in this model. Hypoxic preconditioning has been well documented in many different models, including rat ventricle strips (Button *et al*, 2005). However, in this model the role of the BK<sub>Ca</sub> channel had not been examined. This present study demonstrates that blockade of the BK<sub>Ca</sub> channel is sufficient to significantly inhibit the effect of hypoxic preconditioning in rat ventricle strips.

Preconditioning with selective agonists of adenosine A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> receptors has previously been reported to increase the return of contractile function in this rat ventricle strip model (Button *et al*, 2005). However, in this current study it was observed that the A<sub>1</sub> and A<sub>2A</sub> receptors were capable of inducing preconditioning, but not the A<sub>3</sub> receptor. There is no obvious explanation for this discrepancy, as the same drug was used at the same concentration in both studies (2-CI-IB-MECA, 1 μM) – more work would need to be done to clarify the effects of adenosine A<sub>3</sub> receptor activation.

The roles of the A<sub>1</sub> and A<sub>2A</sub> receptors in preconditioning of rat ventricle strips were confirmed with the observation that the beneficial effect of pre-treating with an agonist at either receptor was blocked by co-treatment with a receptor-appropriate antagonist. Following on from earlier work with H9c2 cells, it was postulated that the BK<sub>Ca</sub> channel – direct stimulation of which has been proven to be beneficial in both the H9c2 cell viability model and the ventricle tissue mechanical function model - was also involved in A<sub>1</sub> receptor-mediated preconditioning in rat ventricle strips. Indeed this was the case, as co-treatment with the A<sub>1</sub> receptor agonist CPA and the BK<sub>Ca</sub> channel blocker iberiotoxin significantly attenuated the protective effect afforded by treatment with CPA alone.

This study also revealed that blockade of the BK<sub>Ca</sub> channel could inhibit preconditioning mediated by the G<sub>s</sub>-coupled adenosine A<sub>2A</sub> receptor in rat ventricle strips. Although the adenosine A<sub>1</sub> and A<sub>2A</sub> receptors couple to different G proteins, they are both reported to activate ERK1/2 (Germack & Dickenson, 2004). It is possible, therefore, that in rat ventricle strips this common ground of ERK1/2 activation provides an intermediate step between adenosine receptor stimulation and BK<sub>Ca</sub> channel activation, or is a consequence of BK<sub>Ca</sub> channel signalling. It would be interesting to further research the signal transduction pathways involving adenosine receptors and the BK<sub>Ca</sub> channel, as this current report demonstrates a beneficial effect of such pathway activation in two separate models.

## **7.5. Conclusions and further work**

### **i) General conclusions**

Overall, this body of work has provided novel data supporting a role for the BK<sub>Ca</sub> channel in adenosine A<sub>1</sub> receptor-mediated protection against hypoxia and hypoxia-reoxygenation-induced cell death in a H9c2 myocardial cell model. This data was then validated using a model utilising isolated rat ventricle strips, and it was discovered that in this more physiologically relevant model the BK<sub>Ca</sub> channel has a pivotal role in hypoxic preconditioning and in pharmacological preconditioning mediated by the adenosine A<sub>1</sub> and adenosine A<sub>2A</sub> receptors.

### **ii) Further work**

If this body of work were to be extended, it would be important to elucidate the signal transduction pathway that occurs between the adenosine A<sub>1</sub> and A<sub>2A</sub> receptors and the BK<sub>Ca</sub> channel. Regarding the H9c2 cell model, by using subcellular fractionation it would be possible to probe distinct localities of the cells for protein kinase activity. The possible role of ERK1/2 and PKB could then be uncovered, and PKA, PKC and PKG would also make good targets for future work as they have all been linked with adenosine A<sub>1</sub> receptor-mediated signalling and/or BK<sub>Ca</sub> channel-mediated signalling. Inhibitors of PKA, PKC and PKG are also commercially available, therefore increasing the scope for examining the signalling pathways and determining the triggers, modulators and effectors.

Although there is not a commercially available direct inhibitor of ERK1/2, inhibitors of MEK1/2 are available (e.g. PD 98059) and are often used to study ERK1/2-mediated responses. The role of ERK1/2 as an upstream second messenger in adenosine A<sub>1</sub> receptor-mediated signalling is confirmed, but it is not known if ERK1/2 is part of the BK<sub>Ca</sub> channel signalling pathway. By preventing ERK1/2 activity via inhibition of MEK1/2 it would be possible to elucidate whether ERK1/2 phosphorylation occurs upstream of the BK<sub>Ca</sub> channel, as if this was the case inhibition of ERK1/2 would prevent NS1619-mediated protection.

Due to the anti-apoptotic nature of adenosine A<sub>1</sub> receptors and BK<sub>Ca</sub> channel activation, it is likely that the signal pathway between these two proteins focuses on the mitochondria. Activation of the mitochondrial BK<sub>Ca</sub> channel has been reported to reduce Ca<sup>2+</sup> overload (Kang *et al*, 2007), which would create an environment favouring closure of the mPTP – indeed it has already been suggested that the mPTP is a downstream modulator of BK<sub>Ca</sub> channel signalling (Cao *et al*, 2005 & 2005a;



Gao *et al*, 2005), and that adenosine A<sub>1</sub> receptor activation leads to inhibition of mPTP (Fei *et al*, 2009), so it appears quite likely that the anti-apoptotic effects of the adenosine A<sub>1</sub> receptor/BK<sub>Ca</sub> channel-mediated signal transduction pathway arises from inhibition of the mPTP. As yet though, this has not been looked into.

Another area of interest would be to determine the BK<sub>Ca</sub> channel subtype/s expressed and responsible for A<sub>1</sub> receptor/BK<sub>Ca</sub> channel-mediated cardioprotection in the rat heart. Western blotting with antibodies to the specific subtypes would reveal which are expressed, and then by using knock-out animals lacking the individual subtypes it would be possible to 1) ascertain the general effects of knocking out each BK<sub>Ca</sub> channel subunit (e.g. β1 or β4), and 2) establish if cardioprotection triggered by the adenosine A<sub>1</sub> receptor can still take place.

A further avenue to explore would be whether the expressions of BK<sub>Ca</sub> channel subunits are upregulated following treatment. It has been shown that the K<sub>ATP</sub> channel – which has a well documented role in preconditioning – contains a hypoxia-inducible Kir6.1 subunit (Melamed-Frank *et al*, 2001); is this also the case for the BK<sub>Ca</sub> channel and if so is this effect modulated by adenosine receptor activation?

### **iii) Concluding remarks**

In conclusion, this study has shown that activation of the BK<sub>Ca</sub> channel can provide protection against hypoxia and hypoxia-reoxygenation-induced cell death and loss of function, and that these effects are mediated by adenosine receptor signalling. Alongside the potential cardioprotective properties, opening of the BK<sub>Ca</sub> channel has been proposed to be beneficial in ischaemic stroke. *In vivo* experiments using the BK<sub>Ca</sub> channel opener BMS-204352 have shown very promising data, but clinical

trials were disappointing (Jenson, 2002), highlighting the need for more research into the mechanisms involved in BK<sub>Ca</sub> channel-mediated signalling. The data in this current report will contribute to the increasing body of knowledge regarding BK<sub>Ca</sub> channel-mediated signal transduction, and hopefully lead to further investigation and potential drug discovery.

## 8. References

- Ahmad N, Wang Y, Haider KH, Wang B, Pasha Z, Uzun O, Ashraf M. Cardiac protection by mitoKATP channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. *Am. J. Physiol. Heart Circ. Physiol.* 2006; 290:H2402–H2408.
- Ardehali H. Cytoprotective channels in mitochondria. *J Bioenerg Biomembr.* 2005; 37(3):171-7.
- Armstrong S, Ganote CE. In vitro ischaemic preconditioning of isolated rabbit cardiomyocytes: effects of selective adenosine receptor blockade and calphostin C. *Cardiovasc Res.* 1995; 29(5):647-52.
- Armstrong S, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: effects of glycolytic blockade, phorbol esters, and ischaemia. *Cardiovasc Res.* 1994; 28(11):1700-6.
- Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. *Am J Physiol.* 1999; 276(3 Pt 2):H1113-6.
- Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, Bolli R. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. *Circ Res.* 1997; 80(6):800-9.
- Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkenin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. *Nat Cell Biol.* 2007; 9(5):550-5.
- Baker JG & Hill SJ. A comparison of the antagonist affinities for the G<sub>i</sub>- and G<sub>s</sub>-coupled states of the human adenosine A<sub>1</sub> receptor. *J Pharmacol Exp Ther.* 2007; 320(1): 218-28.
- Balakumar P, Rohilla A, Singh M. Preconditioning and postconditioning to limit ischemia–reperfusion-induced myocardial injury: What could be the next footstep? *Pharm Res.* 2008; 57(6):403-12.
- Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. *J Biol Chem.* 2005; 280(19):18558-61.
- Baxter GF, Yellon DM. ATP-sensitive K<sup>+</sup> channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation. *J Mol Cell Cardiol.* 1999; 31(5):981-9.
- Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. *Am J Physiol Heart Circ Physiol.* 2007; 292(1):H19-27.
- Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. *Circ Res.* 2004; 95(2):125-34.

- Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M. PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. *Cardiovasc Res.* 2006; 69(1):178-85.
- Boucher M, Pesant S, Falcao S, de Montigny C, Schampaert E, Cardinal R, Rousseau G. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. *J Cardiovasc Pharmacol.* 2004; 43(3):416-22.
- Bravo G, Kurtansky A, López-Muñoz FJ, Hong E, Rojas G, Villalón CM, Huang F. Protective action of amlodipine on cardiac negative inotropism induced by lipopolysaccharide in rats. *Basic Clin Pharmacol Toxicol.* 2007; 100(5):339-44.
- Budas GR, Mochly-Rosen D. Mitochondrial protein kinase Cepsilon (PKCepsilon): emerging role in cardiac protection from ischaemic damage. *Biochem Soc Trans.* 2007; 35(Pt 5):1052-4.
- Budas GR, Sukhodub A, Alessi DR, Jovanović A. 3'Phosphoinositide-dependent kinase-1 is essential for ischemic preconditioning of the myocardium. *FASEB J.* 2006; 20(14):2556-8.
- Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postconditioning. *Curr Opin Pharmacol.* 2009; 9(2):177-88. Review.
- Button L, Mireylees SE, Germack R, Dickenson JM. Phosphatidylinositol 3-kinase and ERK1/2 are not involved in adenosine A1, A2A or A3 receptor-mediated preconditioning in rat ventricle strips. *Exp Physiol.* 2005; 90(5):747-54.
- Cabrera JL, de Freitas F, Satpaev DK, Slepak VZ. Identification of the Gbeta5-RGS7 protein complex in the retina. *Biochem Biophys Res Commun.* 1998; 249(3):898-902.
- Cao CM, Chen M, Wong TM. The K(Ca) channel as a trigger for the cardioprotection induced by kappa-opioid receptor stimulation - its relationship with protein kinase C. *Br J Pharmacol.* 2005; 145(7):984-91.
- Cao CM, Xia Q, Gao Q, Chen M, Wong TM. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. *J Pharmacol Exp Ther.* 2005a; 312(2):644-50.
- Cao Z, Liu L, Van Winkle DM. Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels. *Am J Physiol Heart Circ Physiol.* 2003; 285(3):H1032-9.
- Cheng Y, Gu XQ, Bednarczyk P, Wiedemann FR, Haddad GG, Siemen D. Hypoxia increases activity of the BK-channel in the inner mitochondrial membrane and reduces activity of the permeability transition pore. *Cell Physiol Biochem.* 2008; 22(1-4):127-36.
- Chuderland D, Marmor G, Shainskaya A, Seger R. Calcium-mediated interactions regulate the subcellular localization of extracellular signal-regulated kinases. *J Biol Chem.* 2008; 283(17):11176-88.

- Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. *Basic Res Cardiol.* 2008; 103(3):203-15.
- Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. *Circ Res.* 2001; 89(3):273-8.
- Cogolludo A, Frazziano G, Briones AM, Cobefio L, Moreno L, Lodi F, Salaices M, Tamargo J, Perez-Vizcaino F. The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H<sub>2</sub>O<sub>2</sub>. Role in vasodilatation. *Cardiovasc Res.* 2007; 73(2):424-31.
- Cordeaux Y, Ijzerman AP, Hill SJ. Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. *Br J Pharmacol.* 2004; 143(6):705-14.
- Cordeaux Y, Bridson SJ, Megson AE, McDonnell J, Dickenson JM, Hill SJ. Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. *Mol Pharmacol.* 2000; 58(5):1075-84.
- Costa AD, Quinlan CL, Andrukhiv A, West IC, Jaburek M, Garlid KD. The direct physiological effects of mitoK(ATP) opening on heart mitochondria. *Am J Physiol Heart Circ Physiol.* 2006; 290(1):H406-15.
- Crompton M. The mitochondrial permeability transition pore and its role in cell death. *Biochem J.* 1999; 341(2):233-49.
- Cuong DV, Kim N, Youm JB, Joo H, Warda M, Lee JW, Park WS, Kim T, Kang S, Kim H, Han J. Nitric oxide-cGMP-protein kinase G signaling pathway induces anoxic preconditioning through activation of ATP-sensitive K<sup>+</sup> channels in rat hearts. *Am J Physiol Heart Circ Physiol.* 2006; 290(5):H1808-17.
- Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. *Circ Res.* 2000; 86(9):989-97.
- Dangel V, Giray J, Ratge D, Wisser H. Regulation of beta-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2. *Biochem J.* 1996; 317 (3):925-31.
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell.* 1997; 91(2):231-41.
- Dawn B, Xuan YT, Qiu Y, Takano H, Tang XL, Ping P, Banerjee S, Hill M, Bolli R. Bifunctional role of protein tyrosine kinases in late preconditioning against myocardial stunning in conscious rabbits. *Circ Res.* 1999; 85(12):1154-63.
- Depre C, Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. *Cardiovasc Res.* 2000; 45(3):538-48.

- Diao CT, Li L, Lau SY, Wong TM, Wong NS. kappa-Opioid receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 human epithelial tumor cell line. *Biochim Biophys Acta*. 2000; 1499(1-2):49-62.
- Downey JM, Krieg T, Cohen MV. Mapping preconditioning's signaling pathways: an engineering approach. *Ann N Y Acad Sci*. 2008; 1123:187-96.
- Downward J. How BAD phosphorylation is good for survival. *Nat Cell Biol*. 1999; 1(2):E33-5.
- Dröse S, Brandt U, Hanley PJ. K<sup>+</sup>-independent actions of diazoxide question the role of inner membrane KATP channels in mitochondrial cytoprotective signaling. *J Biol Chem*. 2006; 281(33):23733-9.
- du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K(ATP) channels in pre- and postconditioning induced by levosimendan in the isolated guinea pig heart. *Br J Pharmacol*. 2008; 154(1):41-50.
- Ebina T, Toya Y, Oka N, Schwencke C, Kawabe J, Ishikawa Y. Isoform-specific regulation of adenylyl cyclase by oxidized catecholamines. *J Mol Cell Cardiol*. 1997; 29(4):1247-54.
- Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. *Circulation*. 2007; 115(12):1581-90.
- Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. *Purinergic Signal*. 2008; 4:1-20.
- Facundo HT, de Paula JG, Kowaltowski AJ. Mitochondrial ATP-sensitive K<sup>+</sup> channels prevent oxidative stress, permeability transition and cell death. *J Bioenerg Biomembr*. 2005; 37(2):75-82.
- Falcone C, Guasti L, Ochan M, Codega S, Tortorici M, Angoli L, Bergamaschi R, Montemartini C. Beta-endorphins during coronary angioplasty in patients with silent or symptomatic myocardial ischemia. *J Am Coll Cardiol*. 1993; 22(6):1614-20.
- Fei X, Yue-Sheng H, Dong-Xia Z, Zhi-Gang C, Jia-Ping Z, Qiong Z. Adenosine A1 receptor activation reduces mitochondrial permeability transition pores opening in hypoxic cardiomyocytes. *Clin Exp Pharmacol Physiol*. 2009 [Epub ahead of print].
- Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Ménard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. *Science*. 1996; 271(5247):363-6.
- Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. *Pharmacol Rev*. 2007; 59(4):418-58.
- Flameng W, Andres J, Ferdinande P, Mattheussen M, Van Belle H. Mitochondrial function in myocardial stunning. *J Mol Cell Cardiol*. 1991; 23(1):1-11.



- Flynn SB, Gristwood RW, Owen DA. Differentiation of the roles of histamine H1- and H2-receptors in the mediation of the effects of histamine in the isolated working heart of the guinea-pig. *Br J Pharmacol.* 1979; 65(1):127-37.
- Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. *Circ Res.* 2001; 88(8):802-9.
- Frances C, Nazeyrollas P, Prevost A, Moreau F, Pisani J, Davani S, Kantelip JP, Millart H. Role of beta 1- and beta 2-adrenoceptor subtypes in preconditioning against myocardial dysfunction after ischemia and reperfusion. *J Cardiovasc Pharmacol.* 2003; 41(3):396-405.
- Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.* 2001; 53(4):527-52.
- Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. *Cardiovasc Res.* 2002; 55(3):520-5.
- Fryer RM, Pratt PF, Hsu AK, Gross GJ. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. *J Pharmacol Exp Ther.* 2001; 296(2):642-9.
- Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H. 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a PDE type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca<sup>2+</sup>-activated K<sup>+</sup> channels in rabbit hearts. *J Pharmacol Exp Ther.* 2008; 326(1):100-4.
- Gao H, Chen L, Yang HT. Activation of alpha1B-adrenoceptors alleviates ischemia/reperfusion injury by limitation of mitochondrial Ca<sup>2+</sup> overload in cardiomyocytes. *Cardiovasc Res.* 2007. 75(3):584-95.
- Gao Q, Yang B, Ye ZG, Wang J, Bruce IC, Xia Q. Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin. *Eur J Pharmacol.* 2007; 574(2-3):179-84.
- Gao Q, Zhang SZ, Cao CM, Bruce IC, Xia Q. The mitochondrial permeability transition pore and the Ca<sup>2+</sup>-activated K<sup>+</sup> channel contribute to the cardioprotection conferred by tumor necrosis factor-alpha. *Cytokine.* 2005; 32(5):199-205.
- Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos Santos P. Cardioprotective signaling to mitochondria. *J Mol Cell Cardiol.* 2009; 46(6):858-66.
- Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K<sup>+</sup> channels. Possible mechanism of cardioprotection. *Circ Res.* 1997; 81(6):1072-82.
- Gáspár T, Katakam P, Snipes JA, Kis B, Domoki F, Bari F, Busija DW. Delayed neuronal preconditioning by NS1619 is independent of calcium activated potassium channels. *J Neurochem.* 2008; 105(4):1115-28.

- Gerber BL, Wijns W, Vanoverschelde JL, Heyndrickx GR, De Bruyne B, Bartunek J, Melin JA. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans. *J Am Coll Cardiol.* 1999; 34(7):1939-46.
- Germack R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. *J Mol Cell Cardiol.* 2005; 39(3):429-42.
- Germack R, Dickenson, JM. Characterisation of ERK1/2 signaling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. *Br J Pharmacol.* 2004; 141:329-39.
- Germack R, Griffin M, Dickenson JM. Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. *J Mol Cell Cardiol.* 2004; 37(5):989-99.
- Gessi S, Merighi S, Varani K, Leung E, Lennan S, Borea P. The A<sub>3</sub> adenosine receptor: An enigmatic player in cell biology. *Pharm & Thera.* 2008; 117(1):123-40.
- Gonzalez E, McGraw TE. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. *Proc Natl Acad Sci U S A.* 2009; 106(17):7004-9.
- Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. *Genes Dev.* 2001; 15(11):1406-18.
- Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. *J Mol Cell Cardiol.* 1993; 25(12):1461-9.
- Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. *Biochem J.* 1995; 307 (1):93-8.
- Gross GJ, Auchampach JA. Reperfusion injury: does it exist? *J Mol Cell Cardiol.* 2007; 42(1):12-8.
- Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. *Cardiovasc Res.* 2006; 70(2):212-21.
- Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. *Am J Physiol Heart Circ Physiol.* 2003; 285(3):H921-30.
- Grossini E, Molinari C, Caimmi PP, Uberti F, Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. *Br J Pharmacol.* 2009; 156(2):250-61.
- Gu C, Ma YC, Benjamin J, Littman D, Chao MV, Huang XY. Apoptotic signaling through the beta -adrenergic receptor. A new G<sub>s</sub> effector pathway. *J Biol Chem.* 2000; 275(27):20726-33.
- Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. *Am J Physiol.* 1990; 258(5 Pt 1):C755-86.

- Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. *Am J Physiol.* 1998; 275(4 Pt 2):H1375-87.
- Halestrap AP. What is the mitochondrial permeability transition pore? *J Mol Cell Cardiol.* 2009; 46(6):821-31.
- Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. *J Biol Chem.* 1997; 272(6):3346-54.
- Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. *Circulation.* 1995; 91(6):1872-85.
- Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? *Cardiovasc Res.* 2002; 55(3):534-43.
- Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. *Cardiovasc Res.* 2004; 63(2):305-12.
- Hausenloy DJ, Tsang A and Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. *Trends Cardiovasc Med.* 2005; 15(2):69-75.
- Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. *Am J Physiol Heart Circ Physiol.* 2005a; 288(2):H971-6.
- Hausenloy D, Wynne A, Duchon M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. *Circulation.* 2004; 109(14):1714-7.
- Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. *Cardiovasc Res.* 2006; 70(2):240-53.
- Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. *Heart Fail Rev.* 2007; 12(3-4):217-34.
- Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. *Pharmacol Ther.* 2007a; 116(2):173-91.
- Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. *Atherosclerosis* 2009; 204(2):334-41.
- Hein TW, Wang W, Zoghi B, Muthuchamy M, Kuo L. Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine. *J Mol Cell Cardiol.* 2001; 33(2):271-82.
- Headrick J.P. Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. *J Mol Cell Cardiol.* 1996; 28:1227-1240.

- Hendriks-Balk MC, Peters SL, Michel MC, Alewijnse AE. Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. *Eur J Pharmacol.* 2008; 585(2-3):278-91.
- Henry P, Demolombe S, Pucéat M, Escande D. Adenosine A1 stimulation activates delta-protein kinase C in rat ventricular myocytes. *Circ Res.* 1996; 78(1):161-5.
- Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. *Trends Mol Med.* 2002; 8(4):S27-31.
- Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. *Circ Res.* 1991; 69(6):1476-86.
- Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K<sup>+</sup> channels in cerebral ischemic preconditioning. *Proc Natl Acad Sci USA.* 1995; 92(10):4666-70.
- Hochhauser E, Leshem D, Kaminski O, Cheporko Y, Vidne BA, Shainberg A. The protective effect of prior ischemia reperfusion adenosine A1 or A3 receptor activation in the normal and hypertrophied heart. *Interact Cardiovasc Thorac Surg.* 2007; 6(3):363-8.
- Holmuhamedov EL, Wang L, Terzic A. ATP-sensitive K<sup>+</sup> channel openers prevent Ca<sup>2+</sup> overload in rat cardiac mitochondria. *J Physiol.* 1999; 519 Pt 2:347-60.
- Hommers LG, Lohse MJ, Bünemann M. Regulation of the inward rectifying properties of G-protein-activated inwardly rectifying K<sup>+</sup> (GIRK) channels by Gbeta gamma subunits. *J Biol Chem.* 2003; 278(2):1037-43.
- Hove-Madsen L, Prat-Vidal C, Llach A, Ciruela F, Casadó V, Lluís C, Bayes-Genis A, Cinca J, Franco R. Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. *Cardiovasc Res.* 2006 ; 72(2):292-302.
- Huh J, Gross GJ, Nagase H, Liang BT. Protection of cardiac myocytes via delta(1)-opioid receptors, protein kinase C, and mitochondrial K(ATP) channels. *Am J Physiol Heart Circ Physiol.* 2001; 280(1):H377-83.
- Ianoul A, Grant DD, Rouleau Y, Bani-Yaghoub M, Johnston LJ, Pezacki JP. Imaging nanometer domains of beta-adrenergic receptor complexes on the surface of cardiac myocytes. *Nat Chem Biol.* 2005; 1(4):196-202.
- Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, et al. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. *Circulation.* 2003; 108:2304-7.
- Jacobson KA, Xie R, Young L, Chang L, Liang BT. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. *J Biol Chem.* 2000; 275(39):30272-9.
- Jelsema CL, Axelrod J. Stimulation of phospholipase A2 activity in bovine rod outer segments by the  $\beta\gamma$  subunits of transducin and its inhibition by the alpha subunit.

Proc Natl Acad Sci USA. 1987; 84:3623-3627.

- Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. *CNS Drug Rev.* 2002; 8(4):353-60.
- Jiang Z, Wallner M, Meera P, Toro L. Human and rodent MaxiK channel beta-subunit genes: cloning and characterization. *Genomics.* 1999; 55(1):57-67.
- Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. *Cardiovasc Res.* 1999 Sep; 43(4):860-78.
- Joseph T, Coirault C, Lecarpentier Y. Species-dependent changes in mechanoenergetics of isolated cardiac muscle during hypoxia. *Basic Res Cardiol.* 2000; 95(5):378-84.
- Kang SH, Park WS, Kim N, Youm JB, Warda M, Ko JH, Ko EA, Han J. Mitochondrial Ca<sup>2+</sup>-activated K<sup>+</sup> channels more efficiently reduce mitochondrial Ca<sup>2+</sup> overload in rat ventricular myocytes. *Am J Physiol Heart Circ Physiol.* 2007; 293(1):H307-13.
- Kakinuma Y, Ando M, Kuwabara M, Katare RG, Okudela K, Kobayashi M, Sato T. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1 $\alpha$ . *FEBS Lett.* 2005; 579(10):2111-8.
- Keith D, Garlid, Alexandre D.T. Costa, Casey L. Quinlan, Sandrine V. Pierre, Pierre Dos Santos. Cardioprotective signalling to mitochondria. *J Mol Cell Cardiol.* 2009; 46(6):858-66.
- Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Adenosine A<sub>3</sub> agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A<sub>1</sub> antagonist DPCPX. *Am J Physiol Heart Circ Physiol.* 2001; 281(2):H847-53.
- Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Cardiac myocyte adenosine A<sub>2a</sub> receptor activation fails to alter cAMP or contractility: role of receptor localization. *Am J Physiol Heart Circ Physiol.* 2002; 282(3):H1035-40.
- Kim MY, Kim MJ, Yoon IS, Ahn JH, Lee SH, Baik EJ, Moon CH, Jung YS. Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury. *Br J Pharmacol.* 2006; 149(8):1059-70.
- Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G, Sadoshima J, Vatner DE, Vatner SF. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. *Circ Res.* 2003; 92(11):1233-9.
- Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. *Exp Cell Res.* 1976; 98(2):367-81.
- Ko JH, Ibrahim MA, Park WS, Ko EA, Kim N, Warda M, Lim I, Bang H, Han J. Cloning of large-conductance Ca(2+)-activated K(+) channel alpha-subunits in mouse cardiomyocytes. *Biochem Biophys Res Commun.* 2009; 389(1):74-9.

- Kobayashi S, Millhorn DE. Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. *J Biol Chem.* 1999; 274(29):20358-65.
- Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. *Nature.* 2004; 427(6973):461-5.
- Korge P, Ping P, Weiss JN. Reactive oxygen species production in energized cardiac mitochondria during hypoxia/reoxygenation: modulation by nitric oxide. *Circ Res.* 2008; 103(8):873-80.
- Korovkina VP, England SK. Detection and implications of potassium channel alterations. *Vascul Pharmacol.* 2002; 38(1):3-12.
- Krolkowski JG, Bienengraeber M, Weihrauch D, Warltier DC, Kersten JR, Pagel PS. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. *Anesth Analg.* 2005; 101(6):1590-6.
- Kühn B, Schmid A, Harteneck C, Gudermann T, Schultz G. G proteins of the Gq family couple the H2 histamine receptor to phospholipase C. *Mol Endocrinol.* 1996; 10(12):1697-707.
- Kuno A, Critz SD, Cui L, Solodushko V, Yang XM, Krahn T, Albrecht B, Philipp S, Cohen MV, Downey JM. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. *J Mol Cell Cardiol.* 2007; 43(3):262-71.
- Laurikka J, Wu ZK, Iisalo P, Kaukinen L, Honkonen EL, Kaukinen S, Tarkka MR. Regional ischemic preconditioning enhances myocardial performance in off-pump coronary artery bypass grafting. *Chest.* 2002; 121(4):1183-9.
- Lecour S. Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? *J Mol Cell Cardiol.* 2009, 46(5):607-9. Review.
- Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. *Biochim Biophys Acta.* 2008; 1777(7-8):946-52.
- Leung AW, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. *J Biol Chem.* 2008; 283(39):26312-23.
- Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. *J Mol Cell Cardiol.* 1999; 31(10):1937-48.
- Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. *Circulation.* 1991; 84(1):350-6.
- Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic



preconditioning and the beta-adrenergic signal transduction pathway. *Circulation*. 1999; 100(9):958-66.

- Lohse MJ. Dimerization in GPCR mobility and signaling. *Curr Opin Pharmacol*. 2009. [Epub ahead of print]
- Lorente P, Lacampagne A, Pouzeratte Y, Richards S, Malitschek B, Kuhn R, Bettler B, Vassort G.  $\gamma$ -aminobutyric acid type B receptors are expressed and functional in mammalian cardiomyocytes. *PNAS*. 2000; 97(15): 8664-9.
- Ludwig LM, Weibrauch D, Kersten JR, Pagel PS, Warltier DC. Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. *Anesthesiology*. 2004; 100(3):532-9.
- Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. *J Am Coll Cardiol*. 1999; 34(6):1711-20.
- Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol*. 1995; 146(1):3-15.
- Makaula S, Lochner A, Genade S, Sack MN, Awan MM, Opie LH. H-89, a non-specific inhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery and reduces infarct size. *J Cardiovasc Pharmacol*. 2005; 45(4):341-7.
- Malhotra R, Lin Z, Vincenz C, Brosius FC III. Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. *Am J Physiol Cell Physiol*. 2001; 281(5):C1596-603.
- Melamed-Frank M, Terzic A, Carrasco AJ, Nevo E, Avivi A, Levy AP. Reciprocal regulation of expression of pore-forming KATP channel genes by hypoxia. *Mol Cell Biochem*. 2001; 225(1-):145-50.
- Mironova GD, Negoda AE, Marinov BS, Paucek P, Costa AD, Grigoriev SM, Skarga YY, Garlid KD. Functional distinctions between the mitochondrial ATP-dependent K<sup>+</sup> channel (mitoKATP) and its inward rectifier subunit (mitoKIR). *J Biol Chem*. 2004; 279(31):32562-8.
- Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. *Cell Death Differ*. 2008; 15(3):521-9.
- Mockford KA, Girm HR, Homer-Vanniasinkam S. Postconditioning: current controversies and clinical implications. *Eur J Vasc Endovasc Surg*. 2009; 37(4):437-42.

- de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA. Caspase activation and mitochondrial cytochrome C release during hypoxia-mediated apoptosis of adult ventricular myocytes. *J Mol Cell Cardiol.* 2000; 32(1):53-63.
- Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. *Cardiovasc Res.* 2001; 52(1):25-39.
- Murata M, Akao M, O'Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. *Circ Res.* 2001; 89(10):891-8.
- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation.* 1986; 74(5):1124-36.
- Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. *Handb Exp Pharmacol.* 2009; (193):161-88.
- Nagarkatti DS, Sha'afi RI. Role of p38 MAP kinase in myocardial stress. *J Mol Cell Cardiol.* 1998; 30(8):1651-64.
- Naitoh K, Ichikawa Y, Miura T, Nakamura Y, Miki T, Ikeda Y, Kobayashi H, Nishihara M, Ohori K, Shimamoto K. MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK dependent mechanism. *Cardiovasc. Res.* 2006; 70:374-383.
- Nishida H, Sato T, Miyazaki M, Nakaya H. Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels. *Cardiovasc Res.* 2008; 77(2):398-405.
- Nishida H, Sato T, Ogura T, Nakaya H. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: mitochondrial ion channels and cardioprotection. *J Pharmacol Sci.* 2009; 109(3):341-7.
- Ohya S, Kuwata Y, Sakamoto K, Muraki K, Imaizumi Y. Cardioprotective effects of estradiol include the activation of large-conductance Ca(2+)-activated K(+) channels in cardiac mitochondria. *Am J Physiol Heart Circ Physiol.* 2005; 289(4):H1635-42.
- Okada T, Otani H, Wu Y, Uchiyama T, Kyo S, Hattori R, Sumida T, Fujiwara H, Imamura H. Integrated pharmacological preconditioning and memory of cardioprotection: role of protein kinase C and phosphatidylinositol 3-kinase. *Am J Physiol Heart Circ Physiol.* 2005; 289(2):H761-7.
- Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. *Circulation.* 1987; 76(5):1135-45.
- O'Rourke B. Evidence for mitochondrial K<sup>+</sup> channels and their role in cardioprotection. *Circ Res.* 2004; 94(4):420-32.
- Otani H, Matsuhisa S, Akita Y, Kyo S, Enoki C, Tatsumi K, Fujiwara H, Hattori R,

Imamura H, Iwasaka T. Role of mechanical stress in the form of cardiomyocyte death during the early phase of reperfusion. *Circ J*. 2006; 70(10):1344-55.

- Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. *Science*. 2000; 289(5480):739-45.
- Pan HL, Chen SR, Scicli GM, Carretero OA. Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. *Am J Physiol Heart Circ Physiol*. 2000; 279(1):H116-21.
- Peart J, Gross G. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. *Am J Physiol Heart Circ Physiol*. 2003; 285(1):H81-9.
- Peart J, Willems L, Headrick JP. Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine. *Am J Physiol Heart Circ Physiol*. 2003; 284(2):H519-27.
- Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. *Pharmacol Ther*. 2007; 114(2):208-21.
- Penna C, Perrelli MG, Raimondo S, Tullio F, Merlino A, Moro F, Geuna S, Mancardi D, Pagliaro P. Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. *Biochim Biophys Acta*. 2009; 1787(7):794-801.
- Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. *Cardiovasc Res*. 2006; 70(2):308-14.
- Phillips AB, Ko W. Effects of ischemic preconditioning and adenosine pretreatment on myocardial function and energetics in a clinically relevant model. *Life Sci*. 2007; 81(17-18):1355-61.
- Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. *Cardiovasc Res*. 2006; 70(2):308-14.
- Pinheiro BB, Fiorelli AI, Gomes OM. Effects of ischemic postconditioning on left ventricular function of isolated rat hearts. *Rev Bras Cir Cardiovasc*. 2009; 24(1):31-7.
- Piper HM, Kasseckert S, Abdallah Y. The sarcoplasmic reticulum as the primary target of reperfusion protection. *Cardiovasc Res*. 2006; 70(2):170-3.
- Piwonska M, Wilczek E, Szewczyk A, Wilczynski GM. Differential distribution of Ca<sup>2+</sup>-activated potassium channel beta4 subunit in rat brain: immunolocalization in neuronal mitochondria. *Neuroscience*. 2008; 153(2):446-60.
- Po Yee Chiu, Ka Fai Luk, Hoi Yan Leung, Ka Ming Ng, Kam Ming Ko. Schisandrin B stereoisomers protect against hypoxia/reoxygenation-induced apoptosis and inhibit associated changes in Ca<sup>2+</sup>-induced mitochondrial permeability transition and

mitochondrial membrane potential in H9c2 cardiomyocytes. *Life Sciences* 2008; 82(21-22):1092-1101.

- Poulsen AN, Wulf H, Hay-Schmidt A, Jansen-Olesen I, Olesen J, Klaerke DA. Differential expression of BK channel isoforms and beta-subunits in rat neurovascular tissues. *Biochim Biophys Acta*. 2009; 1788(2):380-9.
- Qin Q, Downey JM, Cohen MV. Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase. *Am J Physiol Heart Circ Physiol*. 2003; 284(2):H727-34.
- Redel A, Lange M, Jazbutyte V, Lotz C, Smul TM, Roewer N, Kehl F. Activation of mitochondrial large-conductance calcium-activated K<sup>+</sup> channels via protein kinase A mediates desflurane-induced preconditioning. *Anesth Analg*. 2008; 106(2):384-91.
- Regan SE, Broad M, Byford AM, Lankford AR, Cerniway RJ, Mayo MW, Matherne GP. A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity. *Am J Physiol Heart Circ Physiol*. 2003; 284(3):H859-66.
- Robinson SW, Caron MG. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. *Mol Pharmacol*. 1997; 52(3):508-14.
- Rodriguez-Enriquez S, He L, Lemasters JJ. Role of mitochondrial permeability transition pores in mitochondrial autophagy. *Int J Biochem Cell Biol*. 2004; 36(12):2463-72.
- Romano MA, Seymour EM, Berry JA, McNish RA, Bolling SF. Relative contribution of endogenous opioids to myocardial ischemic tolerance. *J Surg Res*. 2004; 118(1):32-7.
- Rong F, Peng Z, Ye MX, Zhang QY, Zhao Y, Zhang SM, Guo HT, Hui B, Wang YM, Liang C, Gu CH, Tao C, Cui Q, Yu SQ, Yi DH, Pei JM. Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist. *Arch Med Res*. 2009; 40(4):227-34.
- Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). *J Am Coll Cardiol*. 2005; 45(11):1775-80.
- Saotome M, Katoh H, Yaguchi Y, Tanaka T, Urushida T, Satoh H, Hayashi H. Transient opening of mitochondrial permeability transition pore by reactive oxygen species protects myocardium from ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol*. 2009; 296(4):H1125-32.
- Safran N, Shneyvays V, Balas N, Jacobson KA, Nawrath H, Shainberg A. Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. *Mol Cell Biochem*. 2001; 217(1-2):143-52.
- Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, Kitakaze M. Protein kinase A as another mediator of ischemic

preconditioning independent of protein kinase C. *Circulation*. 2004; 110(1):51-7.

- Sanada S, Kitakaze M. Ischemic preconditioning: emerging evidence, controversy, and translational trials. *Int J Cardiol*. 2004; 97(2):263-76.
- Sato T, Saito T, Saegusa N, Nakaya H. Mitochondrial Ca<sup>2+</sup>-activated K<sup>+</sup> channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. *Circulation* 2005; 111(2):198-203.
- Schaper J, Kostin S. Cell death and adenosine triphosphate: the paradox. *Circulation*. 2005; 112(1):6-8.
- Schömig A. Catecholamines in myocardial ischemia. Systemic and cardiac release. *Circulation*. 1990; 82(3 Suppl):II13-22.
- Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. *Circ Res*. 1990; 66(4):1133-42.
- Schreiber KL, Paquet L, Allen BG, Rindt H. Protein kinase C isoform expression and activity in the mouse heart. *Am J Physiol Heart Circ Physiol*. 2001; 281(5):H2062-71.
- Schröter A, Andrabi SA, Wolf G, Horn TF. Nitric oxide applications prior and simultaneous to potentially excitotoxic NMDA-evoked calcium transients: cell death or survival. *Brain Res*. 2005; 1060(1-2):1-15.
- Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. *Cell Signal*. 2003; 15(9):813-27.
- Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. *J Mol Cell Cardiol*. 1997; 29(8):2187-95.
- Schwartz LM, Lagranha CJ. Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. *Am J Physiol Heart Circ Physiol*. 2006; 290(3):H1011-8.
- Sharma VK, Colecraft HM, Rubin LE, Sheu SS. Does mammalian heart contain only the M2 muscarinic receptor subtype? *Life Sci*. 1997;60(13-14):1023-9.
- Shintani Y, Node K, Asanuma H, Sanada S, Takashima S, Asano Y, Liao Y, Fujita M, Hirata A, Shinozaki Y, Fukushima T, Nagamachi Y, Okuda H, Kim J, Tomoike H, Hori M, Kitakaze M. Opening of Ca<sup>2+</sup>-activated K<sup>+</sup> channels is involved in ischemic preconditioning in canine hearts. *J Mol Cell Cardiol*. 2004; 37(6):1213-8.
- Siemen D, Loupatatzis C, Borecky J, Gulbins E, Lang F. Ca<sup>2+</sup>-activated K channel of the BK-type in the inner mitochondrial membrane of a human glioma cell line. *Biochem Biophys Res Commun*. 1999; 257(2):549-54.
- Simonis G, Briem SK, Schoen SP, Bock M, Marquetant R, Strasser RH. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. *Mol Cell Biochem*. 2007; 305:103-111.

- Sivaraman V, Hausenloy DJ, Kolvekar S, Hayward M, Yap J, Lawrence D, Di Salvo C, Yellon DM. The divergent roles of protein kinase C epsilon and delta in simulated ischaemia/reperfusion injury in human myocardium. *J Mol Cell Cardiol.* 2009; 46(5):758-64.
- Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. *Am J Physiol Heart Circ Physiol.* 2006; 290(1):H441-9.
- Spear JF, Prabu SK, Galati D, Raza H, Anandatheerthavarada HK, Avadhani NG. Beta1-Adrenoreceptor activation contributes to ischemia-reperfusion damage as well as playing a role in ischemic preconditioning. *Am J Physiol Heart Circ Physiol.* 2007; 292(5):H2459-66.
- Spencer JP, Rice-Evans C, Williams RJ. Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. *J Biol Chem.* 2003; 278(37):34783-93.
- Stein AB, Bolli R, Guo Y, Wang OL, Tan W, Wu WJ, Zhu X, Zhu Y, Xuan YT. The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. *J Mol Cell Cardiol.* 2007; 42(6):1075-85.
- Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. *Circ Res.* 1994; 75(3):426-33.
- Tatsumi T, Shiraishi J, Keira N, Akashi K, Mano A, Yamanaka S, Matoba S, Fushiki S, Fliss H, Nakagawa M. Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. *Cardiovasc Res.* 2003; 59(2):428-40.
- Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. *Circulation.* 1992; 85(2):659-65.
- Tong H, Bernstein D, Murphy E, Steenbergen C. The role of beta-adrenergic receptor signaling in cardioprotection. *FASEB J.* 2005; 19(8):983-5.
- Trump BF, Berezsky IK. The role of altered  $[Ca^{2+}]_i$  regulation in apoptosis, oncosis, and necrosis. *Biochim Biophys Acta.* 1996; 1313(3):173-8.
- Uchiyama Y, Otani H, Wakeno M, Okada T, Uchiyama T, Sumida T, Kido M, Imamura H, Nakao S, Shingu K. Role of mitochondrial KATP channels and protein kinase C in ischaemic preconditioning. *Clin Exp Pharmacol Physiol.* 2003; 30(5-6):426-36.
- Urmaliya VB, Church JE, Coupar IM, Rose-Meyer RB, Pouton CW, White PJ. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. *J Cardiovasc Pharmacol.* 2009; 53(5):424-33.
- Vaidehi N, Pease JE, Horuk R. Modeling small molecule-compound binding to G-



protein-coupled receptors. *Methods Enzymol.* 2009; 460:263-88.

- Valtchanova-Matchouganska A, Ojewole JA. Mechanisms of opioid delta and kappa receptors' cardioprotection in ischaemic preconditioning in a rat model of myocardial infarction. *Cardiovasc J S Afr.* 2003; 14(2):73-80.
- Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. *Am J Physiol.* 1994; 266(2 Pt 2):H829-39.
- Varela A, Testoni G, Dalamon V, Kade P, Carregal M, Savino EA. Lack of protective effects of adenosine on the hypoxic and reoxygenated atria and ventricular strips of the rat. *J Physiol Biochem.* 1999; 55(1):17-23.
- Vassallo DV, Lebarch EC, Moreira CM, Wiggers GA, Stefanon I. Lead reduces tension development and the myosin ATPase activity of the rat right ventricular myocardium. *Braz J Med Biol Res.* 2008; 41(9):789-95.
- Velasco CE, Turner M, Cobb MA, Virmani R, Forman MB. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. *Am Heart J.* 1991; 122(6):1561-70.
- Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. *Biochim Biophys Acta.* 1989; 987(1):69-74.
- Venugopal V, Ludman A, Yellon DM, Hausenloy DJ. 'Conditioning' the heart during surgery. *Eur J Cardiothorac Surg.* 2009; 35(6):977-87.
- Viard P, Exner T, Maier U, Mironneau J, Nürnberg B, Macrez N. Gbetagamma dimers stimulate vascular L-type Ca<sup>2+</sup> channels via phosphoinositide 3-kinase. *FASEB J.* 1999; 13(6):685-94.
- Wang GY, Wu S, Pei JM, Yu XC, Wong TM. Kappa- but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. *Am J Physiol Heart Circ Physiol.* 2001; 280(1):H384-91.
- Wang X, Fisher PW, Xi L, Kukreja RC. Essential role of mitochondrial Ca<sup>2+</sup>-activated and ATP-sensitive K<sup>+</sup> channels in sildenafil-induced late cardioprotection. *J Mol Cell Cardiol.* 2008; 44(1):105-13.
- Wang X, Yin C, Xi L, Kukreja RC. Opening of Ca<sup>2+</sup>-activated K<sup>+</sup> channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. *Am J Physiol Heart Circ Physiol.* 2004; 287(5):H2070-7.
- Webster, KA, Discher DJ, Kaiser S, Hernandez O, Sato B, and Bishopric NH. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. *J Clin Invest.* 1999; 104:239-252.
- West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG, Keith RJ, Schrader J, Guo Y, Conklin DJ, Prabhu SD, Zweier JL, Bolli R, Bhatnagar A. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability

transition. *Circulation*. 2008; 118(19):1970-8.

- White TE, Dickenson JM, Alexander SP, Hill SJ. Adenosine A1-receptor stimulation of inositol phospholipid hydrolysis and calcium mobilisation in DDT1 MF-2 cells. *Br J Pharmacol*. 1992; 106(1):215-21.
- Witherow DS, Wang Q, Levay K, Cabrera JL, Chen J, Willars GB, Slepak VZ. Complexes of the G protein subunit  $\beta 5$  with the regulators of G protein signaling RGS7 and RGS9. Characterization in native tissues and in transfected cells. *J Biol Chem*. 2000; 275(32):24872-80.
- Wong TM, Lee AY, Tai KK. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart--an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. *J Mol Cell Cardiol*. 1990; 22(10):1167-75.
- Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. *Circulation*. 2002;106(24):3091-6.
- Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC. Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. *Circulation*. 2008; 118(14):S32-7.
- Xu W, Liu Y, Wang S, McDonald T, Van Eyk JE, Sidor A, O'Rourke B. Cytoprotective role of  $Ca^{2+}$ -activated  $K^{+}$  channels in the cardiac inner mitochondrial membrane. *Science*. 2002; 298(5595):1029-33.
- Xu Z, Downey JM, Cohen MV. Amp 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. *J Cardiovasc Pharmacol*. 2001; 38(3):474-81.
- Xu H, Stein B, Liang B. Characterization of a stimulatory adenosine A2a receptor in adult rat ventricular myocyte. *Am J Physiol*. 1996; 270(5 Pt 2):H1655-61.
- Yang XM, Krieg T, Cui L, Downey JM, Cohen MV. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signalling through PI3K, ERK and NO. *J Mol Cell Cardiol*. 2004a; 36(3):411-421.
- Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. *J Am Coll Cardiol*. 2004b; 44(5):1103-1110.
- Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. *Physiol Rev*. 2003; 83(4):1113-51.
- Yusifov T, Savalli N, Gandhi CS, Ottolia M, Olcese R. The RCK2 domain of the human BKCa channel is a calcium sensor. *Proc Natl Acad Sci U S A*. 2008; 105(1):376-81.
- Zatta AJ, Kin H, Lee G, Wang N, Jiang R, Lust R, Reeves JG, Mykytenko J, Guyton RA, Zhao ZQ, Vinten-Johansen J. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. *Cardiovasc Res*. 2006;

70(2):315-24.

- Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. *Am J Physiol Heart Circ Physiol.* 2003; 285(2):H579-88.
- Zimlichman R, Gefel D, Eliahou H, Matas Z, Rosen B, Gass S, Ela C, Eilam Y, Vogel Z, Barg J. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. *Circulation.* 1996; 93(5):1020-5.
- Zizzo MG, Bonomo A, Belluardo N, Mulè F, Serio R. A<sub>1</sub> receptors mediate adenosine inhibitory effects in mouse ileum via activation of potassium channels. *Life Sci.* 2009; 84(21-22):772-8.
- Zoratti M, De Marchi U, Gulbins E, Szabó I. Novel channels of the inner mitochondrial membrane. *Biochim Biophys Acta* 2009; 1787(5):351-63.
- Zoratti M, Szabó I. Electrophysiology of the inner mitochondrial membrane. *J Bioenerg Biomembr.* 1994; 26(5):543-53.
- Zordoky BN, El-Kadi AO. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. *J Pharmacol Toxicol Methods.* 2007; 56(3):317-22.



## Cardiovascular Pharmacology

Role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels in adenosine  $\text{A}_1$  receptor-mediated pharmacological preconditioning in H9c2 cells

Laurice Fretwell, John M. Dickenson\*

School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, United Kingdom

## ARTICLE INFO

## Article history:

Received 9 February 2009

Received in revised form 12 June 2009

Accepted 9 July 2009

Available online 18 July 2009

## Keywords:

Adenosine

H9c2 cell

Large-conductance  $\text{Ca}^{2+}$ -activated potassium channel

Hypoxia

Adenosine  $\text{A}_1$  receptor

Pharmacological preconditioning

## ABSTRACT

Large-conductance  $\text{Ca}^{2+}$ -activated potassium channels, located on the inner mitochondrial membrane, have recently been implicated in cytoprotection. Therefore, the primary aim of this study was to determine the role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning in the rat embryonic cardiomyoblast-derived cell line H9c2. For pharmacological preconditioning, H9c2 cells were exposed to the adenosine  $\text{A}_1$  receptor agonist  $\text{N}^6$ -cyclopentyladenosine (100 nM) or the  $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 (10  $\mu\text{M}$ ) for 30 min prior to 6 h hypoxia (0.5%  $\text{O}_2$ ) in glucose-free and serum-free media. Where appropriate cells were treated (15 min) before pharmacological preconditioning with the  $\text{Ca}^{2+}$ -activated potassium channels blockers paxilline (1  $\mu\text{M}$ ) or iberiotoxin (100 nM). Cell viability following 6 h hypoxia was assessed by monitoring lactate dehydrogenase (LDH) release and caspase-3 activation.  $\text{Ca}^{2+}$ -activated potassium channel subunit protein expression and cell survival protein kinase (ERK1/2 and PKB/Akt) activation were assessed by Western blotting. The results demonstrate that the adenosine  $\text{A}_1$  receptor is functionally expressed in H9c2 cells and when activated protects against hypoxia-induced LDH release and caspase-3 activation. Treatment with paxilline or iberiotoxin attenuated adenosine  $\text{A}_1$  receptor and NS1619-induced pharmacological preconditioning. Large-conductance  $\text{Ca}^{2+}$ -activated potassium channel  $\alpha$  and  $\beta 4$  protein subunits were detected in mitochondrial fractions isolated from H9c2 cells. NS1619 (10  $\mu\text{M}$ ) induced no significant changes in ERK1/2 or PKB phosphorylation. These results have shown for the first time that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels are involved in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning in a cell model system.

© 2009 Elsevier B.V. All rights reserved.

## 1. Introduction

Ischaemic preconditioning is a well-characterised phenomenon in which a brief period of ischaemia can protect the myocardium from infarction induced by a subsequent and prolonged ischaemic attack (Yellon and Downey, 2003). A number of membrane-bound receptors, belonging to the G-protein-coupled receptor superfamily, have been implicated in ischaemic preconditioning-induced cardioprotection including adenosine  $\text{A}_1$  and  $\text{A}_3$  receptors (Sommerschild and Kirkeboen, 2000; Headrick et al., 2003; Peart and Headrick, 2007). The cardioprotective signalling mechanisms triggered by the adenosine  $\text{A}_1$  receptor have been extensively studied and include the activation of several protein kinases including protein kinase C (Henry et al., 1996), extracellular signal regulated kinase 1/2 (ERK1/2; Germack and Dickenson, 2005), and p38 MAPK (Dana et al., 2000). These pathways enhance cell survival and modulate mitochondrial function in part through the opening of mitochondrial ATP-sensitive

potassium channels located on the inner mitochondrial membrane (Liang, 1996) and inhibition of the mitochondrial permeability transition pore (Juhászova et al., 2004).

In 2002 Xu et al. reported that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels, also located on the inner mitochondrial membrane, mediate cardioprotection against ischaemia and reperfusion injury in isolated perfused guinea-pig heart (Xu et al., 2002). Since this initial observation large-conductance  $\text{Ca}^{2+}$ -activated potassium channels have been implicated in ischaemic preconditioning against ischaemia and reperfusion injury in isolated rat and mouse hearts, anaesthetised dogs and isolated cardiac myocytes (Shintani et al., 2004; Wang et al., 2004; Cao et al., 2005a; Sato et al., 2005). Similarly, large-conductance  $\text{Ca}^{2+}$ -activated potassium channels have been linked with pharmacological preconditioning induced by a wide range of agents including estradiol, desflurane (anesthetic), puerarin (a bioactive isoflavone), tumour necrosis factor- $\alpha$ , and the phosphodiesterase type 5 inhibitor sildenafil (Gao et al., 2005; Ohya et al., 2005; Gao et al., 2007; Redel et al., 2008; Wang et al., 2008). Other studies have indicated that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels are also involved in cardioprotection induced by G-protein coupled receptor agonists including adrenomedullin and U50,488H, a kappa opioid receptor

\* Corresponding author. Tel.: +44 115 948 6683; fax: +44 115 948 6636.  
E-mail address: [john.dickenson@ntu.ac.uk](mailto:john.dickenson@ntu.ac.uk) (J.M. Dickenson).



ligand (Cao et al., 2005a; Nishida et al., 2008). However, at present the role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels in adenosine  $\text{A}_1$  receptor-induced cardioprotection is not known.

The rat embryonic cardiomyoblast-derived cell line H9c2 is increasingly used as an *in vitro* model of cardiac muscle for studies investigating cardioprotection (Katinuma et al., 2005). Previous studies using this cell line have shown that pharmacological preconditioning with adenosine protects against simulated ischaemia (Nagarkatti and Sha'afi, 1998). However, the specific subtype of adenosine receptor involved was not addressed. Therefore, the aims of this study were to determine: firstly the subtypes of adenosine receptor functionally expressed on H9c2 cells, and secondly the role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning in H9c2 cells. The results obtained indicate that H9c2 cells functionally express the adenosine  $\text{A}_1$  receptor which when stimulated mediate protection against hypoxia-induced LDH release and caspase-3 activation via the opening of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels.

## 2. Material and methods

### 2.1. Cell culture

Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Cells were cultured in Dulbecco's modified Eagles Medium (DMEM) supplemented with 2 mM L-glutamine, 10% (v/v) foetal calf serum and penicillin (100 U/ml)/streptomycin (100 µg/ml). Cells were maintained in a humidified incubator (95% air/5%  $\text{CO}_2$  at 37 °C) until 70–80% confluent and sub-cultured (1:5 split ratio) using trypsin (0.05% w/v)/EDTA (0.02% w/v). Cells for [ $^3\text{H}$ ]-cyclic AMP accumulation were grown in 24 well cluster dishes and all experiments performed using confluent monolayers.

### 2.2. Experimental protocol

H9c2 cells in glucose-free and serum-free containing DMEM were exposed to 6 h hypoxia using a hypoxic incubator (5%  $\text{CO}_2$ /0.5%  $\text{O}_2$  at 37 °C), where  $\text{O}_2$  was replaced by  $\text{N}_2$ . For pharmacological preconditioning, cells were exposed to the adenosine  $\text{A}_1$  receptor agonist CPA (100 nM) or the  $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 (10 µM) for 30 min prior to 6 h hypoxia exposure. Where appropriate, cells were also treated for 15 min before the addition of CPA or NS1619 with the large-conductance  $\text{Ca}^{2+}$ -activated potassium channels blockers paxilline (1 µM) or iberiotoxin (100 nM). Medium containing agonists, openers and inhibitors was removed and replaced with fresh glucose-free and serum-free DMEM prior to hypoxia treatment.

### 2.3. Cell viability

H9c2 cells were plated in 96-well flat bottomed plates at a final density of 5000 cells/well and cultured for 24 h in fully supplemented DMEM after which the medium was replaced with glucose- and serum-free DMEM containing 2 mM L-glutamine and penicillin/streptomycin (100 U/ml). Cell viability assays were performed by determining the activity of lactate dehydrogenase (LDH) released into the media and detected colourimetrically (CytoTox 96<sup>®</sup> Non-Radioactive Cytotoxicity LDH assay, Promega, Southampton, UK). Assays were performed according to the manufacturer's instructions.

### 2.4. Caspase 3 activity

H9c2 cells were cultured in 60 mm tissue culture dishes and Caspase 3 activity measured following 6 h hypoxia using a fluorescence-based assay. Cells were harvested using trypsin (0.05% w/v)/EDTA (0.02% w/v), centrifuged (1000 g for 5 min) and the resulting cell pellets re-suspended in 120 µl of lysis buffer (25 mM HEPES, 2.5 mM CHAPS, 2.5 mM DDT, pH

7.4) and incubated on ice for 20 min. Cell lysates were centrifuged (14,000 g, 4 °C) and the supernatant collected and stored on ice. Thirty microliters aliquots of supernatant were transferred to black 96-well microplates (Greiner Bio-One) and 50 µl assay buffer (20 mM HEPES, 5 mM DDT, 0.1% CHAPS, 2 mM EDTA, pH 7.4) and 20 µl caspase 3 substrate (0.5 mM; Acetyl-DEVD-7-amido-methylcoumarin) were added. Fluorescence readings ( $\lambda_{\text{ex}} = 355 \text{ nm}$  and  $\lambda_{\text{em}} = 460 \text{ nm}$ ) were taken over a 2 h period. Protein level was determined using the Bio-Rad DC Protein assay kit (Bio-Rad laboratories, Hertfordshire, UK) and caspase-3 activity per min per µg protein determined and expressed as a percentage of basal activity.

### 2.5. Measurement of cAMP accumulation

Confluent H9c2 cell monolayers were incubated for 2 h at 37 °C with 500 µl serum-free DMEM containing [ $^3\text{H}$ ]adenine (74 kBq/well). [ $^3\text{H}$ ]adenine-labelled cells were washed twice with Hanks buffered saline solution and then incubated in 1 ml/well serum-free DMEM containing the cyclic AMP phosphodiesterase inhibitor, rolipram (10 µM) for 15 min at 37 °C. Agonists were added (in 10 µl of medium) and incubated for a further 10 min. When assessing  $\text{G}_i$ -coupled receptor activity, the agonists were added 5 min prior to the incubation with 10 µM forskolin (10 min). Incubations were terminated by the addition of 500 µl 5% (w/v) trichloroacetic acid after removing the medium. [ $^3\text{H}$ ]-cyclic AMP was isolated by sequential Dowex-alumina chromatography as previously described (Germack and Dickenson, 2006). After elution, the levels of [ $^3\text{H}$ ]-cyclic AMP were determined by liquid scintillation counting.

### 2.6. Isolation of mitochondria

H9c2 cells were cultured in 175  $\text{cm}^2$  flasks and harvested using trypsin (0.05% w/v)/EDTA (0.02% w/v), centrifuged (300 g for 5 min) and the resulting cell pellet re-suspended in 1 ml phosphate-buffered saline (PBS) and centrifuged (300 g for 5 min). The cell pellet was re-suspended in 1 ml PBS and centrifuged (300 g for 5 min). The cell pellet was then homogenised using a dounce tissue grinder and the homogenate re-suspended in 1.5 ml extraction buffer (5 mM HEPES, 1 mM EGTA, 100 mM mannitol, 1 mM sucrose, pH 7.5) and centrifuged (1000 g for 5 min). The supernatant (representing the whole cell fraction) was further centrifuged (10,000 g for 10 min) and the resulting supernatant removed (cytoplasmic fraction). The pellet (mitochondrial fraction) was re-suspended in extraction buffer (500 µl), centrifuged (10,000 g for 10 min), supernatant removed and finally the mitochondrial pellet re-suspended in 500 µl extraction buffer.

### 2.7. Western blot analysis of $\text{Ca}^{2+}$ -activated potassium channel subunit expression and protein kinase phosphorylation

For the determination of large-conductance  $\text{Ca}^{2+}$ -activated potassium channel subunit expression isolated mitochondrial, cytoplasmic and whole cell protein fractions were mixed with an equal volume of SDS-polyacrylamide gel electrophoresis sample buffer. For the assessment of protein kinase activation H9c2 cells were exposed to the conditions and treatments described in the figure legends. Following stimulation cell supernatants were removed and the cells washed twice with ice-cold PBS and lysed in ice-cold lysis buffer [100 µl; 150 mM NaCl, 50 mM Tris HCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS (sodium dodecyl sulphate), 1 mM  $\text{Na}_3\text{VO}_4$ , 1 mM NaF, 1 mM benzamide, 0.1 mM phenylmethylsulphonylfluoride (PMSF), 10 µg/ml aprotinin and 5 µg/ml leupeptin]. Cell lysates were cleared by centrifugation (5 min; 10,000 g) at 4 °C the supernatant collected and mixed with an equal volume of SDS-polyacrylamide gel electrophoresis sample buffer. Samples were heated at 95 °C and stored at -80 °C. Protein concentration was determined using Bio-Rad DC Protein assay (Bio-

Rad laboratories, Hertfordshire, UK) with bovine serum albumin as the standard. Protein samples were separated by Sodium Dodecyl Sulphate/Polyacrylamide Gel Electrophoresis (SDS/PAGE; 12% acrylamide gel) using a Bio-Rad Mini-Protean II system (45 min at 200 V). Proteins were transferred to nitrocellulose membranes using a Bio-Rad Trans-Blot system (1 h at 100 V in 25 mM Tris, 192 mM glycine and 20% MeOH). Following transfer, the membranes were washed with Tris-buffered saline (TBS) and blocked for 1 h at room temperature in blocking buffer (TBS, 5% (w/v) skimmed milk powder, 0.1% Tween-20). Blots were then incubated overnight at 4 °C in blocking buffer with the following primary antibodies: cytochrome *c* (1:500); large-conductance  $\text{Ca}^{2+}$ -activated potassium channel  $\alpha$  subunit (1:250), large-conductance  $\text{Ca}^{2+}$ -activated potassium channel  $\beta$ 4 subunit (1:250), phospho-specific ERK1/2 (1:1000), and phospho-specific PKB (1:500). The primary antibody was removed and the blot extensively washed three times for 5 min in TBS/Tween 20. Blots were then incubated for 1 h at room temperature with the appropriate secondary antibody (1:1000) coupled to horseradish peroxidase (DAKO Ltd, Cambridge, UK) in blocking buffer. Following removal of the secondary antibody, blots were extensively washed as above and developed using the Enhanced Chemiluminescence Detection System (Amersham Pharmacia Biotech, Little Chalfont, UK) and quantified by densitometry using GeneGenius Bioimaging System (Syngene, Synoptics Ltd, UK). The uniform transfer of proteins to the nitrocellulose membrane was routinely monitored by transiently staining the membranes with Ponceau S stain (Sigma Chemical Co.) prior to application of the primary antibody. In addition, replicate samples from each experiment were analysed on separate blots using total unphosphorylated ERK1/2 (1:1000) and PKB (1:1000) primary antibodies in order to confirm the uniformity of protein loading.

### 2.8. Data analysis

Agonist  $\text{pEC}_{50}$  and  $\text{pIC}_{50}$  values (concentrations of drug producing 50% of the maximal stimulation or inhibition) were obtained by computer assisted curve fitting by use of the computer programme Prism (GraphPAD, California, U.S.A.). Statistical significance was determined by ANOVA with a post hoc Tukey's test ( $P < 0.05$  was considered statistically significant). All data are presented as means  $\pm$  S.E.M. The *n* in the text refers to the number of separate experiments.

### 2.9. Materials

[2,8- $^3\text{H}$ ]-adenine was from Amersham International (Aylesbury, Bucks, UK). Forskolin, pertussis toxin, rolipram, CPA ( $\text{N}^6$ -cyclopentyladenosine), DPCPX (1,3-dipropylcyclopentylxanthine), and NS1619 (1,3-dihydro-1-[2-hydroxy-5 (trifluoromethyl)phenyl]-5-trifluoromethyl-2Hbenzimidazol-7-yl)-2-phenyl-2-imidazolidinone) were obtained from Sigma Chemical Co. (Poole, Dorset, UK). CGS 21680 (4-[2-[[6-Amino-9-(*N*-ethyl- $\beta$ -D-ribofuranuronamidoyl)-9H-purin-2-yl]amino]ethyl] benzenepropanoic acid hydrochloride), 2-Cl-IB-MECA (1-[2-Chloro-6-[[3-(3-iodophenyl)-methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl- $\beta$ -D-ribofuranuronamide), MRS 1706 (*N*-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1*H*-purin-8-yl)phenoxy]acetamide), paxilline and ibertoxin were from Tocris (Bristol, UK). DMEM medium, foetal calf serum, trypsin (10X), L-glutamine (200 mM), penicillin (10,000 U/ml)/streptomycin (10,000  $\mu\text{g}/\text{ml}$ ) were purchased from BioWhittaker UK Ltd. Antibodies were obtained from the following suppliers: monoclonal  $\text{Ca}^{2+}$ -activated potassium channels  $\alpha$  subunit from Beckon-Dickinson; polyclonal  $\text{Ca}^{2+}$ -activated potassium channel  $\beta$ 4 subunit and monoclonal phospho-specific ERK1/2 (Thr<sup>202</sup>/Tyr<sup>204</sup>) from Sigma-Aldrich; polyclonal phospho-specific PKB (Ser<sup>473</sup>), monoclonal total unphosphorylated ERK1/2 and polyclonal total unphosphorylated PKB from New England Biolabs (U.K.) Ltd; and monoclonal cytochrome *c* from Santa Cruz Biotechnology. All other chemicals were of analytical grade. Stock concentrations of CPA (10 mM), 2-Cl-IB-MECA (10 mM), CGS 21680

(10 mM), DPCPX (10 mM), forskolin (10 mM), MRS 1706 (5 mM) and NS1619 (10 mM) were dissolved in DMSO.

## 3. Results

### 3.1. Functional expression of the adenosine $\text{A}_1$ receptor in H9c2 cells

Previous studies using H9c2 cells have reported that pharmacological preconditioning with adenosine protects against simulated ischaemia (Nagarkatti and Sha'afi, 1998). However, the specific subtype of adenosine receptor involved was not addressed. As shown in Fig. 1 the selective adenosine  $\text{A}_1$  receptor agonist  $\text{N}^6$ -cyclopentyladenosine (CPA) induced a modest inhibition of 10  $\mu\text{M}$  forskolin-stimulated [ $^3\text{H}$ ]-cyclic AMP accumulation in H9c2 cells. Interestingly, the concentration-response curve for CPA-induced inhibition of forskolin-stimulated [ $^3\text{H}$ ]-cyclic AMP accumulation was biphasic. Lower concentrations of CPA (maximal inhibition occurring at 100 nM;  $22 \pm 4\%$ ;  $n = 5$ ,  $P < 0.0001$ ) inhibited cyclic AMP accumulation induced by 10  $\mu\text{M}$  forskolin, with an approximate  $\text{pIC}_{50}$  of  $8.8 \pm 0.7$  (2 nM;  $n = 5$ ). At 1  $\mu\text{M}$  CPA no inhibition of forskolin-stimulated [ $^3\text{H}$ ]-cyclic AMP accumulation was observed ( $114 \pm 11\%$  of the forskolin alone response = 100%;  $n = 5$ ), whereas 10  $\mu\text{M}$  CPA induced a robust increase in cAMP accumulation ( $288 \pm 56\%$  of the forskolin alone response;  $n = 5$ ;  $P < 0.01$ ). Pre-treatment with pertussis toxin ( $\text{G}_{i/o}$ -protein blocker; 100 ng/ml for 16 h; see Fig. 2A) completely abolished 100 nM CPA-mediated inhibition of forskolin-stimulated [ $^3\text{H}$ ]-cyclic AMP accumulation ( $119 \pm 4\%$  of forskolin response in presence of pertussis toxin = 100%;  $n = 4$ ). The selective adenosine  $\text{A}_1$  receptor antagonist DPCPX (100 nM) also blocked CPA-mediated inhibition of forskolin-stimulated [ $^3\text{H}$ ]-cyclic AMP accumulation (Fig. 2A). Importantly, the selective adenosine  $\text{A}_{2B}$  receptor





Fig. 1. Effect of the adenosine  $\text{A}_1$  receptor agonist CPA on forskolin-stimulated cyclic AMP accumulation in H9c2 cells. (A) Cells were pre-treated for 5 min with the indicated concentrations of CPA prior to stimulation with 10  $\mu\text{M}$  forskolin for 10 min in the continued presence of agonist. Data are expressed as the percentage of the forskolin response (= 100%) and represent the mean  $\pm$  S.E.M. of four independent experiments each performed in triplicate. (B) Corresponds to the enlargement of the frame in (a). \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.0001$  versus forskolin alone response.





**Fig. 2.** Effect of adenosine  $A_1$  and  $A_{2B}$  receptor antagonists and pertussis toxin on CPA-mediated inhibition and stimulation of forskolin-stimulated cAMP accumulation in H9c2 cells. (A) Cells were pre-treated with either pertussis toxin (PTX; 100 ng ml<sup>-1</sup> for 16 h) or DPCPX (100 nM for 30 min) before stimulation with CPA (100 nM) for 5 min prior to forskolin (10  $\mu$ M) for 10 min. (B) Cells were pre-treated with MRS 1706 (100 nM for 30 min) before stimulation with CPA (10  $\mu$ M) for 5 min prior to forskolin (10  $\mu$ M) for 10 min. Data are expressed as the percentage of the forskolin response in control cells (=100%) and represent the mean  $\pm$  S.E.M. of four independent experiments each performed in triplicate. \* $P$ <0.05 versus control forskolin response; \*\* $P$ <0.05 versus control 100 nM CPA; \*\*\* $P$ <0.01 versus control 10  $\mu$ M CPA.

antagonist MRS 1706 had no significant affect on 10  $\mu$ M CPA-induced [<sup>3</sup>H]-cyclic AMP accumulation thus eliminating the possible involvement of the adenosine  $A_{2B}$  receptor (Fig. 2B). The adenosine  $A_3$  receptor agonist CI-IB-MECA (up to 1  $\mu$ M;  $n$ =5) had no significant effect on forskolin-stimulated [<sup>3</sup>H]-cyclic AMP accumulation (data not shown). Finally, the adenosine  $A_{2A}$  receptor agonist CGS 21680 (up to 10  $\mu$ M;  $n$ =5) did not stimulate or inhibit cAMP accumulation in H9c2 cells (data not shown).


### 3.2. Time course of hypoxia-induced cell death in H9c2 cells

H9c2 cells in serum-free and glucose-free medium were exposed to hypoxia (0.5% O<sub>2</sub>) for varying time periods (up to 24 h) as a model of simulated hypoxia. The effects of hypoxia on cell viability were assessed by monitoring LDH activity released into the medium and caspase-3 activity compared to normoxic control cells (Fig. 3). According to the

decrease in cell viability (LDH release) and caspase-3 activation the time period of 6 h of hypoxia was used study the role of Ca<sup>2+</sup>-activated potassium channels in A<sub>1</sub> adenosine receptor-mediated pharmacological preconditioning in H9c2 cells.

### 3.3. Role of large-conductance Ca<sup>2+</sup>-activated potassium channels in CPA and NS1619-induced pharmacological preconditioning


The Ca<sup>2+</sup>-activated potassium channel family comprises of three members; namely small-conductance (SK<sub>Ca</sub>), intermediate-conductance (IK<sub>Ca</sub>) and large-conductance (BK<sub>Ca</sub>) channels (Eichhorn and Dobrev, 2007). As outlined in the Introduction it is the large-conductance Ca<sup>2+</sup>-activated potassium channel that has been implicated in cardioprotection. The experimental evidence for its involvement is based largely on the use of selective pharmacological agents including the selective inhibitors paxilline and iberiotoxin (Eichhorn and Dobrev, 2007). In this study the role of large-conductance Ca<sup>2+</sup>-activated potassium channels in adenosine A<sub>1</sub> receptor-induced pharmacological preconditioning was explored using the aforementioned pharmacological agents. H9c2 cells were pharmacologically preconditioned with the adenosine A<sub>1</sub> receptor agonist CPA (100 nM) or the large-conductance Ca<sup>2+</sup>-activated potassium channel opener NS1619 (10  $\mu$ M) for 30 min prior to 6 h hypoxia. Hypoxia-induced release of LDH (180  $\pm$  9% of normoxic control;  $n$ =11) was significantly reduced by CPA (Fig. 4A; 128  $\pm$  7% of hypoxic control;  $n$ =11;  $P$ <0.01). Furthermore, DPCPX (100 nM) reversed CPA-induced protection (Fig. 4A; 175  $\pm$  12% of hypoxic control;  $n$ =6) confirming the involvement of the adenosine A<sub>1</sub> receptor. The large-conductance Ca<sup>2+</sup>-activated potassium channel inhibitors paxilline (1  $\mu$ M) and iberiotoxin (100 nM) had no effect on hypoxia-induced LDH release




**Fig. 3.** Effect of simulated hypoxia on LDH release and caspase 3 activity in H9c2 cells. Cells in glucose-free and serum-free DMEM were exposed to hypoxia (0.5% O<sub>2</sub>) for the indicated periods of time. Cell viability was assessed by measuring (A) LDH release and (B) caspase-3 activity. Data are expressed as the percentage of the normoxic control (=100%) and represent the mean  $\pm$  S.E.M. of five (A) and four (B) independent experiments each performed in duplicate. \* $P$ <0.05, \*\* $P$ <0.01 and \*\*\* $P$ <0.0001 versus basal response.

but significantly reduced CPA-induced protection (Fig. 4A;  $167 \pm 16\%$  and  $159 \pm 17\%$  respectively of hypoxic control;  $n = 5$ ;  $P < 0.05$ ). In a series of separate experiments hypoxia-induced release of LDH (Fig. 4B;  $161 \pm 12\%$  of normoxic control;  $n = 7$ ) was also reduced by  $10 \mu\text{M}$  NS1619 ( $111 \pm 10\%$  of hypoxic control;  $n = 7$ ;  $P < 0.01$ ). Both paxilline and iberitoxin significantly reduced NS1619-induced protection (Fig. 4B;  $151 \pm 14\%$  and  $140 \pm 12\%$  respectively of hypoxic control;  $n = 5$ ;  $P < 0.05$ ).

Since LDH release does not discriminate between apoptotic and necrotic forms of cell death we subsequently measured caspase 3 activity as a marker of apoptotic cell death. Hypoxia-induced caspase-3 activity ( $176 \pm 18\%$  of normoxic control;  $n = 4$ ) was significantly reduced by CPA (Fig. 5A;  $124 \pm 15\%$ ;  $n = 4$ ;  $P < 0.05$ ). The large-conductance  $\text{Ca}^{2+}$ -activated potassium channel inhibitors paxilline ( $1 \mu\text{M}$ ) and iberitoxin ( $100 \text{ nM}$ ) had no effect on hypoxia-induced caspase-3 activity but significantly reduced CPA-induced protection (Fig. 5A;  $174 \pm 18\%$  and  $179 \pm 38\%$  respectively of hypoxic control;  $n = 4$ ;  $P < 0.05$ ). In a series of separate experiments hypoxia-induced caspase-3 activity (Fig. 5B;  $194 \pm 16\%$  of normoxic control;  $n = 4$ ) was also reduced by  $10 \mu\text{M}$  NS1619 ( $125 \pm 10\%$



**Fig. 4.** The effect of  $\text{Ca}^{2+}$ -activated potassium channel blockers on hypoxia-induced LDH release in H9c2 cells subjected to pharmacological preconditioning with CPA in the absence or presence of the adenosine  $\text{A}_1$  receptor antagonist DPCPX ( $100 \text{ nM}$ ) and NS1619. H9c2 cells were treated for 15 min with either the  $\text{Ca}^{2+}$ -activated potassium channel blockers paxilline ( $1 \mu\text{M}$ ) or iberitoxin (IbTx;  $100 \text{ nM}$ ) before the addition of (A) the selective adenosine  $\text{A}_1$  receptor agonist CPA ( $100 \text{ nM}$ ) or (B) the  $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 ( $10 \mu\text{M}$ ) for 30 min prior to 6 h hypoxia ( $0.5\% \text{ O}_2$ ) or 6 h normoxia ( $21\% \text{ O}_2$ ). After 6 h hypoxia/normoxia cell viability was assessed by monitoring the release of LDH into the culture medium. Data are expressed as the percentage of the normoxic control (= 100%) and represent the mean  $\pm$  S.E.M. of 5–11 independent experiments. \*\* $P < 0.01$  versus hypoxic control; # $P < 0.05$  versus hypoxia/CPA or hypoxia/NS1619.



**Fig. 5.** The effect of  $\text{Ca}^{2+}$ -activated potassium channel blockers on hypoxia-induced caspase-3 activation in H9c2 cells subjected to pharmacological preconditioning with CPA and NS1619. H9c2 cells were treated for 15 min with either the  $\text{Ca}^{2+}$ -activated potassium channel blocker paxilline ( $1 \mu\text{M}$ ) or iberitoxin (IbTx;  $100 \text{ nM}$ ) before the addition of (A) the selective adenosine  $\text{A}_1$  receptor agonist CPA ( $100 \text{ nM}$ ) or (B) the  $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 ( $10 \mu\text{M}$ ) for 30 min prior to 6 h hypoxia ( $0.5\% \text{ O}_2$ ) or 6 h normoxia ( $21\% \text{ O}_2$ ). After 6 h hypoxia/normoxia cell viability was assessed by monitoring caspase-3 activation. Data are expressed as the percentage of the normoxic control (= 100%) and represent the mean  $\pm$  S.E.M. of four independent experiments. \* $P < 0.05$  versus hypoxic control; # $P < 0.05$  versus hypoxia/CPA or hypoxia/NS1619.

of hypoxic control;  $n = 4$ ;  $P < 0.05$ ). Although paxilline significantly reduced NS1619-induced protection (Fig. 5B;  $206 \pm 26\%$ ;  $n = 4$ ;  $P < 0.05$ ), iberitoxin had no significant effect.


#### 3.4. Expression of large-conductance $\text{Ca}^{2+}$ -activated potassium channel protein subunits in H9c2 cells

The expression of large-conductance  $\text{Ca}^{2+}$ -activated potassium channel  $\alpha$  and  $\beta 4$  subunits was investigated in mitochondria isolated from H9c2 cells. Both subunits were detected in mitochondrial fractions but not in either the cytosolic or whole cell protein extracts (Fig. 6). The purity of the mitochondrial fraction was assessed by confirming the expression of cytochrome *c*, which as expected was not detected in the cytosolic fraction.

#### 3.5. Effect of the large-conductance $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 on ERK1/2 and PKB phosphorylation

In view of the apparent anti-apoptotic effect of large-conductance  $\text{Ca}^{2+}$ -activated potassium channel opening in H9c2 cells the possible





**Fig. 6.** Expression of  $\text{Ca}^{2+}$ -activated potassium channel subunits in mitochondrial preparations from H9c2 cells. Cytoplasmic (Cyto), mitochondrial (mito), and whole cell (TE) protein fractions (30  $\mu\text{g}$ ) were monitored for  $\text{Ca}^{2+}$ -activated potassium channel  $\alpha$  and  $\beta 4$  subunit expression using Western blot analysis. Protein samples were also analysed for cytochrome c expression to confirm mitochondrial fraction purity. Similar results were obtained in 2 further preparations.

regulation of ERK1/2 and PKB by NS1619 was explored. Potential changes in ERK1/2 and PKB phosphorylation, which reflects the activation of these protein kinases, were monitored by Western blotting using phospho-specific ERK1/2 ( $\text{Thr}^{202}/\text{Tyr}^{204}$ ) and PKB ( $\text{Ser}^{473}$ ) antibodies. Time course experiments (15, 30, 60, 120 and 180 min) revealed no significant effect of NS1619 (10  $\mu\text{M}$ ) on PKB or ERK1/2 phosphorylation in H9c2 cells (data not shown). In subsequent experiments levels of phosphorylated ERK1/2 and PKB were monitored in cells treated with NS1619 (10  $\mu\text{M}$ ) for 30 min prior to hypoxia (0.5%  $\text{O}_2$ ) for varying time periods (1, 2, 4, and 6 h) and compared to normoxic controls. Pharmacological preconditioning with NS1619 (10  $\mu\text{M}$ ) revealed no significant affect on PKB or ERK1/2 phosphorylation under hypoxic (0.5%  $\text{O}_2$ ) conditions (data not shown).

#### 4. Discussion

The initial aim of this study was to identify which subtype(s) of adenosine receptor are functionally expressed on H9c2 cells. Previous studies have shown that rat ventricular cardiomyocytes functionally express adenosine  $\text{A}_1$ ,  $\text{A}_{2A}$  and  $\text{A}_3$  receptors (Martens et al., 1987; Linden, 1994; Dixon et al., 1996; Xu et al., 1996; Dobson and Fenton, 1997; Germack and Dickenson, 2004). Of the four cloned subtypes of adenosine receptor the adenosine  $\text{A}_1$  and  $\text{A}_3$  receptors activate  $\text{G}_{i/o}$  protein and inhibit adenylyl cyclase whereas, adenosine  $\text{A}_{2A}$  and  $\text{A}_{2B}$  receptors signal through  $\text{G}_s$  and activate adenylyl cyclase (Headrick et al., 2003). In this study the functional expression of adenosine receptor subtypes was determined by measuring the effect of selective adenosine receptor agonists on forskolin-stimulated cAMP accumulation ( $\text{G}_{i/o}$ -coupled) or cAMP accumulation directly ( $\text{G}_s$ -coupled). The adenosine  $\text{A}_1$  receptor agonist CPA attenuated forskolin-stimulated cAMP accumulation in a pertussis toxin sensitive manner, which is indicative of  $\text{G}_{i/o}$ -protein coupling. However, it is notable that the concentration–response curve for CPA-induced inhibition of forskolin-stimulated cAMP accumulation was biphasic (Fig. 1). Inhibition of forskolin-stimulated cAMP accumulation was observed at lower concentrations of CPA (<100 nM), whereas at concentrations above 100 nM, the inhibitory effect was reversed resulting in a marked cAMP accumulation at 10  $\mu\text{M}$  CPA. These observations suggest that the endogenously expressed adenosine  $\text{A}_1$  receptor in H9c2 cells may also couple to  $\text{G}_s$ -protein. Coupling of the human adenosine  $\text{A}_1$  receptor to  $\text{G}_s$ -protein has been observed in transfected CHO-K1 cells treated with pertussis toxin to prevent  $\text{G}_{i/o}$ -protein coupling (Cordeaux et al., 2004). Finally, selective adenosine  $\text{A}_3$  and  $\text{A}_{2A}$  receptor agonists did not inhibit or stimulate cAMP accumulation suggesting that these two adenosine receptor subtypes are not functionally expressed on H9c2 cells. Overall, these data suggest functional expression of the adenosine  $\text{A}_1$  receptor in H9c2 cells.

The role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning was subsequently investigated using an *in vitro* model of simulated hypoxia. Hypoxia-induced LDH release was significantly reduced by pharmaco-

logical preconditioning with the adenosine  $\text{A}_1$  receptor agonist CPA. The role of large-conductance  $\text{Ca}^{2+}$ -activated potassium channels was investigated pharmacologically using two distinct  $\text{Ca}^{2+}$ -activated potassium channel inhibitors, paxilline (Sanchez and McNanus, 1996) and iberiotoxin (Giangiacomo et al., 1992). Both of these inhibitors attenuated protection triggered by the adenosine  $\text{A}_1$  receptor agonist CPA indicating for the first time that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels are involved in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning. The selective large-conductance  $\text{Ca}^{2+}$ -activated potassium channel opener NS1619 (Olesen et al., 1994) also reversed hypoxia-induced LDH release in H9c2 cells supporting the observation that these channels are involved in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning. Furthermore, the protection induced by NS1619 was blocked by the large-conductance  $\text{Ca}^{2+}$ -activated potassium channel inhibitors paxilline and iberiotoxin. This is an important observation since recent data suggests that NS1619 may mediate cellular protection via  $\text{Ca}^{2+}$ -activated potassium channel-independent pathways (Cancherini et al., 2007; Gáspár et al., 2008). For example, it has been reported that NS1619 promotes non-selective permeabilization of the inner mitochondrial membrane to ions in isolated heart mitochondria and  $\text{Ca}^{2+}$ -activated potassium channel-independent delayed preconditioning in rat cortical neuronal cultures (Cancherini et al., 2007; Gáspár et al., 2008). It is important to note that the concentrations of paxilline (1  $\mu\text{M}$ ), iberiotoxin (100 nM) and NS1619 (10  $\mu\text{M}$ ) used in this study are comparable to those employed in published data (Cao et al., 2005a,b; Gao et al., 2005).

Since monitoring cell viability by LDH release does not discriminate between apoptotic and necrotic forms of cell death we also monitored caspase-3 activity during simulated hypoxia. Hypoxia-induced caspase-3 activity was significantly reduced by adenosine  $\text{A}_1$  receptor-mediated pharmacological preconditioning. These data are in agreement with our previous work showing that adenosine  $\text{A}_1$  receptor-mediated preconditioning inhibits hypoxia/reoxygenation-induced caspase-3 activation in neonatal rat cardiomyocytes (Germack and Dickenson, 2005). Notably both paxilline and iberiotoxin attenuated the ability of CPA to block hypoxia-induced caspase-3 activity indicating for the first time that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels are involved in the anti-apoptotic effect of adenosine  $\text{A}_1$  receptor-induced protection. Similarly, NS1619 also reversed hypoxia-induced caspase-3 activation and this protection was blocked by paxilline. To our knowledge this is the first report of NS1619 triggering an anti-apoptotic effect which appears to be large-conductance  $\text{Ca}^{2+}$ -activated potassium channel dependent. Previous studies exploring the cardioprotective effects of NS1619 have predominantly monitored either infarct size, LDH release or cell viability via trypan blue exclusion, which do not indicate whether the mode of cell death is apoptotic or necrotic (Xu et al., 2002; Wang et al., 2004; Cao et al., 2005a,b; Gao et al., 2005; Sato et al., 2005; Gao et al., 2007; Wang et al., 2008; Nishida et al., 2008). Although it is interesting to note that Gáspár et al. (2008) reported that NS1619 induced neuroprotection involved caspase-3/7 inhibition which was  $\text{Ca}^{2+}$ -activated potassium channel-independent.

Large-conductance  $\text{Ca}^{2+}$ -activated potassium channels are tetramers of four pore-forming  $\alpha$  subunits surrounded by four  $\beta$  subunits, which can be  $\beta 1$ ,  $\beta 2$ ,  $\beta 3$  or  $\beta 4$ , and modulate channel activity (Torres et al., 2007). Furthermore, the large-conductance  $\text{Ca}^{2+}$ -activated potassium channel  $\beta$  subunits display tissue-specific expression and generate large-conductance  $\text{Ca}^{2+}$ -activated potassium channels with differing pharmacological and biophysical properties (Torres et al., 2007). The large-conductance  $\text{Ca}^{2+}$ -activated potassium channels is thought to mediate cardioprotection via its proposed location on the inner mitochondrial membrane (Xu et al., 2002). Indeed, protein expression of the  $\text{Ca}^{2+}$ -activated potassium channels  $\beta 1$  subunit has been reported in mitochondria isolated from rat and mouse ventricular tissue (Wang et al., 2004; Ohya et al., 2005). In this study we detected large-conductance  $\text{Ca}^{2+}$ -activated potassium channels  $\alpha$  and  $\beta 4$  subunit protein expression in mitochondrial fractions isolated from H9c2 cells.



However, we did not detect the expression of  $\beta 1$  subunit using a commercially available antibody. The presence of the  $\beta 4$  subunit generates large-conductance  $\text{Ca}^{2+}$ -activated potassium channels, which are less sensitive to iberiotoxin, which may explain the lack of significant effect of this inhibitor on NS1619-induced attenuation of hypoxia-induced caspase-3 activation (Meera et al., 2000). Overall, these observations further support the hypothesis that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels, located within the mitochondria, are involved in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning.

The finding in this study that large-conductance  $\text{Ca}^{2+}$ -activated potassium channels activation promotes cell survival via an anti-apoptotic effect (inhibition of caspase 3) suggests that channel opening may modulate the activity of protein kinases associated with cell survival, namely protein kinase B (PKB or Akt) and/or ERK1/2 (Armstrong, 2004; Hausenloy and Yellon, 2007). Activation of these protein kinases elicits cardioprotection and they are key players in the Reperfusion-Injury Salvage Kinase pathway (Hausenloy and Yellon, 2004). It is worth noting that mitochondrial ATP-sensitive potassium channel openers induce the activation of PKB (Ahmad et al., 2006) and ERK1/2 (Naitoh et al., 2006) suggesting these protein kinases are downstream of the channel. In this study, using NS1619 (10  $\mu\text{M}$ ) at the concentration shown to induce protection and at the time points indicated, we did not observe any significant activation of PKB or ERK1/2. It is interesting to note that NS1619-induced activation of PKB has been observed in cortical neurons using similar time points to this study but at a concentration of 100  $\mu\text{M}$  (Gáspár et al., 2008). However, we have observed a significant inhibition of PKB and ERK1/2 phosphorylation by 100  $\mu\text{M}$  NS1619 in H9c2 cells (data not shown). Furthermore no significant changes in PKB and ERK1/2 phosphorylation were observed following pharmacological preconditioning with NS1619 under hypoxic conditions using cell lysates. However, this may reflect compartmentalisation of PKB and/or ERK1/2 activation to a particular subcellular location which is not apparent when monitoring activation using whole cell lysates. We have previously shown that adenosine  $\text{A}_1$  receptor-mediated pharmacological preconditioning inhibits hypoxia/reoxygenation-induced caspase-3 activation via an ERK1/2-dependent pathway in neonatal rat cardiomyocytes (Germack and Dickenson, 2005). Adenosine  $\text{A}_1$  receptor stimulation in H9c2 cells induces ERK1/2 activation which appears to be independent of large-conductance  $\text{Ca}^{2+}$ -activated potassium channel opening since paxilline and iberiotoxin had no significant effect on CPA-induced ERK1/2 activation (Dickenson and Fretwell; unpublished observations). Overall these data suggest that the anti-apoptotic effect of large-conductance  $\text{Ca}^{2+}$ -activated potassium channel opening in H9c2 cells is independent of PKB and ERK1/2 activation.

The anti-apoptotic effect of  $\text{Ca}^{2+}$ -activated potassium channel opening observed in this study may reflect inhibition of the mitochondrial permeability transition pore which is thought to be located downstream of this channel (Cao et al., 2005a,b; Gao et al., 2005). Additional protective mechanisms associated with  $\text{Ca}^{2+}$ -activated potassium channel opening include reduction in mitochondrial  $\text{Ca}^{2+}$  overload (Kang et al., 2007), which would aid mitochondrial permeability transition pore closure, and the generation of reactive oxygen species (Heinen et al., 2006). Hence, in view of the suggested involvement of mitochondrial permeability transition pore inhibition in adenosine  $\text{A}_1$  receptor-induced cardioprotection (Juhászova et al., 2004) future experiments will seek to establish the precise role of  $\text{Ca}^{2+}$ -activated potassium channel opening in this process.

In conclusion, the adenosine  $\text{A}_1$  receptor is functionally expressed on the rat cardiomyoblast cell line H9c2 and when activated mediates pharmacological preconditioning against hypoxia-induced LDH release and caspase-3 activation. Importantly, we have shown for the first time that the large-conductance  $\text{Ca}^{2+}$ -activated potassium channel is involved in adenosine  $\text{A}_1$  receptor-induced pharmacological preconditioning.

## Acknowledgement

This work was funded by The Nottingham Trent University.

## References

- Ahmad, N., Wang, Y., Haider, K.H., Wang, B., Pasha, Z., Uzun, O., Ashraf, M., 2006. Cardiac protection by  $\text{mitoK}_{\text{ATP}}$  channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. *Am. J. Physiol. Heart Circ. Physiol.* 290, H2402–H2408.
- Armstrong, S.C., 2004. Protein kinase activation and myocardial ischemia/reperfusion injury. *Cardiovasc. Res.* 61, 427–436.
- Cancherini, D.V., Queliconi, B.B., Kowaltowski, A.J., 2007. Pharmacological and physiological stimuli do not promote  $\text{Ca}^{2+}$ -sensitive  $\text{K}^+$  channel activity in isolated heart mitochondria. *Cardiovasc. Res.* 73, 720–728.
- Cao, C.-M., Chen, M., Wong, T.-M., 2005a. The  $\text{K}_{\text{Ca}}$  channel as a trigger for the cardioprotection induced by kappa-opioid receptor stimulation – its relationship with protein kinase C. *Br. J. Pharmacol.* 145, 984–991.
- Cao, C.-M., Xia, Q., Gao, Q., Chen, M., Wong, T.-M., 2005b. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. *J. Pharmacol. Exp. Ther.* 312, 644–650.
- Cordeaux, Y., Ijzerman, A.P., Hill, S.J., 2004. Coupling of the human  $\text{A}_1$  adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. *Br. J. Pharmacol.* 143, 705–714.
- Dana, A., Skarli, M., Papakrivopoulou, J., Yellon, D.M., 2000. Adenosine  $\text{A}_1$  receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase and protein kinase C-dependent mechanism. *Circ. Res.* 86, 989–997.
- Dixon, A.K., Gubitzi, A.K., Sirinathsinghi, D.J.S., Richardson, P.J., Freeman, T.C., 1996. Tissue distribution of adenosine receptor mRNAs in the rat. *Br. J. Pharmacol.* 118, 1461–1468.
- Dobson Jr., J.G., Fenton, R.A., 1997. Adenosine  $\text{A}_2$  receptor function in rat ventricular myocytes. *Cardiovasc. Res.* 34, 337–347.
- Eichhorn, B., Dobrev, D., 2007. Vascular large conductance calcium-activated potassium channels: functional role and therapeutic potential. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 376, 145–155.
- Gao, Q., Zhang, S.-Z., Cao, C.-M., Bruce, I.C., Xia, Q., 2005. The mitochondrial permeability transition pore and the  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channel contribute to the cardioprotection conferred by tumor necrosis factor- $\alpha$ . *Cytokine* 32, 199–205.
- Gao, Q., Yang, B., Ye, Z., Wang, J., Bruce, I.C., Xia, Q., 2007. Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin. *Eur. J. Pharmacol.* 574, 179–184.
- Gáspár, T., Katakam, P., Snipes, J.A., Kis, B., Domoki, F., Bari, F., Busija, D.W., 2008. Delayed neuronal preconditioning by NS1619 is independent of calcium activated potassium channels. *J. Neurochem.* 105, 1115–1128.
- Germack, R., Dickenson, J.M., 2004. Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. *Br. J. Pharmacol.* 141, 329–339.
- Germack, R., Dickenson, J.M., 2005. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. *J. Mol. Cell. Cardiol.* 39, 429–442.
- Germack, R., Dickenson, J.M., 2006. Induction of  $\beta_3$ -adrenoceptor receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. *J. Pharmacol. Exp. Ther.* 316, 392–402.
- Giangiacomo, K.M., Garcia, M.K., McManus, O.B., 1992. Mechanism of iberiotoxin block of large-conductance calcium-activated potassium channel from bovine aortic smooth muscle. *Biochemistry* 31, 6719–6727.
- Hausenloy, D.J., Yellon, D.M., 2004. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion-Injury Salvage Kinase (RISK)-pathway. *Cardiovasc. Res.* 61, 448–460.
- Hausenloy, D.J., Yellon, D.M., 2007. Preconditioning and postconditioning: united at reperfusion. *Pharmacol. Ther.* 116, 173–191.
- Headrick, J.P., Hack, B., Ashton, K.J., 2003. Acute adenosinergic cardioprotection in ischemic-reperfused heart. *Am. J. Physiol. Circ. Physiol.* 285, H1797–H1818.
- Heinen, A., Camara, A.K.S., Aldakkak, M., Rhodes, S.S., Riess, M.L., Stowe, D.F., 2006. Mitochondrial  $\text{Ca}^{2+}$ -induced  $\text{K}^+$  influx increases respiration and enhances ROS production while maintaining membrane potential. *Am. J. Physiol. Cell. Physiol.* 292, C148–C156.
- Henry, P., Demolombe, S., Puceat, M., Escande, D., 1996. Adenosine  $\text{A}_1$ AR stimulation activates  $\delta$ -protein kinase C in rat ventricular myocytes. *Circ. Res.* 78, 161–165.
- Juhászova, M., Zorov, D.B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K.W., Ziman, B.D., Wang, S., Ytrehus, K., Antos, C.L., Olson, E.N., Sollott, S.J., 2004. Glycogen synthase kinase-3 $\beta$  mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. *J. Clin. Invest.* 113, 1535–1549.
- Kang, S.H., Park, W.S., Kim, N., Youm, J.B., Warda, M., Ko, J.-H., Ko, E.A., Han, J., 2007. Mitochondrial  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels more efficiently reduce mitochondrial  $\text{Ca}^{2+}$  overload in rat ventricular myocytes. *Am. J. Physiol. Heart Circ. Physiol.* 293, H307–H313.
- Katsuma, Y., Ando, M., Kuwabara, M., Katare, R.G., Okudela, K., Kabayashi, M., Sato, T., 2005. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxia induction of HIF-1 $\alpha$ . *FEBS Lett.* 579, 2111–2118.
- Liang, B.T., 1996. Direct preconditioning of cardiac ventricular myocytes via adenosine  $\text{A}_1$  receptor and  $\text{K}_{\text{ATP}}$  channel. *Am. J. Physiol. Circ. Physiol.* 40, H1769–1777.
- Linden, J., 1994. Cloned adenosine  $\text{A}_3$  receptors: pharmacological properties, species differences and receptor functions. *Trends Pharmacol. Sci.* 15, 298–306.

- Martens, D., Lohse, M.J., Rauch, B., Schwabe, U., 1987. Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes. *Naunyn-Schmiedeberg Arch. Pharmacol.* 336, 342–348.
- Meera, P., Wallner, M., Toro, L., 2000. A neuronal beta subunit (KCNMB4) makes the large conductance, voltage- and  $Ca^{2+}$ -activated  $K^+$  channel resistant to charybdotoxin and iberiotoxin. *Proc. Natl. Acad. Sci. U.S.A.* 97, 5562–5567.
- Nagarkatti, D.S., Sha'afi, R.I., 1998. Role of p38 MAP kinase in myocardial stress. *J. Mol. Cell. Cardiol.* 30, 1651–1664.
- Naitoh, K., Ichikawa, Y., Miura, T., Nakamura, Y., Miki, T., Ikeda, Y., Kobayashi, H., Nishihara, M., Otori, K., Shimamoto, K., 2006. Mitochondrial  $K_{ATP}$  channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. *Cardiovasc. Res.* 70, 374–383.
- Nishida, H., Sato, T., Miyazaki, M., Nakaya, H., 2008. Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial  $K_{Ca}$  channels. *Cardiovasc. Res.* 77, 398–405.
- Ohya, S., Kuwata, Y., Sakamoto, K., Muraki, K., Imaizumi, Y., 2005. Cardioprotective effects of estradiol include the activation of large-conductance  $Ca^{2+}$ -activated  $K^+$  channels in cardiac mitochondria. *Am. J. Physiol. Heart Circ. Physiol.* 289, H1635–H1642.
- Olesen, S.P., Munch, E., Moldt, P., Drejer, J., 1994. Selective activation of  $Ca^{2+}$ -dependent  $K^+$  channels by novel benzimidazolone. *Eur. J. Pharmacol.* 251, 53–59.
- Peart, J.N., Headrick, J.P., 2007. Adenosinergic cardioprotection: multiple receptors, multiple pathways. *Pharmacol. Ther.* 114, 208–221.
- Redel, A., Lange, M., Jazbutyte, V., Lotz, C., Smul, T.M., Roewer, N., Kehf, F., 2008. Activation of mitochondrial large-conductance calcium-activated  $K^+$  channels via protein kinase A mediated desflurane-induced preconditioning. *Anesth. Analg.* 106, 384–391.
- Sanchez, M., McNanus, O.B., 1996. Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. *Neuropharmacology* 35, 963–968.
- Sato, T., Saito, T., Saegusa, N., Nakaya, H., 2005. Mitochondrial  $Ca^{2+}$ -activated channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. *Circulation* 111, 198–203.
- Shintani, Y., Node, K., Asanuma, H., Sanada, S., Takashima, S., Asano, Y., Liao, Y., Fujita, M., Hirata, A., Shinozaki, Y., Fukushima, T., Nagamachi, Y., Okuda, H., Kim, J., Tomoike, H., Hori, M., Kitakaze, M., 2004. Opening of  $Ca^{2+}$ -activated  $K^+$  channels is involved in ischemic preconditioning in canine hearts. *J. Mol. Cell. Cardiol.* 37, 1213–1218.
- Sommerschild, H.T., Kirkebaen, K.A., 2000. Adenosine and cardioprotection during ischaemia and reperfusion – an overview. *Acta Anaesthesiol. Scand.* 44, 1038–1055.
- Torres, Y.P., Morera, F.J., Carvacho, I., Latorre, R., 2007. A marriage of convenience:  $\beta$ -subunits and voltage-dependent  $K^+$  channels. *J. Biol. Chem.* 282, 24485–24489.
- Wang, X., Yin, C., Xi, L., Kukreja, R.C., 2004. Opening of  $Ca^{2+}$ -activated  $K^+$  channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. *Am. J. Physiol. Heart Circ. Physiol.* 287, H2070–H2077.
- Wang, X., Fisher, P.W., Xi, L., Kukreja, R.C., 2008. Essential role of mitochondrial  $Ca^{2+}$ -activated and ATP-sensitive  $K^+$  channels in sildenafil-induced late cardioprotection. *J. Mol. Cell. Cardiol.* 44, 105–113.
- Xu, H., Stein, B., Liang, B., 1996. Characterization of a stimulatory adenosine  $A_{2A}$  receptor in adult rat ventricular myocyte. *Am. J. Physiol.* 270, H1655–H1661.
- Xu, W., Liu, Y., Wang, S., McDonald, T., Van Eyk, J.E., Sidor, A., O'Rourke, B., 2002. Cytoprotective role of  $Ca^{2+}$ -activated  $K^+$  channels in the cardiac inner mitochondrial membrane. *Science* 298, 1029–1033.
- Yellon, D.M., Downey, J.M., 2003. Preconditioning the myocardium: from cellular physiology to clinical cardiology. *Physiol. Rev.* 83, 1113–1151.